fact_key,concept,context_ref,value,unit_ref,decimals,numeric_value,period_type,period_instant,entity_identifier,entity_scheme,period_key,label,original_label,statement_type,statement_role,period_start,period_end,dim_us-gaap_StatementEquityComponentsAxis,dim_srt_MajorCustomersAxis,dim_us-gaap_ConcentrationRiskByTypeAxis,dim_srt_ProductOrServiceAxis,dim_us-gaap_TypeOfArrangementAxis,dim_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis,dim_us-gaap_FairValueByMeasurementFrequencyAxis,dim_us-gaap_FinancialInstrumentAxis,dim_us-gaap_FairValueByFairValueHierarchyLevelAxis,dim_srt_RangeAxis,dim_us-gaap_FairValueByAssetClassAxis,dim_us-gaap_TaxCreditCarryforwardAxis,dim_us-gaap_IncomeStatementLocationAxis,dim_us-gaap_SubsidiarySaleOfStockAxis,dim_us-gaap_BusinessAcquisitionAxis,dim_srt_OwnershipAxis,dim_us-gaap_StatementBusinessSegmentsAxis,dim_us-gaap_DebtInstrumentAxis,dim_us-gaap_LongtermDebtTypeAxis,dim_us-gaap_SubsequentEventTypeAxis,dim_us-gaap_DebtInstrumentRedemptionPeriodAxis,ticker,filing_date,quarter,year,company_name
us-gaap_CommonStockSharesOutstanding_As_Of_3_31_2024_Ebq-QFBYXEGIOthDpC9wWw,us-gaap:CommonStockSharesOutstanding,As_Of_3_31_2024_Ebq-QFBYXEGIOthDpC9wWw,1532974878,Unit_Standard_shares_KIp_HZ7W0kSuHGlx3Wi_-g,INF,1532974878.0,instant,2024-03-31,0001621227,http://www.sec.gov/CIK,instant_2024-03-31,"Common stock, shares outstanding","Common stock, shares outstanding",BalanceSheetParenthetical,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
dei_EntityCentralIndexKey_Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,dei:EntityCentralIndexKey,Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,0001621227,None,None,1621227.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Entity Central Index Key,Entity Central Index Key,CoverPage,http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
dei_CurrentFiscalYearEndDate_Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,dei:CurrentFiscalYearEndDate,Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,--12-31,None,None,,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Current Fiscal Year End Date,Current Fiscal Year End Date,CoverPage,http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
dei_DocumentFiscalYearFocus_Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,dei:DocumentFiscalYearFocus,Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,2024,None,None,2024.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Document Fiscal Year Focus,Document Fiscal Year Focus,CoverPage,http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
dei_DocumentFiscalPeriodFocus_Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,dei:DocumentFiscalPeriodFocus,Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,Q1,None,None,,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Document Fiscal Period Focus,Document Fiscal Period Focus,CoverPage,http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
dei_AmendmentFlag_Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,dei:AmendmentFlag,Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,false,None,None,,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Amendment Flag,Amendment Flag,CoverPage,http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
dei_EntityTaxIdentificationNumber_Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,dei:EntityTaxIdentificationNumber,Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,00-0000000,None,None,,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Entity Tax Identification Number,Entity Tax Identification Number,CoverPage,http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_CommonStockSharesOutstanding_As_Of_12_31_2023_m48jnprDr0mqVxN2-uk6kw,us-gaap:CommonStockSharesOutstanding,As_Of_12_31_2023_m48jnprDr0mqVxN2-uk6kw,1363008102,Unit_Standard_shares_KIp_HZ7W0kSuHGlx3Wi_-g,INF,1363008102.0,instant,2023-12-31,0001621227,http://www.sec.gov/CIK,instant_2023-12-31,"Common stock, shares outstanding","Common stock, shares outstanding",BalanceSheetParenthetical,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted,Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,-48503000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,-48503000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Net (loss)/profit attributable to ordinary shareholders used for diluted (loss)/profit per share,Net (loss)/profit attributable to ordinary shareholders used for diluted (loss)/profit per share,Disclosures,http://www.adaptimmune.com/role/DisclosureLossPerShareBasicAndDilutedLossPerShareDetails,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_Duration_1_1_2023_To_3_31_2023_y-zxPPLZtEmUIwfawHojag,us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted,Duration_1_1_2023_To_3_31_2023_y-zxPPLZtEmUIwfawHojag,1036000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,1036000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Net (loss)/profit attributable to ordinary shareholders used for diluted (loss)/profit per share,Net (loss)/profit attributable to ordinary shareholders used for diluted (loss)/profit per share,Disclosures,http://www.adaptimmune.com/role/DisclosureLossPerShareBasicAndDilutedLossPerShareDetails,2023-01-01,2023-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
dei_EntityFilerCategory_Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,dei:EntityFilerCategory,Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,Non-accelerated Filer,None,None,,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Entity Filer Category,Entity Filer Category,CoverPage,http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
dei_SecurityExchangeName_Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,dei:SecurityExchangeName,Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,NASDAQ,None,None,,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Security Exchange Name,Security Exchange Name,CoverPage,http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
dei_DocumentType_Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,dei:DocumentType,Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,10-Q,None,None,,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Document Type,Document Type,CoverPage,http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
dei_DocumentQuarterlyReport_Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,dei:DocumentQuarterlyReport,Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,true,None,None,,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Document Quarterly Report,Document Quarterly Report,CoverPage,http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
dei_DocumentPeriodEndDate_Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,dei:DocumentPeriodEndDate,Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,2024-03-31,None,None,,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Document Period End Date,Document Period End Date,CoverPage,http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
dei_DocumentTransitionReport_Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,dei:DocumentTransitionReport,Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,false,None,None,,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Document Transition Report,Document Transition Report,CoverPage,http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
dei_EntityFileNumber_Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,dei:EntityFileNumber,Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,001-37368,None,None,,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Entity File Number,Entity File Number,CoverPage,http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
dei_EntityRegistrantName_Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,dei:EntityRegistrantName,Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,ADAPTIMMUNE THERAPEUTICS PLC,None,None,,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Entity Registrant Name,Entity Registrant Name,CoverPage,http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
dei_EntityIncorporationStateCountryCode_Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,dei:EntityIncorporationStateCountryCode,Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,X0,None,None,,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,"Entity Incorporation, State or Country Code","Entity Incorporation, State or Country Code",CoverPage,http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
dei_EntityAddressAddressLine1_Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,dei:EntityAddressAddressLine1,Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,"60 Jubilee Avenue, Milton Park",None,None,,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,"Entity Address, Address Line One","Entity Address, Address Line One",CoverPage,http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
dei_EntityAddressCityOrTown_Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,dei:EntityAddressCityOrTown,Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,"Abingdon, Oxfordshire",None,None,,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,"Entity Address, City or Town","Entity Address, City or Town",CoverPage,http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
dei_EntityAddressPostalZipCode_Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,dei:EntityAddressPostalZipCode,Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,OX14 4RX,None,None,,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,"Entity Address, Postal Zip Code","Entity Address, Postal Zip Code",CoverPage,http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
dei_EntityAddressCountry_Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,dei:EntityAddressCountry,Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,GB,None,None,,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,"Entity Address, Country","Entity Address, Country",CoverPage,http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
dei_CityAreaCode_Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,dei:CityAreaCode,Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,44,None,None,44.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,City Area Code,City Area Code,CoverPage,http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
dei_LocalPhoneNumber_Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,dei:LocalPhoneNumber,Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,1235 430000,None,None,,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Local Phone Number,Local Phone Number,CoverPage,http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
dei_Security12bTitle_Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,dei:Security12bTitle,Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,"American Depositary Shares, each representing 6 Ordinary Shares, par value £0.001 per share",None,None,,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Title of 12(b) Security,Title of 12(b) Security,CoverPage,http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
dei_TradingSymbol_Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,dei:TradingSymbol,Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,ADAP,None,None,,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Trading Symbol,Trading Symbol,CoverPage,http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
dei_EntityCurrentReportingStatus_Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,dei:EntityCurrentReportingStatus,Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,Yes,None,None,,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Entity Current Reporting Status,Entity Current Reporting Status,CoverPage,http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
dei_EntityInteractiveDataCurrent_Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,dei:EntityInteractiveDataCurrent,Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,Yes,None,None,,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Entity Interactive Data Current,Entity Interactive Data Current,CoverPage,http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
dei_EntitySmallBusiness_Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,dei:EntitySmallBusiness,Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,true,None,None,,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Entity Small Business,Entity Small Business,CoverPage,http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
dei_EntityEmergingGrowthCompany_Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,dei:EntityEmergingGrowthCompany,Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,false,None,None,,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Entity Emerging Growth Company,Entity Emerging Growth Company,CoverPage,http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
dei_EntityShellCompany_Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,dei:EntityShellCompany,Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,false,None,None,,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Entity Shell Company,Entity Shell Company,CoverPage,http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
dei_EntityCommonStockSharesOutstanding_As_Of_5_13_2024_0jGVNQuTPUOOcqDinZWy3A,dei:EntityCommonStockSharesOutstanding,As_Of_5_13_2024_0jGVNQuTPUOOcqDinZWy3A,1533371874,Unit_Standard_shares_KIp_HZ7W0kSuHGlx3Wi_-g,INF,1533371874.0,instant,2024-05-13,0001621227,http://www.sec.gov/CIK,instant_2024-05-13,"Entity Common Stock, Shares Outstanding","Entity Common Stock, Shares Outstanding",CoverPage,http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_CashAndCashEquivalentsAtCarryingValue_As_Of_12_31_2023_m48jnprDr0mqVxN2-uk6kw,us-gaap:CashAndCashEquivalentsAtCarryingValue,As_Of_12_31_2023_m48jnprDr0mqVxN2-uk6kw,143991000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,143991000.0,instant,2023-12-31,0001621227,http://www.sec.gov/CIK,instant_2023-12-31,Cash and cash equivalents,Cash and cash equivalents,BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLossCurrent_As_Of_3_31_2024_Ebq-QFBYXEGIOthDpC9wWw,us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLossCurrent,As_Of_3_31_2024_Ebq-QFBYXEGIOthDpC9wWw,2981000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,2981000.0,instant,2024-03-31,0001621227,http://www.sec.gov/CIK,instant_2024-03-31,Marketable securities - amortized cost,Marketable securities - amortized cost,BalanceSheetParenthetical,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLossCurrent_As_Of_12_31_2023_m48jnprDr0mqVxN2-uk6kw,us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLossCurrent,As_Of_12_31_2023_m48jnprDr0mqVxN2-uk6kw,2940000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,2940000.0,instant,2023-12-31,0001621227,http://www.sec.gov/CIK,instant_2023-12-31,Marketable securities - amortized cost,Marketable securities - amortized cost,BalanceSheetParenthetical,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossCurrent_As_Of_3_31_2024_Ebq-QFBYXEGIOthDpC9wWw,us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossCurrent,As_Of_3_31_2024_Ebq-QFBYXEGIOthDpC9wWw,0,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,0.0,instant,2024-03-31,0001621227,http://www.sec.gov/CIK,instant_2024-03-31,Marketable securities - Net of allowance for expected credit losses,Marketable securities - Net of allowance for expected credit losses,BalanceSheetParenthetical,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossCurrent_As_Of_12_31_2023_m48jnprDr0mqVxN2-uk6kw,us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossCurrent,As_Of_12_31_2023_m48jnprDr0mqVxN2-uk6kw,0,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,0.0,instant,2023-12-31,0001621227,http://www.sec.gov/CIK,instant_2023-12-31,Marketable securities - Net of allowance for expected credit losses,Marketable securities - Net of allowance for expected credit losses,BalanceSheetParenthetical,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_As_Of_12_31_2023_m48jnprDr0mqVxN2-uk6kw,us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent,As_Of_12_31_2023_m48jnprDr0mqVxN2-uk6kw,2947000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,2947000.0,instant,2023-12-31,0001621227,http://www.sec.gov/CIK,instant_2023-12-31,"Marketable securities - available-for-sale debt securities (amortized cost of $2,981 and $2,940) net of allowance for expected credit losses of $0 and $0","Marketable securities - available-for-sale debt securities (amortized cost of $2,981 and $2,940) net of allowance for expected credit losses of $0 and $0",BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_As_Of_3_31_2024_Ebq-QFBYXEGIOthDpC9wWw,us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent,As_Of_3_31_2024_Ebq-QFBYXEGIOthDpC9wWw,0,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,0.0,instant,2024-03-31,0001621227,http://www.sec.gov/CIK,instant_2024-03-31,Allowance for expected credit losses,Allowance for expected credit losses,BalanceSheetParenthetical,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_As_Of_12_31_2023_m48jnprDr0mqVxN2-uk6kw,us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent,As_Of_12_31_2023_m48jnprDr0mqVxN2-uk6kw,0,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,0.0,instant,2023-12-31,0001621227,http://www.sec.gov/CIK,instant_2023-12-31,Allowance for expected credit losses,Allowance for expected credit losses,BalanceSheetParenthetical,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_AccountsReceivableNetCurrent_As_Of_3_31_2024_Ebq-QFBYXEGIOthDpC9wWw,us-gaap:AccountsReceivableNetCurrent,As_Of_3_31_2024_Ebq-QFBYXEGIOthDpC9wWw,8404000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,8404000.0,instant,2024-03-31,0001621227,http://www.sec.gov/CIK,instant_2024-03-31,"Accounts receivable, net of allowance for expected credit losses of $0 and $0","Accounts receivable, net of allowance for expected credit losses of $0 and $0",BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_AccountsReceivableNetCurrent_As_Of_12_31_2023_m48jnprDr0mqVxN2-uk6kw,us-gaap:AccountsReceivableNetCurrent,As_Of_12_31_2023_m48jnprDr0mqVxN2-uk6kw,821000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,821000.0,instant,2023-12-31,0001621227,http://www.sec.gov/CIK,instant_2023-12-31,"Accounts receivable, net of allowance for expected credit losses of $0 and $0","Accounts receivable, net of allowance for expected credit losses of $0 and $0",BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_PrepaidExpenseAndOtherAssetsCurrent_As_Of_3_31_2024_Ebq-QFBYXEGIOthDpC9wWw,us-gaap:PrepaidExpenseAndOtherAssetsCurrent,As_Of_3_31_2024_Ebq-QFBYXEGIOthDpC9wWw,34847000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,34847000.0,instant,2024-03-31,0001621227,http://www.sec.gov/CIK,instant_2024-03-31,Other current assets and prepaid expenses,Other current assets and prepaid expenses,BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_PrepaidExpenseAndOtherAssetsCurrent_As_Of_12_31_2023_m48jnprDr0mqVxN2-uk6kw,us-gaap:PrepaidExpenseAndOtherAssetsCurrent,As_Of_12_31_2023_m48jnprDr0mqVxN2-uk6kw,59793000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,59793000.0,instant,2023-12-31,0001621227,http://www.sec.gov/CIK,instant_2023-12-31,Other current assets and prepaid expenses,Other current assets and prepaid expenses,BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_AssetsCurrent_As_Of_3_31_2024_Ebq-QFBYXEGIOthDpC9wWw,us-gaap:AssetsCurrent,As_Of_3_31_2024_Ebq-QFBYXEGIOthDpC9wWw,186903000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,186903000.0,instant,2024-03-31,0001621227,http://www.sec.gov/CIK,instant_2024-03-31,Total current assets,Total current assets,BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_AssetsCurrent_As_Of_12_31_2023_m48jnprDr0mqVxN2-uk6kw,us-gaap:AssetsCurrent,As_Of_12_31_2023_m48jnprDr0mqVxN2-uk6kw,207552000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,207552000.0,instant,2023-12-31,0001621227,http://www.sec.gov/CIK,instant_2023-12-31,Total current assets,Total current assets,BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_As_Of_3_31_2024_Ebq-QFBYXEGIOthDpC9wWw,us-gaap:RestrictedCashAndCashEquivalentsNoncurrent,As_Of_3_31_2024_Ebq-QFBYXEGIOthDpC9wWw,2858000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,2858000.0,instant,2024-03-31,0001621227,http://www.sec.gov/CIK,instant_2024-03-31,Restricted cash,Restricted cash,BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_As_Of_12_31_2023_m48jnprDr0mqVxN2-uk6kw,us-gaap:RestrictedCashAndCashEquivalentsNoncurrent,As_Of_12_31_2023_m48jnprDr0mqVxN2-uk6kw,3026000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,3026000.0,instant,2023-12-31,0001621227,http://www.sec.gov/CIK,instant_2023-12-31,Restricted cash,Restricted cash,BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
adap_OperatingLeaseRightOfUseAssetAccumulatedAmortization_Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,adap:OperatingLeaseRightOfUseAssetAccumulatedAmortization,Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,14381000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,14381000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,"Operating lease right-of-use assets, accumulated amortization","Operating lease right-of-use assets, accumulated amortization",BalanceSheetParenthetical,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
adap_OperatingLeaseRightOfUseAssetAccumulatedAmortization_Duration_1_1_2023_To_12_31_2023_ywGyk4hUCkahRa47Ahko7A,adap:OperatingLeaseRightOfUseAssetAccumulatedAmortization,Duration_1_1_2023_To_12_31_2023_ywGyk4hUCkahRa47Ahko7A,13220000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,13220000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-12-31,"Operating lease right-of-use assets, accumulated amortization","Operating lease right-of-use assets, accumulated amortization",BalanceSheetParenthetical,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical,2023-01-01,2023-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_OperatingLeaseRightOfUseAsset_As_Of_3_31_2024_Ebq-QFBYXEGIOthDpC9wWw,us-gaap:OperatingLeaseRightOfUseAsset,As_Of_3_31_2024_Ebq-QFBYXEGIOthDpC9wWw,19434000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,19434000.0,instant,2024-03-31,0001621227,http://www.sec.gov/CIK,instant_2024-03-31,"Operating lease right-of-use assets, net of accumulated amortization of $14,381 and $13,220","Operating lease right-of-use assets, net of accumulated amortization of $14,381 and $13,220",BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_OperatingLeaseRightOfUseAsset_As_Of_12_31_2023_m48jnprDr0mqVxN2-uk6kw,us-gaap:OperatingLeaseRightOfUseAsset,As_Of_12_31_2023_m48jnprDr0mqVxN2-uk6kw,20762000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,20762000.0,instant,2023-12-31,0001621227,http://www.sec.gov/CIK,instant_2023-12-31,"Operating lease right-of-use assets, net of accumulated amortization of $14,381 and $13,220","Operating lease right-of-use assets, net of accumulated amortization of $14,381 and $13,220",BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_As_Of_3_31_2024_Ebq-QFBYXEGIOthDpC9wWw,us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment,As_Of_3_31_2024_Ebq-QFBYXEGIOthDpC9wWw,48445000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,48445000.0,instant,2024-03-31,0001621227,http://www.sec.gov/CIK,instant_2024-03-31,"Property, plant and equipment, accumulated depreciation","Property, plant and equipment, accumulated depreciation",BalanceSheetParenthetical,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_As_Of_12_31_2023_m48jnprDr0mqVxN2-uk6kw,us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment,As_Of_12_31_2023_m48jnprDr0mqVxN2-uk6kw,46020000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,46020000.0,instant,2023-12-31,0001621227,http://www.sec.gov/CIK,instant_2023-12-31,"Property, plant and equipment, accumulated depreciation","Property, plant and equipment, accumulated depreciation",BalanceSheetParenthetical,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_PropertyPlantAndEquipmentNet_As_Of_3_31_2024_Ebq-QFBYXEGIOthDpC9wWw,us-gaap:PropertyPlantAndEquipmentNet,As_Of_3_31_2024_Ebq-QFBYXEGIOthDpC9wWw,48291000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,48291000.0,instant,2024-03-31,0001621227,http://www.sec.gov/CIK,instant_2024-03-31,"Property, plant and equipment, net of accumulated depreciation of $48,445 and $46,020","Property, plant and equipment, net of accumulated depreciation of $48,445 and $46,020",BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_PropertyPlantAndEquipmentNet_As_Of_12_31_2023_m48jnprDr0mqVxN2-uk6kw,us-gaap:PropertyPlantAndEquipmentNet,As_Of_12_31_2023_m48jnprDr0mqVxN2-uk6kw,50946000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,50946000.0,instant,2023-12-31,0001621227,http://www.sec.gov/CIK,instant_2023-12-31,"Property, plant and equipment, net of accumulated depreciation of $48,445 and $46,020","Property, plant and equipment, net of accumulated depreciation of $48,445 and $46,020",BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_As_Of_3_31_2024_Ebq-QFBYXEGIOthDpC9wWw,us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization,As_Of_3_31_2024_Ebq-QFBYXEGIOthDpC9wWw,5198000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,5198000.0,instant,2024-03-31,0001621227,http://www.sec.gov/CIK,instant_2024-03-31,"Intangibles, accumulated amortization","Intangibles, accumulated amortization",BalanceSheetParenthetical,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_As_Of_12_31_2023_m48jnprDr0mqVxN2-uk6kw,us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization,As_Of_12_31_2023_m48jnprDr0mqVxN2-uk6kw,5155000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,5155000.0,instant,2023-12-31,0001621227,http://www.sec.gov/CIK,instant_2023-12-31,"Intangibles, accumulated amortization","Intangibles, accumulated amortization",BalanceSheetParenthetical,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_IntangibleAssetsNetExcludingGoodwill_As_Of_3_31_2024_Ebq-QFBYXEGIOthDpC9wWw,us-gaap:IntangibleAssetsNetExcludingGoodwill,As_Of_3_31_2024_Ebq-QFBYXEGIOthDpC9wWw,524000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,524000.0,instant,2024-03-31,0001621227,http://www.sec.gov/CIK,instant_2024-03-31,"Intangible assets, net of accumulated amortization of $5,198 and $5,155","Intangible assets, net of accumulated amortization of $5,198 and $5,155",BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_IntangibleAssetsNetExcludingGoodwill_As_Of_12_31_2023_m48jnprDr0mqVxN2-uk6kw,us-gaap:IntangibleAssetsNetExcludingGoodwill,As_Of_12_31_2023_m48jnprDr0mqVxN2-uk6kw,330000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,330000.0,instant,2023-12-31,0001621227,http://www.sec.gov/CIK,instant_2023-12-31,"Intangible assets, net of accumulated amortization of $5,198 and $5,155","Intangible assets, net of accumulated amortization of $5,198 and $5,155",BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_Assets_As_Of_3_31_2024_Ebq-QFBYXEGIOthDpC9wWw,us-gaap:Assets,As_Of_3_31_2024_Ebq-QFBYXEGIOthDpC9wWw,258010000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,258010000.0,instant,2024-03-31,0001621227,http://www.sec.gov/CIK,instant_2024-03-31,Total assets,Total assets,BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_Assets_As_Of_12_31_2023_m48jnprDr0mqVxN2-uk6kw,us-gaap:Assets,As_Of_12_31_2023_m48jnprDr0mqVxN2-uk6kw,282616000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,282616000.0,instant,2023-12-31,0001621227,http://www.sec.gov/CIK,instant_2023-12-31,Total assets,Total assets,BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_AccountsPayableCurrent_As_Of_3_31_2024_Ebq-QFBYXEGIOthDpC9wWw,us-gaap:AccountsPayableCurrent,As_Of_3_31_2024_Ebq-QFBYXEGIOthDpC9wWw,6587000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,6587000.0,instant,2024-03-31,0001621227,http://www.sec.gov/CIK,instant_2024-03-31,Accounts payable,Accounts payable,BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_AccountsPayableCurrent_As_Of_12_31_2023_m48jnprDr0mqVxN2-uk6kw,us-gaap:AccountsPayableCurrent,As_Of_12_31_2023_m48jnprDr0mqVxN2-uk6kw,8128000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,8128000.0,instant,2023-12-31,0001621227,http://www.sec.gov/CIK,instant_2023-12-31,Accounts payable,Accounts payable,BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_OperatingLeaseLiabilityCurrent_As_Of_3_31_2024_Ebq-QFBYXEGIOthDpC9wWw,us-gaap:OperatingLeaseLiabilityCurrent,As_Of_3_31_2024_Ebq-QFBYXEGIOthDpC9wWw,5250000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,5250000.0,instant,2024-03-31,0001621227,http://www.sec.gov/CIK,instant_2024-03-31,"Operating lease liabilities, current","Operating lease liabilities, current",BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_OperatingLeaseLiabilityCurrent_As_Of_12_31_2023_m48jnprDr0mqVxN2-uk6kw,us-gaap:OperatingLeaseLiabilityCurrent,As_Of_12_31_2023_m48jnprDr0mqVxN2-uk6kw,5384000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,5384000.0,instant,2023-12-31,0001621227,http://www.sec.gov/CIK,instant_2023-12-31,"Operating lease liabilities, current","Operating lease liabilities, current",BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_ContractWithCustomerLiabilityCurrent_As_Of_3_31_2024_Ebq-QFBYXEGIOthDpC9wWw,us-gaap:ContractWithCustomerLiabilityCurrent,As_Of_3_31_2024_Ebq-QFBYXEGIOthDpC9wWw,31524000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,31524000.0,instant,2024-03-31,0001621227,http://www.sec.gov/CIK,instant_2024-03-31,"Deferred revenue, current","Deferred revenue, current",BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_ContractWithCustomerLiabilityCurrent_As_Of_12_31_2023_m48jnprDr0mqVxN2-uk6kw,us-gaap:ContractWithCustomerLiabilityCurrent,As_Of_12_31_2023_m48jnprDr0mqVxN2-uk6kw,28973000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,28973000.0,instant,2023-12-31,0001621227,http://www.sec.gov/CIK,instant_2023-12-31,"Deferred revenue, current","Deferred revenue, current",BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_LiabilitiesCurrent_As_Of_3_31_2024_Ebq-QFBYXEGIOthDpC9wWw,us-gaap:LiabilitiesCurrent,As_Of_3_31_2024_Ebq-QFBYXEGIOthDpC9wWw,66411000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,66411000.0,instant,2024-03-31,0001621227,http://www.sec.gov/CIK,instant_2024-03-31,Total current liabilities,Total current liabilities,BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_LiabilitiesCurrent_As_Of_12_31_2023_m48jnprDr0mqVxN2-uk6kw,us-gaap:LiabilitiesCurrent,As_Of_12_31_2023_m48jnprDr0mqVxN2-uk6kw,72788000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,72788000.0,instant,2023-12-31,0001621227,http://www.sec.gov/CIK,instant_2023-12-31,Total current liabilities,Total current liabilities,BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_OperatingLeaseLiabilityNoncurrent_As_Of_3_31_2024_Ebq-QFBYXEGIOthDpC9wWw,us-gaap:OperatingLeaseLiabilityNoncurrent,As_Of_3_31_2024_Ebq-QFBYXEGIOthDpC9wWw,18442000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,18442000.0,instant,2024-03-31,0001621227,http://www.sec.gov/CIK,instant_2024-03-31,"Operating lease liabilities, non-current","Operating lease liabilities, non-current",BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_OperatingLeaseLiabilityNoncurrent_As_Of_12_31_2023_m48jnprDr0mqVxN2-uk6kw,us-gaap:OperatingLeaseLiabilityNoncurrent,As_Of_12_31_2023_m48jnprDr0mqVxN2-uk6kw,19851000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,19851000.0,instant,2023-12-31,0001621227,http://www.sec.gov/CIK,instant_2023-12-31,"Operating lease liabilities, non-current","Operating lease liabilities, non-current",BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_ContractWithCustomerLiabilityNoncurrent_As_Of_3_31_2024_Ebq-QFBYXEGIOthDpC9wWw,us-gaap:ContractWithCustomerLiabilityNoncurrent,As_Of_3_31_2024_Ebq-QFBYXEGIOthDpC9wWw,147365000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,147365000.0,instant,2024-03-31,0001621227,http://www.sec.gov/CIK,instant_2024-03-31,"Deferred revenue, non-current","Deferred revenue, non-current",BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_ContractWithCustomerLiabilityNoncurrent_As_Of_12_31_2023_m48jnprDr0mqVxN2-uk6kw,us-gaap:ContractWithCustomerLiabilityNoncurrent,As_Of_12_31_2023_m48jnprDr0mqVxN2-uk6kw,149060000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,149060000.0,instant,2023-12-31,0001621227,http://www.sec.gov/CIK,instant_2023-12-31,"Deferred revenue, non-current","Deferred revenue, non-current",BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_OtherLiabilitiesNoncurrent_As_Of_3_31_2024_Ebq-QFBYXEGIOthDpC9wWw,us-gaap:OtherLiabilitiesNoncurrent,As_Of_3_31_2024_Ebq-QFBYXEGIOthDpC9wWw,1417000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,1417000.0,instant,2024-03-31,0001621227,http://www.sec.gov/CIK,instant_2024-03-31,"Other liabilities, non-current","Other liabilities, non-current",BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_OtherLiabilitiesNoncurrent_As_Of_12_31_2023_m48jnprDr0mqVxN2-uk6kw,us-gaap:OtherLiabilitiesNoncurrent,As_Of_12_31_2023_m48jnprDr0mqVxN2-uk6kw,1404000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,1404000.0,instant,2023-12-31,0001621227,http://www.sec.gov/CIK,instant_2023-12-31,"Other liabilities, non-current","Other liabilities, non-current",BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_Liabilities_As_Of_3_31_2024_Ebq-QFBYXEGIOthDpC9wWw,us-gaap:Liabilities,As_Of_3_31_2024_Ebq-QFBYXEGIOthDpC9wWw,233635000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,233635000.0,instant,2024-03-31,0001621227,http://www.sec.gov/CIK,instant_2024-03-31,Total liabilities,Total liabilities,BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_Liabilities_As_Of_12_31_2023_m48jnprDr0mqVxN2-uk6kw,us-gaap:Liabilities,As_Of_12_31_2023_m48jnprDr0mqVxN2-uk6kw,243103000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,243103000.0,instant,2023-12-31,0001621227,http://www.sec.gov/CIK,instant_2023-12-31,Total liabilities,Total liabilities,BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_CommonStockParOrStatedValuePerShare_As_Of_3_31_2024_Ebq-QFBYXEGIOthDpC9wWw,us-gaap:CommonStockParOrStatedValuePerShare,As_Of_3_31_2024_Ebq-QFBYXEGIOthDpC9wWw,0.001,Unit_Divide_GBP_shares_4Vg-znNmm0232I0fGOkzFw,3,0.001,instant,2024-03-31,0001621227,http://www.sec.gov/CIK,instant_2024-03-31,"Common stock, par value","Common stock, par value",BalanceSheetParenthetical,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_CommonStockParOrStatedValuePerShare_As_Of_12_31_2023_m48jnprDr0mqVxN2-uk6kw,us-gaap:CommonStockParOrStatedValuePerShare,As_Of_12_31_2023_m48jnprDr0mqVxN2-uk6kw,0.001,Unit_Divide_GBP_shares_4Vg-znNmm0232I0fGOkzFw,3,0.001,instant,2023-12-31,0001621227,http://www.sec.gov/CIK,instant_2023-12-31,"Common stock, par value","Common stock, par value",BalanceSheetParenthetical,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_CommonStockSharesAuthorized_As_Of_3_31_2024_Ebq-QFBYXEGIOthDpC9wWw,us-gaap:CommonStockSharesAuthorized,As_Of_3_31_2024_Ebq-QFBYXEGIOthDpC9wWw,1702760280,Unit_Standard_shares_KIp_HZ7W0kSuHGlx3Wi_-g,INF,1702760280.0,instant,2024-03-31,0001621227,http://www.sec.gov/CIK,instant_2024-03-31,"Common stock, shares authorized","Common stock, shares authorized",BalanceSheetParenthetical,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_CommonStockSharesIssued_As_Of_3_31_2024_Ebq-QFBYXEGIOthDpC9wWw,us-gaap:CommonStockSharesIssued,As_Of_3_31_2024_Ebq-QFBYXEGIOthDpC9wWw,1532974878,Unit_Standard_shares_KIp_HZ7W0kSuHGlx3Wi_-g,INF,1532974878.0,instant,2024-03-31,0001621227,http://www.sec.gov/CIK,instant_2024-03-31,"Common stock, shares issued","Common stock, shares issued",BalanceSheetParenthetical,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_CommonStockSharesAuthorized_As_Of_12_31_2023_m48jnprDr0mqVxN2-uk6kw,us-gaap:CommonStockSharesAuthorized,As_Of_12_31_2023_m48jnprDr0mqVxN2-uk6kw,1702760280,Unit_Standard_shares_KIp_HZ7W0kSuHGlx3Wi_-g,INF,1702760280.0,instant,2023-12-31,0001621227,http://www.sec.gov/CIK,instant_2023-12-31,"Common stock, shares authorized","Common stock, shares authorized",BalanceSheetParenthetical,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_CommonStockSharesIssued_As_Of_12_31_2023_m48jnprDr0mqVxN2-uk6kw,us-gaap:CommonStockSharesIssued,As_Of_12_31_2023_m48jnprDr0mqVxN2-uk6kw,1363008102,Unit_Standard_shares_KIp_HZ7W0kSuHGlx3Wi_-g,INF,1363008102.0,instant,2023-12-31,0001621227,http://www.sec.gov/CIK,instant_2023-12-31,"Common stock, shares issued","Common stock, shares issued",BalanceSheetParenthetical,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_CommonStockValue_As_Of_3_31_2024_Ebq-QFBYXEGIOthDpC9wWw,us-gaap:CommonStockValue,As_Of_3_31_2024_Ebq-QFBYXEGIOthDpC9wWw,2081000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,2081000.0,instant,2024-03-31,0001621227,http://www.sec.gov/CIK,instant_2024-03-31,"Common stock - Ordinary shares par value £0.001, 1,702,760,280 authorized and 1,532,974,878 issued and outstanding (2023: 1,702,760,280 authorized and 1,363,008,102 issued and outstanding)","Common stock - Ordinary shares par value £0.001, 1,702,760,280 authorized and 1,532,974,878 issued and outstanding (2023: 1,702,760,280 authorized and 1,363,008,102 issued and outstanding)",BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_CommonStockValue_As_Of_12_31_2023_m48jnprDr0mqVxN2-uk6kw,us-gaap:CommonStockValue,As_Of_12_31_2023_m48jnprDr0mqVxN2-uk6kw,1865000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,1865000.0,instant,2023-12-31,0001621227,http://www.sec.gov/CIK,instant_2023-12-31,"Common stock - Ordinary shares par value £0.001, 1,702,760,280 authorized and 1,532,974,878 issued and outstanding (2023: 1,702,760,280 authorized and 1,363,008,102 issued and outstanding)","Common stock - Ordinary shares par value £0.001, 1,702,760,280 authorized and 1,532,974,878 issued and outstanding (2023: 1,702,760,280 authorized and 1,363,008,102 issued and outstanding)",BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_AdditionalPaidInCapital_As_Of_3_31_2024_Ebq-QFBYXEGIOthDpC9wWw,us-gaap:AdditionalPaidInCapital,As_Of_3_31_2024_Ebq-QFBYXEGIOthDpC9wWw,1096690000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,1096690000.0,instant,2024-03-31,0001621227,http://www.sec.gov/CIK,instant_2024-03-31,Additional paid in capital,Additional paid in capital,BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_AdditionalPaidInCapital_As_Of_12_31_2023_m48jnprDr0mqVxN2-uk6kw,us-gaap:AdditionalPaidInCapital,As_Of_12_31_2023_m48jnprDr0mqVxN2-uk6kw,1064569000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,1064569000.0,instant,2023-12-31,0001621227,http://www.sec.gov/CIK,instant_2023-12-31,Additional paid in capital,Additional paid in capital,BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_As_Of_3_31_2024_Ebq-QFBYXEGIOthDpC9wWw,us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax,As_Of_3_31_2024_Ebq-QFBYXEGIOthDpC9wWw,-2720000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,-2720000.0,instant,2024-03-31,0001621227,http://www.sec.gov/CIK,instant_2024-03-31,Accumulated other comprehensive loss,Accumulated other comprehensive loss,BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_As_Of_12_31_2023_m48jnprDr0mqVxN2-uk6kw,us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax,As_Of_12_31_2023_m48jnprDr0mqVxN2-uk6kw,-3748000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,-3748000.0,instant,2023-12-31,0001621227,http://www.sec.gov/CIK,instant_2023-12-31,Accumulated other comprehensive loss,Accumulated other comprehensive loss,BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_RetainedEarningsAccumulatedDeficit_As_Of_12_31_2023_m48jnprDr0mqVxN2-uk6kw,us-gaap:RetainedEarningsAccumulatedDeficit,As_Of_12_31_2023_m48jnprDr0mqVxN2-uk6kw,-1023173000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,-1023173000.0,instant,2023-12-31,0001621227,http://www.sec.gov/CIK,instant_2023-12-31,Accumulated deficit,Accumulated deficit,BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_LiabilitiesAndStockholdersEquity_As_Of_3_31_2024_Ebq-QFBYXEGIOthDpC9wWw,us-gaap:LiabilitiesAndStockholdersEquity,As_Of_3_31_2024_Ebq-QFBYXEGIOthDpC9wWw,258010000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,258010000.0,instant,2024-03-31,0001621227,http://www.sec.gov/CIK,instant_2024-03-31,Total liabilities and stockholders' equity,Total liabilities and stockholders' equity,BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_LiabilitiesAndStockholdersEquity_As_Of_12_31_2023_m48jnprDr0mqVxN2-uk6kw,us-gaap:LiabilitiesAndStockholdersEquity,As_Of_12_31_2023_m48jnprDr0mqVxN2-uk6kw,282616000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,282616000.0,instant,2023-12-31,0001621227,http://www.sec.gov/CIK,instant_2023-12-31,Total liabilities and stockholders' equity,Total liabilities and stockholders' equity,BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_ResearchAndDevelopmentExpense_Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,us-gaap:ResearchAndDevelopmentExpense,Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,35207000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,35207000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Research and development,Research and development,IncomeStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_ResearchAndDevelopmentExpense_Duration_1_1_2023_To_3_31_2023_y-zxPPLZtEmUIwfawHojag,us-gaap:ResearchAndDevelopmentExpense,Duration_1_1_2023_To_3_31_2023_y-zxPPLZtEmUIwfawHojag,25548000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,25548000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Research and development,Research and development,IncomeStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations,2023-01-01,2023-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_GeneralAndAdministrativeExpense_Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,us-gaap:GeneralAndAdministrativeExpense,Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,19732000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,19732000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,General and administrative,General and administrative,IncomeStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_GeneralAndAdministrativeExpense_Duration_1_1_2023_To_3_31_2023_y-zxPPLZtEmUIwfawHojag,us-gaap:GeneralAndAdministrativeExpense,Duration_1_1_2023_To_3_31_2023_y-zxPPLZtEmUIwfawHojag,20397000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,20397000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,General and administrative,General and administrative,IncomeStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations,2023-01-01,2023-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest,Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,-47977000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,-47977000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,(Loss)/profit before income tax expense,(Loss)/profit before income tax expense,IncomeStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_Duration_1_1_2023_To_3_31_2023_y-zxPPLZtEmUIwfawHojag,us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest,Duration_1_1_2023_To_3_31_2023_y-zxPPLZtEmUIwfawHojag,1661000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,1661000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,(Loss)/profit before income tax expense,(Loss)/profit before income tax expense,IncomeStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations,2023-01-01,2023-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_EarningsPerShareBasic_Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,us-gaap:EarningsPerShareBasic,Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,-0.03,Unit_Divide_USD_shares_xtly01YGSEyZ3gCwnLlqCg,2,-0.03,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Basic (in dollars per share),Basic (in dollars per share),IncomeStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_EarningsPerShareBasic_Duration_1_1_2023_To_3_31_2023_y-zxPPLZtEmUIwfawHojag,us-gaap:EarningsPerShareBasic,Duration_1_1_2023_To_3_31_2023_y-zxPPLZtEmUIwfawHojag,0.00,Unit_Divide_USD_shares_xtly01YGSEyZ3gCwnLlqCg,2,0.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Basic (in dollars per share),Basic (in dollars per share),IncomeStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations,2023-01-01,2023-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_EarningsPerShareDiluted_Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,us-gaap:EarningsPerShareDiluted,Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,-0.03,Unit_Divide_USD_shares_xtly01YGSEyZ3gCwnLlqCg,2,-0.03,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Diluted (in dollars per share),Diluted (in dollars per share),IncomeStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_EarningsPerShareDiluted_Duration_1_1_2023_To_3_31_2023_y-zxPPLZtEmUIwfawHojag,us-gaap:EarningsPerShareDiluted,Duration_1_1_2023_To_3_31_2023_y-zxPPLZtEmUIwfawHojag,0.00,Unit_Divide_USD_shares_xtly01YGSEyZ3gCwnLlqCg,2,0.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Diluted (in dollars per share),Diluted (in dollars per share),IncomeStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations,2023-01-01,2023-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_NetIncomeLoss_Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw_0,us-gaap:NetIncomeLoss,Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,-48503000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,-48503000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Net (loss)/profit attributable to ordinary shareholders,Net (loss)/profit attributable to ordinary shareholders,IncomeStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_NetIncomeLoss_Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw_1,us-gaap:NetIncomeLoss,Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,-48503000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,-48503000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Net (loss)/profit attributable to ordinary shareholders,Net (loss)/profit attributable to ordinary shareholders,IncomeStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_NetIncomeLoss_Duration_1_1_2023_To_3_31_2023_y-zxPPLZtEmUIwfawHojag_0,us-gaap:NetIncomeLoss,Duration_1_1_2023_To_3_31_2023_y-zxPPLZtEmUIwfawHojag,1036000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,1036000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Net (loss)/profit attributable to ordinary shareholders,Net (loss)/profit attributable to ordinary shareholders,IncomeStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations,2023-01-01,2023-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_NetIncomeLoss_Duration_1_1_2023_To_3_31_2023_y-zxPPLZtEmUIwfawHojag_1,us-gaap:NetIncomeLoss,Duration_1_1_2023_To_3_31_2023_y-zxPPLZtEmUIwfawHojag,1036000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,1036000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Net (loss)/profit attributable to ordinary shareholders,Net (loss)/profit attributable to ordinary shareholders,IncomeStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations,2023-01-01,2023-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent_Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent,Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,0,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,0.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,"Foreign currency translation adjustments, tax","Foreign currency translation adjustments, tax",ComprehensiveIncomeParenthetical,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLossParenthetical,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent_Duration_1_1_2023_To_3_31_2023_y-zxPPLZtEmUIwfawHojag,us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent,Duration_1_1_2023_To_3_31_2023_y-zxPPLZtEmUIwfawHojag,0,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,0.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,"Foreign currency translation adjustments, tax","Foreign currency translation adjustments, tax",ComprehensiveIncomeParenthetical,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLossParenthetical,2023-01-01,2023-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent,Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,6815000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,6815000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,"Foreign currency translation adjustments, net of tax of $0, and $0","Foreign currency translation adjustments, net of tax of $0, and $0",ComprehensiveIncome,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_Duration_1_1_2023_To_3_31_2023_y-zxPPLZtEmUIwfawHojag,us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent,Duration_1_1_2023_To_3_31_2023_y-zxPPLZtEmUIwfawHojag,-16908000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,-16908000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,"Foreign currency translation adjustments, net of tax of $0, and $0","Foreign currency translation adjustments, net of tax of $0, and $0",ComprehensiveIncome,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss,2023-01-01,2023-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax,Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,-5782000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,-5782000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,"Foreign currency gains (losses) on intercompany loan of a long-term investment nature, net of tax of $0, and $0","Foreign currency gains (losses) on intercompany loan of a long-term investment nature, net of tax of $0, and $0",ComprehensiveIncome,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_Duration_1_1_2023_To_3_31_2023_y-zxPPLZtEmUIwfawHojag,us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax,Duration_1_1_2023_To_3_31_2023_y-zxPPLZtEmUIwfawHojag,15526000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,15526000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,"Foreign currency gains (losses) on intercompany loan of a long-term investment nature, net of tax of $0, and $0","Foreign currency gains (losses) on intercompany loan of a long-term investment nature, net of tax of $0, and $0",ComprehensiveIncome,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss,2023-01-01,2023-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax,Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,-5000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,-5000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,"Unrealized holding gains (losses) on available-for-sale debt securities, net of tax of $0, and $0","Unrealized holding gains (losses) on available-for-sale debt securities, net of tax of $0, and $0",ComprehensiveIncome,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_Duration_1_1_2023_To_3_31_2023_y-zxPPLZtEmUIwfawHojag,us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax,Duration_1_1_2023_To_3_31_2023_y-zxPPLZtEmUIwfawHojag,472000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,472000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,"Unrealized holding gains (losses) on available-for-sale debt securities, net of tax of $0, and $0","Unrealized holding gains (losses) on available-for-sale debt securities, net of tax of $0, and $0",ComprehensiveIncome,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss,2023-01-01,2023-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_ComprehensiveIncomeNetOfTax_Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,us-gaap:ComprehensiveIncomeNetOfTax,Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,-47475000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,-47475000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Total comprehensive (loss)/profit for the period,Total comprehensive (loss)/profit for the period,ComprehensiveIncome,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_ComprehensiveIncomeNetOfTax_Duration_1_1_2023_To_3_31_2023_y-zxPPLZtEmUIwfawHojag,us-gaap:ComprehensiveIncomeNetOfTax,Duration_1_1_2023_To_3_31_2023_y-zxPPLZtEmUIwfawHojag,126000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,126000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Total comprehensive (loss)/profit for the period,Total comprehensive (loss)/profit for the period,ComprehensiveIncome,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss,2023-01-01,2023-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_CommonStockSharesOutstanding_As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_s0ZB1xbbd06xJWtCHj_Hcw,us-gaap:CommonStockSharesOutstanding,As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_s0ZB1xbbd06xJWtCHj_Hcw,1363008102,Unit_Standard_shares_KIp_HZ7W0kSuHGlx3Wi_-g,INF,1363008102.0,instant,2023-12-31,0001621227,http://www.sec.gov/CIK,instant_2023-12-31,"Common stock, shares outstanding","Common stock, shares outstanding",BalanceSheetParenthetical,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical,None,None,us-gaap:CommonStockMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_StockholdersEquity_As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_s0ZB1xbbd06xJWtCHj_Hcw,us-gaap:StockholdersEquity,As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_s0ZB1xbbd06xJWtCHj_Hcw,1865000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,1865000.0,instant,2023-12-31,0001621227,http://www.sec.gov/CIK,instant_2023-12-31,Total stockholders' equity,Total stockholders' equity,BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,us-gaap:CommonStockMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_StockholdersEquity_As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_VCukJAX_VkCLNv1biRznuQ,us-gaap:StockholdersEquity,As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_VCukJAX_VkCLNv1biRznuQ,1064569000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,1064569000.0,instant,2023-12-31,0001621227,http://www.sec.gov/CIK,instant_2023-12-31,Total stockholders' equity,Total stockholders' equity,BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,us-gaap:AdditionalPaidInCapitalMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_StockholdersEquity_As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_tkvdGIkNGU63Xe1bah-Tww,us-gaap:StockholdersEquity,As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_tkvdGIkNGU63Xe1bah-Tww,-3748000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,-3748000.0,instant,2023-12-31,0001621227,http://www.sec.gov/CIK,instant_2023-12-31,Total stockholders' equity,Total stockholders' equity,BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,us-gaap:AccumulatedOtherComprehensiveIncomeMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_StockholdersEquity_As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_zCaUSu4OaU2zJnTmIgy-xg,us-gaap:StockholdersEquity,As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_zCaUSu4OaU2zJnTmIgy-xg,-1023173000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,-1023173000.0,instant,2023-12-31,0001621227,http://www.sec.gov/CIK,instant_2023-12-31,Total stockholders' equity,Total stockholders' equity,BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,us-gaap:RetainedEarningsMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_StockholdersEquity_As_Of_12_31_2023_m48jnprDr0mqVxN2-uk6kw_0,us-gaap:StockholdersEquity,As_Of_12_31_2023_m48jnprDr0mqVxN2-uk6kw,39513000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,39513000.0,instant,2023-12-31,0001621227,http://www.sec.gov/CIK,instant_2023-12-31,Total stockholders' equity,Total stockholders' equity,BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_StockholdersEquity_As_Of_12_31_2023_m48jnprDr0mqVxN2-uk6kw_1,us-gaap:StockholdersEquity,As_Of_12_31_2023_m48jnprDr0mqVxN2-uk6kw,39513000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,39513000.0,instant,2023-12-31,0001621227,http://www.sec.gov/CIK,instant_2023-12-31,Total stockholders' equity,Total stockholders' equity,BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_NetIncomeLoss_Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_3yX5sLfxjkGnEBUxu4efBw,us-gaap:NetIncomeLoss,Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_3yX5sLfxjkGnEBUxu4efBw,-48503000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,-48503000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Net (loss)/profit attributable to ordinary shareholders,Net (loss)/profit attributable to ordinary shareholders,IncomeStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations,2024-01-01,2024-03-31,us-gaap:RetainedEarningsMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_NetIncomeLoss_Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw_2,us-gaap:NetIncomeLoss,Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,-48503000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,-48503000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Net (loss)/profit attributable to ordinary shareholders,Net (loss)/profit attributable to ordinary shareholders,IncomeStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ik82ej81LUa-lrat2TUS3A,us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent,Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ik82ej81LUa-lrat2TUS3A,1028000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,1028000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Other comprehensive loss (gain),Other comprehensive loss (gain),StatementOfEquity,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfChangeInEquity,2024-01-01,2024-03-31,us-gaap:AccumulatedOtherComprehensiveIncomeMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent,Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,1028000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,1028000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Other comprehensive loss (gain),Other comprehensive loss (gain),StatementOfEquity,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfChangeInEquity,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_EhmCXut-u0eHIzr14TUIUA,us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised,Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_EhmCXut-u0eHIzr14TUIUA,6297720,Unit_Standard_shares_KIp_HZ7W0kSuHGlx3Wi_-g,INF,6297720.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Issuance of shares upon exercise of stock options (in shares),Issuance of shares upon exercise of stock options (in shares),StatementOfEquity,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfChangeInEquity,2024-01-01,2024-03-31,us-gaap:CommonStockMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_EhmCXut-u0eHIzr14TUIUA,us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised,Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_EhmCXut-u0eHIzr14TUIUA,8000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,8000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Issuance of shares upon exercise of stock options,Issuance of shares upon exercise of stock options,StatementOfEquity,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfChangeInEquity,2024-01-01,2024-03-31,us-gaap:CommonStockMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_2QJHZLLUqkKJM5HuobgXSg,us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised,Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_2QJHZLLUqkKJM5HuobgXSg,66000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,66000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Issuance of shares upon exercise of stock options,Issuance of shares upon exercise of stock options,StatementOfEquity,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfChangeInEquity,2024-01-01,2024-03-31,us-gaap:AdditionalPaidInCapitalMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised,Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,74000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,74000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Issuance of shares upon exercise of stock options,Issuance of shares upon exercise of stock options,StatementOfEquity,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfChangeInEquity,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
adap_StockSoldDuringPeriodOrdinaryShares_Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_EhmCXut-u0eHIzr14TUIUA,adap:StockSoldDuringPeriodOrdinaryShares,Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_EhmCXut-u0eHIzr14TUIUA,163669056,Unit_Standard_shares_KIp_HZ7W0kSuHGlx3Wi_-g,INF,163669056.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,"Issue of shares under At The Market sales agreement, net of commission and expenses (in shares)","Issue of shares under At The Market sales agreement, net of commission and expenses (in shares)",StatementOfEquity,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfChangeInEquity,2024-01-01,2024-03-31,us-gaap:CommonStockMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
adap_StockSoldDuringPeriodOrdinarySharesValue_Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_EhmCXut-u0eHIzr14TUIUA,adap:StockSoldDuringPeriodOrdinarySharesValue,Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_EhmCXut-u0eHIzr14TUIUA,208000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,208000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,"Issue of shares under At The Market sales agreement, net of commission and expenses","Issue of shares under At The Market sales agreement, net of commission and expenses",StatementOfEquity,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfChangeInEquity,2024-01-01,2024-03-31,us-gaap:CommonStockMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
adap_StockSoldDuringPeriodOrdinarySharesValue_Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_2QJHZLLUqkKJM5HuobgXSg,adap:StockSoldDuringPeriodOrdinarySharesValue,Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_2QJHZLLUqkKJM5HuobgXSg,28953000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,28953000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,"Issue of shares under At The Market sales agreement, net of commission and expenses","Issue of shares under At The Market sales agreement, net of commission and expenses",StatementOfEquity,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfChangeInEquity,2024-01-01,2024-03-31,us-gaap:AdditionalPaidInCapitalMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
adap_StockSoldDuringPeriodOrdinarySharesValue_Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,adap:StockSoldDuringPeriodOrdinarySharesValue,Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,29161000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,29161000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,"Issue of shares under At The Market sales agreement, net of commission and expenses","Issue of shares under At The Market sales agreement, net of commission and expenses",StatementOfEquity,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfChangeInEquity,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_2QJHZLLUqkKJM5HuobgXSg,us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue,Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_2QJHZLLUqkKJM5HuobgXSg,3102000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,3102000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Share-based compensation expense,Share-based compensation expense,StatementOfEquity,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfChangeInEquity,2024-01-01,2024-03-31,us-gaap:AdditionalPaidInCapitalMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue,Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,3102000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,3102000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Share-based compensation expense,Share-based compensation expense,StatementOfEquity,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfChangeInEquity,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_CommonStockSharesOutstanding_As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_OOGIGgvEv0CpBvWTi5dwtQ,us-gaap:CommonStockSharesOutstanding,As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_OOGIGgvEv0CpBvWTi5dwtQ,1532974878,Unit_Standard_shares_KIp_HZ7W0kSuHGlx3Wi_-g,INF,1532974878.0,instant,2024-03-31,0001621227,http://www.sec.gov/CIK,instant_2024-03-31,"Common stock, shares outstanding","Common stock, shares outstanding",BalanceSheetParenthetical,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical,None,None,us-gaap:CommonStockMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_StockholdersEquity_As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_OOGIGgvEv0CpBvWTi5dwtQ,us-gaap:StockholdersEquity,As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_OOGIGgvEv0CpBvWTi5dwtQ,2081000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,2081000.0,instant,2024-03-31,0001621227,http://www.sec.gov/CIK,instant_2024-03-31,Total stockholders' equity,Total stockholders' equity,BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,us-gaap:CommonStockMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_StockholdersEquity_As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_vy22uCZEAE-rg-PhSvCCaQ,us-gaap:StockholdersEquity,As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_vy22uCZEAE-rg-PhSvCCaQ,1096690000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,1096690000.0,instant,2024-03-31,0001621227,http://www.sec.gov/CIK,instant_2024-03-31,Total stockholders' equity,Total stockholders' equity,BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,us-gaap:AdditionalPaidInCapitalMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_StockholdersEquity_As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_v2ut_2fa5ESuyOEeiRPKyg,us-gaap:StockholdersEquity,As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_v2ut_2fa5ESuyOEeiRPKyg,-2720000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,-2720000.0,instant,2024-03-31,0001621227,http://www.sec.gov/CIK,instant_2024-03-31,Total stockholders' equity,Total stockholders' equity,BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,us-gaap:AccumulatedOtherComprehensiveIncomeMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_StockholdersEquity_As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_bVEE-Hc98kinr-zkpD3TcQ,us-gaap:StockholdersEquity,As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_bVEE-Hc98kinr-zkpD3TcQ,-1071676000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,-1071676000.0,instant,2024-03-31,0001621227,http://www.sec.gov/CIK,instant_2024-03-31,Total stockholders' equity,Total stockholders' equity,BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,us-gaap:RetainedEarningsMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_StockholdersEquity_As_Of_3_31_2024_Ebq-QFBYXEGIOthDpC9wWw_0,us-gaap:StockholdersEquity,As_Of_3_31_2024_Ebq-QFBYXEGIOthDpC9wWw,24375000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,24375000.0,instant,2024-03-31,0001621227,http://www.sec.gov/CIK,instant_2024-03-31,Total stockholders' equity,Total stockholders' equity,BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_StockholdersEquity_As_Of_3_31_2024_Ebq-QFBYXEGIOthDpC9wWw_1,us-gaap:StockholdersEquity,As_Of_3_31_2024_Ebq-QFBYXEGIOthDpC9wWw,24375000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,24375000.0,instant,2024-03-31,0001621227,http://www.sec.gov/CIK,instant_2024-03-31,Total stockholders' equity,Total stockholders' equity,BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_CommonStockSharesOutstanding_As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_wH8h4X1Y60mQ2HtpAU9tqQ,us-gaap:CommonStockSharesOutstanding,As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_wH8h4X1Y60mQ2HtpAU9tqQ,987109890,Unit_Standard_shares_KIp_HZ7W0kSuHGlx3Wi_-g,INF,987109890.0,instant,2022-12-31,0001621227,http://www.sec.gov/CIK,instant_2022-12-31,"Common stock, shares outstanding","Common stock, shares outstanding",BalanceSheetParenthetical,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical,None,None,us-gaap:CommonStockMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_StockholdersEquity_As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_wH8h4X1Y60mQ2HtpAU9tqQ,us-gaap:StockholdersEquity,As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_wH8h4X1Y60mQ2HtpAU9tqQ,1399000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,1399000.0,instant,2022-12-31,0001621227,http://www.sec.gov/CIK,instant_2022-12-31,Total stockholders' equity,Total stockholders' equity,BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,us-gaap:CommonStockMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_StockholdersEquity_As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ioc7fybIAUSUW8BsIsWSrg,us-gaap:StockholdersEquity,As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ioc7fybIAUSUW8BsIsWSrg,990656000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,990656000.0,instant,2022-12-31,0001621227,http://www.sec.gov/CIK,instant_2022-12-31,Total stockholders' equity,Total stockholders' equity,BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,us-gaap:AdditionalPaidInCapitalMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_StockholdersEquity_As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_hME9tfmP2kaZUkIIyxGkiw,us-gaap:StockholdersEquity,As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_hME9tfmP2kaZUkIIyxGkiw,-875000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,-875000.0,instant,2022-12-31,0001621227,http://www.sec.gov/CIK,instant_2022-12-31,Total stockholders' equity,Total stockholders' equity,BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,us-gaap:AccumulatedOtherComprehensiveIncomeMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_StockholdersEquity_As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_7yHododDw0CL7fu-e9hRDw,us-gaap:StockholdersEquity,As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_7yHododDw0CL7fu-e9hRDw,-909302000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,-909302000.0,instant,2022-12-31,0001621227,http://www.sec.gov/CIK,instant_2022-12-31,Total stockholders' equity,Total stockholders' equity,BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,us-gaap:RetainedEarningsMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_StockholdersEquity_As_Of_12_31_2022_aIRltQ4-eU6S3p9bqmhjag,us-gaap:StockholdersEquity,As_Of_12_31_2022_aIRltQ4-eU6S3p9bqmhjag,81878000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,81878000.0,instant,2022-12-31,0001621227,http://www.sec.gov/CIK,instant_2022-12-31,Total stockholders' equity,Total stockholders' equity,BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_NetIncomeLoss_Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Bd8gD_oKmE-Iptg5CUmB8w,us-gaap:NetIncomeLoss,Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Bd8gD_oKmE-Iptg5CUmB8w,1036000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,1036000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Net (loss)/profit attributable to ordinary shareholders,Net (loss)/profit attributable to ordinary shareholders,IncomeStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations,2023-01-01,2023-03-31,us-gaap:RetainedEarningsMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_NetIncomeLoss_Duration_1_1_2023_To_3_31_2023_y-zxPPLZtEmUIwfawHojag_2,us-gaap:NetIncomeLoss,Duration_1_1_2023_To_3_31_2023_y-zxPPLZtEmUIwfawHojag,1036000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,1036000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Net (loss)/profit attributable to ordinary shareholders,Net (loss)/profit attributable to ordinary shareholders,IncomeStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations,2023-01-01,2023-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_brTNdJkkYEGDtW7dPYUueg,us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent,Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_brTNdJkkYEGDtW7dPYUueg,-910000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,-910000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Other comprehensive loss (gain),Other comprehensive loss (gain),StatementOfEquity,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfChangeInEquity,2023-01-01,2023-03-31,us-gaap:AccumulatedOtherComprehensiveIncomeMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_Duration_1_1_2023_To_3_31_2023_y-zxPPLZtEmUIwfawHojag,us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent,Duration_1_1_2023_To_3_31_2023_y-zxPPLZtEmUIwfawHojag,-910000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,-910000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Other comprehensive loss (gain),Other comprehensive loss (gain),StatementOfEquity,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfChangeInEquity,2023-01-01,2023-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_qNCKBdPFH02vUp7r8Cr9Aw,us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised,Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_qNCKBdPFH02vUp7r8Cr9Aw,6035574,Unit_Standard_shares_KIp_HZ7W0kSuHGlx3Wi_-g,INF,6035574.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Issuance of shares upon exercise of stock options (in shares),Issuance of shares upon exercise of stock options (in shares),StatementOfEquity,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfChangeInEquity,2023-01-01,2023-03-31,us-gaap:CommonStockMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_qNCKBdPFH02vUp7r8Cr9Aw,us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised,Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_qNCKBdPFH02vUp7r8Cr9Aw,7000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,7000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Issuance of shares upon exercise of stock options,Issuance of shares upon exercise of stock options,StatementOfEquity,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfChangeInEquity,2023-01-01,2023-03-31,us-gaap:CommonStockMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ILb4UoHa2kCDkaSEdzZSFw,us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised,Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ILb4UoHa2kCDkaSEdzZSFw,1000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,1000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Issuance of shares upon exercise of stock options,Issuance of shares upon exercise of stock options,StatementOfEquity,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfChangeInEquity,2023-01-01,2023-03-31,us-gaap:AdditionalPaidInCapitalMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_Duration_1_1_2023_To_3_31_2023_y-zxPPLZtEmUIwfawHojag,us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised,Duration_1_1_2023_To_3_31_2023_y-zxPPLZtEmUIwfawHojag,8000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,8000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Issuance of shares upon exercise of stock options,Issuance of shares upon exercise of stock options,StatementOfEquity,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfChangeInEquity,2023-01-01,2023-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_StockIssuedDuringPeriodSharesNewIssues_Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_qNCKBdPFH02vUp7r8Cr9Aw,us-gaap:StockIssuedDuringPeriodSharesNewIssues,Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_qNCKBdPFH02vUp7r8Cr9Aw,554496,Unit_Standard_shares_KIp_HZ7W0kSuHGlx3Wi_-g,INF,554496.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,"Issuance of shares upon completion of public offering, net of issuance costs (in shares)","Issuance of shares upon completion of public offering, net of issuance costs (in shares)",StatementOfEquity,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfChangeInEquity,2023-01-01,2023-03-31,us-gaap:CommonStockMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_StockIssuedDuringPeriodValueNewIssues_Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_qNCKBdPFH02vUp7r8Cr9Aw,us-gaap:StockIssuedDuringPeriodValueNewIssues,Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_qNCKBdPFH02vUp7r8Cr9Aw,1000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,1000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,"Issuance of shares upon completion of public offering, net of issuance costs","Issuance of shares upon completion of public offering, net of issuance costs",StatementOfEquity,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfChangeInEquity,2023-01-01,2023-03-31,us-gaap:CommonStockMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_StockIssuedDuringPeriodValueNewIssues_Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ILb4UoHa2kCDkaSEdzZSFw,us-gaap:StockIssuedDuringPeriodValueNewIssues,Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ILb4UoHa2kCDkaSEdzZSFw,187000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,187000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,"Issuance of shares upon completion of public offering, net of issuance costs","Issuance of shares upon completion of public offering, net of issuance costs",StatementOfEquity,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfChangeInEquity,2023-01-01,2023-03-31,us-gaap:AdditionalPaidInCapitalMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_StockIssuedDuringPeriodValueNewIssues_Duration_1_1_2023_To_3_31_2023_y-zxPPLZtEmUIwfawHojag,us-gaap:StockIssuedDuringPeriodValueNewIssues,Duration_1_1_2023_To_3_31_2023_y-zxPPLZtEmUIwfawHojag,188000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,188000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,"Issuance of shares upon completion of public offering, net of issuance costs","Issuance of shares upon completion of public offering, net of issuance costs",StatementOfEquity,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfChangeInEquity,2023-01-01,2023-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ILb4UoHa2kCDkaSEdzZSFw,us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue,Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ILb4UoHa2kCDkaSEdzZSFw,1676000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,1676000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Share-based compensation expense,Share-based compensation expense,StatementOfEquity,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfChangeInEquity,2023-01-01,2023-03-31,us-gaap:AdditionalPaidInCapitalMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_Duration_1_1_2023_To_3_31_2023_y-zxPPLZtEmUIwfawHojag,us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue,Duration_1_1_2023_To_3_31_2023_y-zxPPLZtEmUIwfawHojag,1676000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,1676000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Share-based compensation expense,Share-based compensation expense,StatementOfEquity,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfChangeInEquity,2023-01-01,2023-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_CommonStockSharesOutstanding_As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_YvoVRNPKqUaOMqQKt6n4sg,us-gaap:CommonStockSharesOutstanding,As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_YvoVRNPKqUaOMqQKt6n4sg,993699960,Unit_Standard_shares_KIp_HZ7W0kSuHGlx3Wi_-g,INF,993699960.0,instant,2023-03-31,0001621227,http://www.sec.gov/CIK,instant_2023-03-31,"Common stock, shares outstanding","Common stock, shares outstanding",BalanceSheetParenthetical,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical,None,None,us-gaap:CommonStockMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_StockholdersEquity_As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_YvoVRNPKqUaOMqQKt6n4sg,us-gaap:StockholdersEquity,As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_YvoVRNPKqUaOMqQKt6n4sg,1407000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,1407000.0,instant,2023-03-31,0001621227,http://www.sec.gov/CIK,instant_2023-03-31,Total stockholders' equity,Total stockholders' equity,BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,us-gaap:CommonStockMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_StockholdersEquity_As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Vc1kp0SOrUGz1zv0oCPRbg,us-gaap:StockholdersEquity,As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Vc1kp0SOrUGz1zv0oCPRbg,992520000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,992520000.0,instant,2023-03-31,0001621227,http://www.sec.gov/CIK,instant_2023-03-31,Total stockholders' equity,Total stockholders' equity,BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,us-gaap:AdditionalPaidInCapitalMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_StockholdersEquity_As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_eUwaKI6UPUS6nbtSznTejA,us-gaap:StockholdersEquity,As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_eUwaKI6UPUS6nbtSznTejA,-1785000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,-1785000.0,instant,2023-03-31,0001621227,http://www.sec.gov/CIK,instant_2023-03-31,Total stockholders' equity,Total stockholders' equity,BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,us-gaap:AccumulatedOtherComprehensiveIncomeMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_StockholdersEquity_As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_7slT0IaI_kiwq9Lu_VftmA,us-gaap:StockholdersEquity,As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_7slT0IaI_kiwq9Lu_VftmA,-908266000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,-908266000.0,instant,2023-03-31,0001621227,http://www.sec.gov/CIK,instant_2023-03-31,Total stockholders' equity,Total stockholders' equity,BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,us-gaap:RetainedEarningsMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_StockholdersEquity_As_Of_3_31_2023_E8kJdIyzokqSPfzFvPVD9g,us-gaap:StockholdersEquity,As_Of_3_31_2023_E8kJdIyzokqSPfzFvPVD9g,83876000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,83876000.0,instant,2023-03-31,0001621227,http://www.sec.gov/CIK,instant_2023-03-31,Total stockholders' equity,Total stockholders' equity,BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_ProfitLoss_Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,us-gaap:ProfitLoss,Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,-48503000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,-48503000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Net (loss)/profit,Net (loss)/profit,CashFlowStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlows,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_ProfitLoss_Duration_1_1_2023_To_3_31_2023_y-zxPPLZtEmUIwfawHojag,us-gaap:ProfitLoss,Duration_1_1_2023_To_3_31_2023_y-zxPPLZtEmUIwfawHojag,1036000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,1036000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Net (loss)/profit,Net (loss)/profit,CashFlowStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlows,2023-01-01,2023-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_Depreciation_Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,us-gaap:Depreciation,Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,2771000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,2771000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Depreciation,Depreciation,CashFlowStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlows,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_Depreciation_Duration_1_1_2023_To_3_31_2023_y-zxPPLZtEmUIwfawHojag,us-gaap:Depreciation,Duration_1_1_2023_To_3_31_2023_y-zxPPLZtEmUIwfawHojag,1659000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,1659000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Depreciation,Depreciation,CashFlowStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlows,2023-01-01,2023-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_AdjustmentForAmortization_Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,us-gaap:AdjustmentForAmortization,Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,59000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,59000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Amortization,Amortization,CashFlowStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlows,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_AdjustmentForAmortization_Duration_1_1_2023_To_3_31_2023_y-zxPPLZtEmUIwfawHojag,us-gaap:AdjustmentForAmortization,Duration_1_1_2023_To_3_31_2023_y-zxPPLZtEmUIwfawHojag,186000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,186000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Amortization,Amortization,CashFlowStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlows,2023-01-01,2023-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_ShareBasedCompensation_Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,us-gaap:ShareBasedCompensation,Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,3102000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,3102000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Share-based compensation expense,Share-based compensation expense,CashFlowStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlows,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_ShareBasedCompensation_Duration_1_1_2023_To_3_31_2023_y-zxPPLZtEmUIwfawHojag,us-gaap:ShareBasedCompensation,Duration_1_1_2023_To_3_31_2023_y-zxPPLZtEmUIwfawHojag,1676000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,1676000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Share-based compensation expense,Share-based compensation expense,CashFlowStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlows,2023-01-01,2023-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_ForeignCurrencyTransactionGainLossUnrealized_Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,us-gaap:ForeignCurrencyTransactionGainLossUnrealized,Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,305000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,305000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Unrealized foreign exchange losses,Unrealized foreign exchange losses,CashFlowStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlows,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_ForeignCurrencyTransactionGainLossUnrealized_Duration_1_1_2023_To_3_31_2023_y-zxPPLZtEmUIwfawHojag,us-gaap:ForeignCurrencyTransactionGainLossUnrealized,Duration_1_1_2023_To_3_31_2023_y-zxPPLZtEmUIwfawHojag,563000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,563000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Unrealized foreign exchange losses,Unrealized foreign exchange losses,CashFlowStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlows,2023-01-01,2023-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
adap_AccretionAmortizationOnAvailableForSaleDebtSecurities_Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,adap:AccretionAmortizationOnAvailableForSaleDebtSecurities,Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,-23000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,-23000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,(Accretion)/amortization on available-for-sale debt securities,(Accretion)/amortization on available-for-sale debt securities,CashFlowStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlows,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
adap_AccretionAmortizationOnAvailableForSaleDebtSecurities_Duration_1_1_2023_To_3_31_2023_y-zxPPLZtEmUIwfawHojag,adap:AccretionAmortizationOnAvailableForSaleDebtSecurities,Duration_1_1_2023_To_3_31_2023_y-zxPPLZtEmUIwfawHojag,112000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,112000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,(Accretion)/amortization on available-for-sale debt securities,(Accretion)/amortization on available-for-sale debt securities,CashFlowStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlows,2023-01-01,2023-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_OtherOperatingActivitiesCashFlowStatement_Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,us-gaap:OtherOperatingActivitiesCashFlowStatement,Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,-19000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,-19000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Other,Other,CashFlowStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlows,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_OtherOperatingActivitiesCashFlowStatement_Duration_1_1_2023_To_3_31_2023_y-zxPPLZtEmUIwfawHojag,us-gaap:OtherOperatingActivitiesCashFlowStatement,Duration_1_1_2023_To_3_31_2023_y-zxPPLZtEmUIwfawHojag,134000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,134000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Other,Other,CashFlowStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlows,2023-01-01,2023-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
adap_IncreaseDecreaseInCurrentAssets_Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,adap:IncreaseDecreaseInCurrentAssets,Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,15620000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,15620000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Decrease in receivables and other operating assets,Decrease in receivables and other operating assets,CashFlowStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlows,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
adap_IncreaseDecreaseInCurrentAssets_Duration_1_1_2023_To_3_31_2023_y-zxPPLZtEmUIwfawHojag,adap:IncreaseDecreaseInCurrentAssets,Duration_1_1_2023_To_3_31_2023_y-zxPPLZtEmUIwfawHojag,3683000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,3683000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Decrease in receivables and other operating assets,Decrease in receivables and other operating assets,CashFlowStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlows,2023-01-01,2023-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities_Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities,Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,-7650000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,-7650000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,(Decrease)/increase in payables and other current liabilities,(Decrease)/increase in payables and other current liabilities,CashFlowStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlows,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities_Duration_1_1_2023_To_3_31_2023_y-zxPPLZtEmUIwfawHojag,us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities,Duration_1_1_2023_To_3_31_2023_y-zxPPLZtEmUIwfawHojag,21000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,21000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,(Decrease)/increase in payables and other current liabilities,(Decrease)/increase in payables and other current liabilities,CashFlowStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlows,2023-01-01,2023-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_IncreaseDecreaseInContractWithCustomerLiability_Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,us-gaap:IncreaseDecreaseInContractWithCustomerLiability,Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,2388000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,2388000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Increase/(decrease) in deferred revenue,Increase/(decrease) in deferred revenue,CashFlowStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlows,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_IncreaseDecreaseInContractWithCustomerLiability_Duration_1_1_2023_To_3_31_2023_y-zxPPLZtEmUIwfawHojag,us-gaap:IncreaseDecreaseInContractWithCustomerLiability,Duration_1_1_2023_To_3_31_2023_y-zxPPLZtEmUIwfawHojag,-46353000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,-46353000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Increase/(decrease) in deferred revenue,Increase/(decrease) in deferred revenue,CashFlowStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlows,2023-01-01,2023-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_NetCashProvidedByUsedInOperatingActivities_Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,us-gaap:NetCashProvidedByUsedInOperatingActivities,Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,-31950000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,-31950000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Net cash used in operating activities,Net cash used in operating activities,CashFlowStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlows,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_NetCashProvidedByUsedInOperatingActivities_Duration_1_1_2023_To_3_31_2023_y-zxPPLZtEmUIwfawHojag,us-gaap:NetCashProvidedByUsedInOperatingActivities,Duration_1_1_2023_To_3_31_2023_y-zxPPLZtEmUIwfawHojag,-37283000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,-37283000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Net cash used in operating activities,Net cash used in operating activities,CashFlowStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlows,2023-01-01,2023-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,us-gaap:PaymentsToAcquirePropertyPlantAndEquipment,Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,-102000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,-102000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,"Acquisition of property, plant and equipment","Acquisition of property, plant and equipment",CashFlowStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlows,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_Duration_1_1_2023_To_3_31_2023_y-zxPPLZtEmUIwfawHojag,us-gaap:PaymentsToAcquirePropertyPlantAndEquipment,Duration_1_1_2023_To_3_31_2023_y-zxPPLZtEmUIwfawHojag,-2349000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,-2349000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,"Acquisition of property, plant and equipment","Acquisition of property, plant and equipment",CashFlowStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlows,2023-01-01,2023-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_PaymentsToAcquireIntangibleAssets_Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,us-gaap:PaymentsToAcquireIntangibleAssets,Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,-256000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,-256000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Acquisition of intangible assets,Acquisition of intangible assets,CashFlowStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlows,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_PaymentsToAcquireIntangibleAssets_Duration_1_1_2023_To_3_31_2023_y-zxPPLZtEmUIwfawHojag,us-gaap:PaymentsToAcquireIntangibleAssets,Duration_1_1_2023_To_3_31_2023_y-zxPPLZtEmUIwfawHojag,-173000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,-173000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Acquisition of intangible assets,Acquisition of intangible assets,CashFlowStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlows,2023-01-01,2023-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_Duration_1_1_2023_To_3_31_2023_y-zxPPLZtEmUIwfawHojag,us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities,Duration_1_1_2023_To_3_31_2023_y-zxPPLZtEmUIwfawHojag,50863000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,50863000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Maturity or redemption of marketable securities,Maturity or redemption of marketable securities,CashFlowStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlows,2023-01-01,2023-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_NetCashProvidedByUsedInInvestingActivities_Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,us-gaap:NetCashProvidedByUsedInInvestingActivities,Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,-358000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,-358000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Net cash (used in)/provided by investing activities,Net cash (used in)/provided by investing activities,CashFlowStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlows,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_NetCashProvidedByUsedInInvestingActivities_Duration_1_1_2023_To_3_31_2023_y-zxPPLZtEmUIwfawHojag,us-gaap:NetCashProvidedByUsedInInvestingActivities,Duration_1_1_2023_To_3_31_2023_y-zxPPLZtEmUIwfawHojag,48341000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,48341000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Net cash (used in)/provided by investing activities,Net cash (used in)/provided by investing activities,CashFlowStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlows,2023-01-01,2023-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_ProceedsFromIssuanceOfCommonStock_Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,us-gaap:ProceedsFromIssuanceOfCommonStock,Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,29161000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,29161000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,"Proceeds from issuance of common stock from offerings, net of commissions and issuance costs","Proceeds from issuance of common stock from offerings, net of commissions and issuance costs",CashFlowStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlows,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_ProceedsFromIssuanceOfCommonStock_Duration_1_1_2023_To_3_31_2023_y-zxPPLZtEmUIwfawHojag,us-gaap:ProceedsFromIssuanceOfCommonStock,Duration_1_1_2023_To_3_31_2023_y-zxPPLZtEmUIwfawHojag,188000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,188000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,"Proceeds from issuance of common stock from offerings, net of commissions and issuance costs","Proceeds from issuance of common stock from offerings, net of commissions and issuance costs",CashFlowStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlows,2023-01-01,2023-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_ProceedsFromStockOptionsExercised_Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,us-gaap:ProceedsFromStockOptionsExercised,Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,74000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,74000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Proceeds from exercise of stock options,Proceeds from exercise of stock options,CashFlowStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlows,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_ProceedsFromStockOptionsExercised_Duration_1_1_2023_To_3_31_2023_y-zxPPLZtEmUIwfawHojag,us-gaap:ProceedsFromStockOptionsExercised,Duration_1_1_2023_To_3_31_2023_y-zxPPLZtEmUIwfawHojag,8000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,8000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Proceeds from exercise of stock options,Proceeds from exercise of stock options,CashFlowStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlows,2023-01-01,2023-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_NetCashProvidedByUsedInFinancingActivities_Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,us-gaap:NetCashProvidedByUsedInFinancingActivities,Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,29235000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,29235000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Net cash provided by financing activities,Net cash provided by financing activities,CashFlowStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlows,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_NetCashProvidedByUsedInFinancingActivities_Duration_1_1_2023_To_3_31_2023_y-zxPPLZtEmUIwfawHojag,us-gaap:NetCashProvidedByUsedInFinancingActivities,Duration_1_1_2023_To_3_31_2023_y-zxPPLZtEmUIwfawHojag,196000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,196000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Net cash provided by financing activities,Net cash provided by financing activities,CashFlowStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlows,2023-01-01,2023-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents,Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,-416000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,-416000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,"Effect of currency exchange rate changes on cash, cash equivalents and restricted cash","Effect of currency exchange rate changes on cash, cash equivalents and restricted cash",CashFlowStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlows,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_Duration_1_1_2023_To_3_31_2023_y-zxPPLZtEmUIwfawHojag,us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents,Duration_1_1_2023_To_3_31_2023_y-zxPPLZtEmUIwfawHojag,588000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,588000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,"Effect of currency exchange rate changes on cash, cash equivalents and restricted cash","Effect of currency exchange rate changes on cash, cash equivalents and restricted cash",CashFlowStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlows,2023-01-01,2023-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect,Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,-3489000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,-3489000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,"Net (decrease)/increase in cash, cash equivalents and restricted cash","Net (decrease)/increase in cash, cash equivalents and restricted cash",CashFlowStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlows,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_Duration_1_1_2023_To_3_31_2023_y-zxPPLZtEmUIwfawHojag,us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect,Duration_1_1_2023_To_3_31_2023_y-zxPPLZtEmUIwfawHojag,11842000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,11842000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,"Net (decrease)/increase in cash, cash equivalents and restricted cash","Net (decrease)/increase in cash, cash equivalents and restricted cash",CashFlowStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlows,2023-01-01,2023-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_As_Of_12_31_2023_m48jnprDr0mqVxN2-uk6kw,us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents,As_Of_12_31_2023_m48jnprDr0mqVxN2-uk6kw,147017000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,147017000.0,instant,2023-12-31,0001621227,http://www.sec.gov/CIK,instant_2023-12-31,"Cash, cash equivalents and restricted cash at end of period","Cash, cash equivalents and restricted cash at end of period",CashFlowStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlows,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_As_Of_12_31_2022_aIRltQ4-eU6S3p9bqmhjag,us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents,As_Of_12_31_2022_aIRltQ4-eU6S3p9bqmhjag,109602000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,109602000.0,instant,2022-12-31,0001621227,http://www.sec.gov/CIK,instant_2022-12-31,"Cash, cash equivalents and restricted cash at end of period","Cash, cash equivalents and restricted cash at end of period",CashFlowStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlows,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_As_Of_3_31_2024_Ebq-QFBYXEGIOthDpC9wWw,us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents,As_Of_3_31_2024_Ebq-QFBYXEGIOthDpC9wWw,143528000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,143528000.0,instant,2024-03-31,0001621227,http://www.sec.gov/CIK,instant_2024-03-31,"Cash, cash equivalents and restricted cash at end of period","Cash, cash equivalents and restricted cash at end of period",CashFlowStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlows,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_As_Of_3_31_2023_E8kJdIyzokqSPfzFvPVD9g,us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents,As_Of_3_31_2023_E8kJdIyzokqSPfzFvPVD9g,121444000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,121444000.0,instant,2023-03-31,0001621227,http://www.sec.gov/CIK,instant_2023-03-31,"Cash, cash equivalents and restricted cash at end of period","Cash, cash equivalents and restricted cash at end of period",CashFlowStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlows,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_NatureOfOperations_Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,us-gaap:NatureOfOperations,Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,"<p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;""><b style=""font-weight:bold;"">Note 1 </b><b style=""font-weight:bold;"">—</b><b style=""font-weight:bold;""> General</b></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">Adaptimmune Therapeutics plc is registered in England and Wales. Its registered office is 60 Jubilee Avenue, Milton Park, Abingdon, Oxfordshire, OX14 4RX, United Kingdom. Adaptimmune Therapeutics plc and its subsidiaries (collectively “Adaptimmune” or the “Company”) is a clinical-stage biopharmaceutical company primarily focused on providing novel cell therapies to people with cancer. We are a leader in the development of T-cell therapies for solid tumors. The Company’s proprietary platform enables it to identify cancer targets, find and develop cell therapy candidates active against those targets and produce therapeutic candidates for administration to patients. </p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">The Company is subject to a number of risks similar to other biopharmaceutical companies in the clinical development stage including, but not limited to, the need to obtain adequate additional funding, possible failure of preclinical programs or clinical programs, the need to obtain marketing approval for its cell therapies, competitors developing new technological innovations, the need to successfully commercialize and gain market acceptance of its cell therapies, the need to develop a reliable commercial manufacturing process, the need to commercialize any cell therapies that may be approved for marketing, and protection of proprietary technology. If the Company does not successfully commercialize any of its cell therapies, it will be unable to generate product revenue or achieve profitability. The Company had an accumulated deficit of $1,071,676,000 as of March 31, 2024.</p>",None,None,,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,General,General,Disclosures,http://www.adaptimmune.com/role/DisclosureGeneral,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_RetainedEarningsAccumulatedDeficit_As_Of_3_31_2024_Ebq-QFBYXEGIOthDpC9wWw_0,us-gaap:RetainedEarningsAccumulatedDeficit,As_Of_3_31_2024_Ebq-QFBYXEGIOthDpC9wWw,-1071676000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,-1071676000.0,instant,2024-03-31,0001621227,http://www.sec.gov/CIK,instant_2024-03-31,Accumulated deficit,Accumulated deficit,BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_RetainedEarningsAccumulatedDeficit_As_Of_3_31_2024_Ebq-QFBYXEGIOthDpC9wWw_1,us-gaap:RetainedEarningsAccumulatedDeficit,As_Of_3_31_2024_Ebq-QFBYXEGIOthDpC9wWw,-1071676000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,-1071676000.0,instant,2024-03-31,0001621227,http://www.sec.gov/CIK,instant_2024-03-31,Accumulated deficit,Accumulated deficit,BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock,Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,"<p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;""><b style=""font-weight:bold;"">Note 2 </b><b style=""font-weight:bold;"">—</b><b style=""font-weight:bold;""> Summary of Significant Accounting Policies </b></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;""><b style=""font-weight:bold;"">(a)          Basis of presentation</b></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">The condensed consolidated financial statements of Adaptimmune Therapeutics plc and its subsidiaries and other financial information included in this Quarterly Report are unaudited and have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”) and are presented in U.S. dollars. All significant intercompany accounts and transactions between the Company and its subsidiaries have been eliminated on consolidation.</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">The unaudited condensed consolidated financial statements presented in this Quarterly Report should be read in conjunction with the consolidated financial statements and accompanying notes included in the Company’s Annual Report on Form 10-K filed with the SEC on March 6, 2024 (the “Annual Report”). The balance sheet as of December 31, 2023 was derived from audited consolidated financial statements included in the Company’s Annual Report but does not include all disclosures required by U.S. GAAP. The Company’s significant accounting policies are described in Note 2 to those consolidated financial statements.</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted from these interim financial statements. However, these interim financial statements include all adjustments, consisting only of normal recurring adjustments, which are, in the opinion of management, necessary to fairly state the results of the interim period. The interim results are not necessarily indicative of results to be expected for the full year.</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;""><b style=""font-weight:bold;"">(b)          Use of estimates in interim financial statements</b></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">The preparation of interim financial statements, in conformity with U.S. GAAP and SEC regulations, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the interim financial statements and reported amounts of revenues and expenses during the reporting period. Estimates and assumptions are made in various areas, including in relation to valuation allowances relating to deferred tax assets, revenue recognition, the fair value of assets acquired, liabilities assumed and consideration transferred in business combinations, and estimation of the incremental borrowing rate for operating leases. If actual results differ from the Company’s estimates, or to the extent these estimates are adjusted in future periods, the Company’s results of operations could either benefit from, or be adversely affected by, any such change in estimate.</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;""><b style=""font-weight:bold;"">(c)          Fair value measurements</b></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">The Company is required to disclose information on all assets and liabilities reported at fair value that enables an assessment of the inputs used in determining the reported fair values. The fair value hierarchy prioritizes valuation inputs based on the observable nature of those inputs. The hierarchy defines three levels of valuation inputs:</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">Level 1 - Quoted prices in active markets for identical assets or liabilities</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">Level 2 - Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">Level 3 - Unobservable inputs that reflect the Company's own assumptions about the assumptions market participants would use in pricing the asset or liability</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">The carrying amounts of the Company’s cash and cash equivalents, restricted cash, accounts receivable, accounts payable and accrued expenses approximate fair value because of the short-term nature of these instruments. The fair value of marketable securities, which are measured at fair value on a recurring basis is detailed in Note 6, Fair value measurements.</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;""><b style=""font-weight:bold;"">(d</b><b style=""font-weight:bold;"">)          Significant concentrations of credit risk</b></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">The Company held cash and cash equivalents of $140,670,000, marketable securities of $2,982,000 and restricted cash of $2,858,000 as of March 31, 2024. The cash and cash equivalents and restricted cash are held with multiple banks and the Company monitors the credit rating of those banks. The Company maintains cash balances in excess of amounts insured by the Federal Deposit Insurance Corporation in the United States and the U.K. Government Financial Services Compensation Scheme in the United Kingdom. The Company’s investment policy limits investments to certain types of instruments, such as money market instruments, corporate debt securities and commercial paper, places restrictions on maturities and concentration by type and issuer and specifies the minimum credit ratings for all investments and the average credit quality of the portfolio.</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">The Company had two customers during the three months ended March 31, 2024 which are Genentech and GSK. There were accounts receivable of $8,404,000 as of March 31, 2024 and $821,000 as of December 31, 2023. The Company has been transacting with Genentech since 2021 and GSK since 2014, during which time no credit losses have been recognized. As of March 31, 2024, no allowance for expected credit losses is recognized on the basis that the possibility of credit losses arising on its receivables as of March 31, 2024 is considered to be remote. As of March 31, 2024 there are no receivables, either accrued or billed, due from Genentech that are no longer recoverable following the termination of the Genentech Collaboration and License Agreement.</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">Management analyses current and past due accounts and determines if an allowance for credit losses is required based on collection experience, credit worthiness of customers and other relevant information. The process of estimating the uncollectible accounts involves assumptions and judgments and the ultimate amounts of uncollectible accounts receivable could be in excess of the amounts provided.</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;""><b style=""font-weight:bold;white-space:pre-wrap;"">(e)          New accounting pronouncements</b></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;""><i style=""font-style:italic;"">Adopted in the current period</i></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><i style=""font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"">Improvements to Reportable Segment Disclosures</i></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""display:inline-block;text-indent:0pt;width:36pt;""></span>In November 2023, the FASB issued ASU 2023-07 – Segment Reporting (Topic 280) – Improvements to Reportable Segment Disclosures, which improves segment disclosure requirements, primarily through enhanced disclosure requirements for significant segment expenses. The improved disclosure requirements apply to all public entities that are required to report segment information, including those with only one reportable segment. The Company adopted the guidance in the fiscal year beginning January 1, 2024. There was no impact on the Company’s reportable segments identified and additional required disclosures have been included in Note 14.</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-style:italic;visibility:hidden;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-style:italic;visibility:hidden;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-style:italic;visibility:hidden;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><i style=""font-style:italic;"">To be adopted in future periods</i></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-style:italic;visibility:hidden;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><i style=""font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"">Improves to Income Tax Disclosures</i></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"">In December 2023, the FASB issued ASU 2023-09 – Income Taxes (Topic 740) – Improvements to Income Tax Disclosures, which improves income tax disclosures primarily relating to the rate reconciliation and income taxes paid information. This includes a tabular reconciliation using both percentages and reporting currency amounts, covering various tax and reconciling items, and disaggregated summaries of income taxes paid during the period. For public business entities, the guidance is effective for annual periods beginning after December 15, 2024, with early adoption permitted. The Company intends to adopt the guidance in the fiscal year beginning January 1, 2025. The Company is currently evaluating the impact of the guidance on its Consolidated financial statements.</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:28.35pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p>",None,None,,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Summary of Significant Accounting Policies,Summary of Significant Accounting Policies,Disclosures,http://www.adaptimmune.com/role/DisclosureSummaryOfSignificantAccountingPolicies,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_BasisOfAccountingPolicyPolicyTextBlock_Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,us-gaap:BasisOfAccountingPolicyPolicyTextBlock,Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,"<p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;""><b style=""font-weight:bold;"">(a)          Basis of presentation</b></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">The condensed consolidated financial statements of Adaptimmune Therapeutics plc and its subsidiaries and other financial information included in this Quarterly Report are unaudited and have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”) and are presented in U.S. dollars. All significant intercompany accounts and transactions between the Company and its subsidiaries have been eliminated on consolidation.</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">The unaudited condensed consolidated financial statements presented in this Quarterly Report should be read in conjunction with the consolidated financial statements and accompanying notes included in the Company’s Annual Report on Form 10-K filed with the SEC on March 6, 2024 (the “Annual Report”). The balance sheet as of December 31, 2023 was derived from audited consolidated financial statements included in the Company’s Annual Report but does not include all disclosures required by U.S. GAAP. The Company’s significant accounting policies are described in Note 2 to those consolidated financial statements.</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted from these interim financial statements. However, these interim financial statements include all adjustments, consisting only of normal recurring adjustments, which are, in the opinion of management, necessary to fairly state the results of the interim period. The interim results are not necessarily indicative of results to be expected for the full year.</p>",None,None,,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Basis of presentation,Basis of presentation,Disclosures,http://www.adaptimmune.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_UseOfEstimates_Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,us-gaap:UseOfEstimates,Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,"<p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;""><b style=""font-weight:bold;"">(b)          Use of estimates in interim financial statements</b></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">The preparation of interim financial statements, in conformity with U.S. GAAP and SEC regulations, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the interim financial statements and reported amounts of revenues and expenses during the reporting period. Estimates and assumptions are made in various areas, including in relation to valuation allowances relating to deferred tax assets, revenue recognition, the fair value of assets acquired, liabilities assumed and consideration transferred in business combinations, and estimation of the incremental borrowing rate for operating leases. If actual results differ from the Company’s estimates, or to the extent these estimates are adjusted in future periods, the Company’s results of operations could either benefit from, or be adversely affected by, any such change in estimate.</p>",None,None,,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Use of estimates in interim financial statements,Use of estimates in interim financial statements,Disclosures,http://www.adaptimmune.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_FairValueMeasurementPolicyPolicyTextBlock_Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,us-gaap:FairValueMeasurementPolicyPolicyTextBlock,Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,"<p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;""><b style=""font-weight:bold;"">(c)          Fair value measurements</b></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">The Company is required to disclose information on all assets and liabilities reported at fair value that enables an assessment of the inputs used in determining the reported fair values. The fair value hierarchy prioritizes valuation inputs based on the observable nature of those inputs. The hierarchy defines three levels of valuation inputs:</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">Level 1 - Quoted prices in active markets for identical assets or liabilities</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">Level 2 - Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">Level 3 - Unobservable inputs that reflect the Company's own assumptions about the assumptions market participants would use in pricing the asset or liability</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">The carrying amounts of the Company’s cash and cash equivalents, restricted cash, accounts receivable, accounts payable and accrued expenses approximate fair value because of the short-term nature of these instruments. The fair value of marketable securities, which are measured at fair value on a recurring basis is detailed in Note 6, Fair value measurements.</p>",None,None,,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Fair value measurements,Fair value measurements,Disclosures,http://www.adaptimmune.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_ConcentrationRiskCreditRisk_Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,us-gaap:ConcentrationRiskCreditRisk,Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,"<p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;""><b style=""font-weight:bold;"">(d</b><b style=""font-weight:bold;"">)          Significant concentrations of credit risk</b></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">The Company held cash and cash equivalents of $140,670,000, marketable securities of $2,982,000 and restricted cash of $2,858,000 as of March 31, 2024. The cash and cash equivalents and restricted cash are held with multiple banks and the Company monitors the credit rating of those banks. The Company maintains cash balances in excess of amounts insured by the Federal Deposit Insurance Corporation in the United States and the U.K. Government Financial Services Compensation Scheme in the United Kingdom. The Company’s investment policy limits investments to certain types of instruments, such as money market instruments, corporate debt securities and commercial paper, places restrictions on maturities and concentration by type and issuer and specifies the minimum credit ratings for all investments and the average credit quality of the portfolio.</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">The Company had two customers during the three months ended March 31, 2024 which are Genentech and GSK. There were accounts receivable of $8,404,000 as of March 31, 2024 and $821,000 as of December 31, 2023. The Company has been transacting with Genentech since 2021 and GSK since 2014, during which time no credit losses have been recognized. As of March 31, 2024, no allowance for expected credit losses is recognized on the basis that the possibility of credit losses arising on its receivables as of March 31, 2024 is considered to be remote. As of March 31, 2024 there are no receivables, either accrued or billed, due from Genentech that are no longer recoverable following the termination of the Genentech Collaboration and License Agreement.</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">Management analyses current and past due accounts and determines if an allowance for credit losses is required based on collection experience, credit worthiness of customers and other relevant information. The process of estimating the uncollectible accounts involves assumptions and judgments and the ultimate amounts of uncollectible accounts receivable could be in excess of the amounts provided.</p>",None,None,,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Significant concentrations of credit risk,Significant concentrations of credit risk,Disclosures,http://www.adaptimmune.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_CashAndCashEquivalentsAtCarryingValue_As_Of_3_31_2024_Ebq-QFBYXEGIOthDpC9wWw_0,us-gaap:CashAndCashEquivalentsAtCarryingValue,As_Of_3_31_2024_Ebq-QFBYXEGIOthDpC9wWw,140670000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,140670000.0,instant,2024-03-31,0001621227,http://www.sec.gov/CIK,instant_2024-03-31,Cash and cash equivalents,Cash and cash equivalents,BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_CashAndCashEquivalentsAtCarryingValue_As_Of_3_31_2024_Ebq-QFBYXEGIOthDpC9wWw_1,us-gaap:CashAndCashEquivalentsAtCarryingValue,As_Of_3_31_2024_Ebq-QFBYXEGIOthDpC9wWw,140670000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,0,140670000.0,instant,2024-03-31,0001621227,http://www.sec.gov/CIK,instant_2024-03-31,Cash and cash equivalents,Cash and cash equivalents,BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_As_Of_3_31_2024_Ebq-QFBYXEGIOthDpC9wWw_0,us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent,As_Of_3_31_2024_Ebq-QFBYXEGIOthDpC9wWw,2982000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,2982000.0,instant,2024-03-31,0001621227,http://www.sec.gov/CIK,instant_2024-03-31,"Marketable securities - available-for-sale debt securities (amortized cost of $2,981 and $2,940) net of allowance for expected credit losses of $0 and $0","Marketable securities - available-for-sale debt securities (amortized cost of $2,981 and $2,940) net of allowance for expected credit losses of $0 and $0",BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_As_Of_3_31_2024_Ebq-QFBYXEGIOthDpC9wWw_1,us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent,As_Of_3_31_2024_Ebq-QFBYXEGIOthDpC9wWw,2982000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,0,2982000.0,instant,2024-03-31,0001621227,http://www.sec.gov/CIK,instant_2024-03-31,"Marketable securities - available-for-sale debt securities (amortized cost of $2,981 and $2,940) net of allowance for expected credit losses of $0 and $0","Marketable securities - available-for-sale debt securities (amortized cost of $2,981 and $2,940) net of allowance for expected credit losses of $0 and $0",BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_RestrictedCash_As_Of_3_31_2024_Ebq-QFBYXEGIOthDpC9wWw,us-gaap:RestrictedCash,As_Of_3_31_2024_Ebq-QFBYXEGIOthDpC9wWw,2858000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,0,2858000.0,instant,2024-03-31,0001621227,http://www.sec.gov/CIK,instant_2024-03-31,Restricted Cash,Restricted Cash,Disclosures,http://www.adaptimmune.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
adap_NumberOfCustomers_As_Of_3_31_2024_srt_MajorCustomersAxis_adap_GenentechAndGskMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_XM9rvPFK6kGfJyFQiKhwMg,adap:NumberOfCustomers,As_Of_3_31_2024_srt_MajorCustomersAxis_adap_GenentechAndGskMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_XM9rvPFK6kGfJyFQiKhwMg,2,Unit_Standard_customer_-t4rwr78SESfHCWx-BOAUA,INF,2.0,instant,2024-03-31,0001621227,http://www.sec.gov/CIK,instant_2024-03-31,Number of customers,Number of customers,Disclosures,http://www.adaptimmune.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAccountsReceivableDetails,None,None,None,adap:GenentechAndGskMember,us-gaap:CustomerConcentrationRiskMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_AccountsReceivableNetCurrent_As_Of_3_31_2024_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_eUR7V0s-OEaLM-Us7erDhg,us-gaap:AccountsReceivableNetCurrent,As_Of_3_31_2024_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_eUR7V0s-OEaLM-Us7erDhg,8404000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,0,8404000.0,instant,2024-03-31,0001621227,http://www.sec.gov/CIK,instant_2024-03-31,"Accounts receivable, net of allowance for expected credit losses of $0 and $0","Accounts receivable, net of allowance for expected credit losses of $0 and $0",BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,None,us-gaap:CustomerConcentrationRiskMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_AccountsReceivableNetCurrent_As_Of_12_31_2023_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_deXYvOynf0KNLHS3TGfbWw,us-gaap:AccountsReceivableNetCurrent,As_Of_12_31_2023_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_deXYvOynf0KNLHS3TGfbWw,821000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,0,821000.0,instant,2023-12-31,0001621227,http://www.sec.gov/CIK,instant_2023-12-31,"Accounts receivable, net of allowance for expected credit losses of $0 and $0","Accounts receivable, net of allowance for expected credit losses of $0 and $0",BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,None,us-gaap:CustomerConcentrationRiskMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_AllowanceForDoubtfulAccountsReceivable_As_Of_3_31_2024_Ebq-QFBYXEGIOthDpC9wWw,us-gaap:AllowanceForDoubtfulAccountsReceivable,As_Of_3_31_2024_Ebq-QFBYXEGIOthDpC9wWw,0,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,0.0,instant,2024-03-31,0001621227,http://www.sec.gov/CIK,instant_2024-03-31,Allowance for doubtful accounts,Allowance for doubtful accounts,Disclosures,http://www.adaptimmune.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAccountsReceivableDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_AccountsReceivableNetCurrent_As_Of_3_31_2024_srt_MajorCustomersAxis_adap_GenentechInc.Member_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_1SRCT2dx1EG70tvjQVmaQQ,us-gaap:AccountsReceivableNetCurrent,As_Of_3_31_2024_srt_MajorCustomersAxis_adap_GenentechInc.Member_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_1SRCT2dx1EG70tvjQVmaQQ,0,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,0.0,instant,2024-03-31,0001621227,http://www.sec.gov/CIK,instant_2024-03-31,"Accounts receivable, net of allowance for expected credit losses of $0 and $0","Accounts receivable, net of allowance for expected credit losses of $0 and $0",BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,adap:GenentechInc.Member,us-gaap:CustomerConcentrationRiskMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock,Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,"<p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;""><b style=""font-weight:bold;white-space:pre-wrap;"">(e)          New accounting pronouncements</b></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;""><i style=""font-style:italic;"">Adopted in the current period</i></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><i style=""font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"">Improvements to Reportable Segment Disclosures</i></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""display:inline-block;text-indent:0pt;width:36pt;""></span>In November 2023, the FASB issued ASU 2023-07 – Segment Reporting (Topic 280) – Improvements to Reportable Segment Disclosures, which improves segment disclosure requirements, primarily through enhanced disclosure requirements for significant segment expenses. The improved disclosure requirements apply to all public entities that are required to report segment information, including those with only one reportable segment. The Company adopted the guidance in the fiscal year beginning January 1, 2024. There was no impact on the Company’s reportable segments identified and additional required disclosures have been included in Note 14.</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-style:italic;visibility:hidden;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-style:italic;visibility:hidden;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-style:italic;visibility:hidden;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><i style=""font-style:italic;"">To be adopted in future periods</i></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-style:italic;visibility:hidden;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><i style=""font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"">Improves to Income Tax Disclosures</i></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"">In December 2023, the FASB issued ASU 2023-09 – Income Taxes (Topic 740) – Improvements to Income Tax Disclosures, which improves income tax disclosures primarily relating to the rate reconciliation and income taxes paid information. This includes a tabular reconciliation using both percentages and reporting currency amounts, covering various tax and reconciling items, and disaggregated summaries of income taxes paid during the period. For public business entities, the guidance is effective for annual periods beginning after December 15, 2024, with early adoption permitted. The Company intends to adopt the guidance in the fiscal year beginning January 1, 2025. The Company is currently evaluating the impact of the guidance on its Consolidated financial statements.</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:28.35pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p>",None,None,,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,New accounting pronouncements,New accounting pronouncements,Disclosures,http://www.adaptimmune.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_RevenueFromContractWithCustomerTextBlock_Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,us-gaap:RevenueFromContractWithCustomerTextBlock,Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,"<p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;""><b style=""font-weight:bold;"">Note 3 </b><b style=""font-weight:bold;"">—</b><b style=""font-weight:bold;""> Revenue</b></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:33.75pt;margin:0pt 0pt 12pt 0pt;"">The Company generates development revenue from collaboration agreements with customers. The Company had two revenue-generating contracts with customers in the three months ended March 31, 2024, compared to two in the three months ended March 31, 2023: a termination and transfer agreement with GSK that was effective on April 6, 2023, a strategic collaboration and license agreement with Genentech and a collaboration agreement with Astellas that was terminated as of March 6, 2023. The collaboration and licence agreement with Genentech was terminated in April 2024.</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:33.75pt;margin:0pt;"">Revenue comprises the following categories (in thousands):</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p><table style=""border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;""><tr style=""height:1pt;""><td style=""vertical-align:bottom;width:51.01%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:17.5%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.62%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:17.5%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td></tr><tr><td style=""vertical-align:bottom;width:51.01%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""5"" style=""vertical-align:bottom;white-space:nowrap;width:45.66%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Three months ended </b></p></td></tr><tr><td style=""vertical-align:bottom;width:51.01%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;""> </b></p></td><td colspan=""5"" style=""vertical-align:bottom;white-space:nowrap;width:45.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">March 31, </b></p></td></tr><tr><td style=""vertical-align:bottom;width:51.01%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">     </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:19.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2024</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.62%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">     </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:19.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2023</b></p></td></tr><tr><td style=""vertical-align:bottom;width:51.01%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:17.5%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""font-size:8pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.62%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:17.5%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""font-size:8pt;visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;width:51.01%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Development revenue</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:17.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 5,678</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.62%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:17.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 47,601</p></td></tr><tr><td style=""vertical-align:bottom;width:51.01%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:17.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 5,678</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.62%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:17.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 47,601</b></p></td></tr></table><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;""><span style=""visibility:hidden;background:#ffff00;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"">Deferred revenue decreased by $856,000 from $178,033,000 at December 31, 2023 to $178,889,000 at March 31, 2024 due to revenue recognized during the quarter of $5,678,000 that was included in deferred revenue at December 31, 2023 and a $1,507,000 decrease caused by the change in the exchange rate between pound sterling and the U.S. dollar from £1.00 to $1.27 at December 31, 2023 to £1.00 to $1.26 at March 31, 2024. This was partially offset by a milestone of $7,574,000 from GSK that was met and accrued at March 31, 2024. </p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;background:#ffff00;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">The aggregate amount of the transaction price that is allocated to performance obligations that are unsatisfied or partially satisfied under the agreements as of March 31, 2024 was $305,509,000. </p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;""><i style=""font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"">The Genentech Collaboration and License Agreement</i></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">The amount of the transaction price that is allocated to performance obligations that are unsatisfied or partially satisfied under the Genentech agreement as of March 31, 2024 was $271,015,000. Of this amount $165,672,000 is allocated to the research services and rights granted for the initial ‘off-the-shelf’ collaboration targets, $85,963,000 is allocated to the research services and rights granted for the personalized therapies, $13,081,000 is allocated to the material rights to designate the additional ‘off-the-shelf’ collaboration targets, $5,039,000 is allocated to the material right for the first option to extend the research term and $1,260,000 is allocated to the material right for the option to extend the research term a second time. </p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"">The Company originally expected to satisfy the performance obligations relating to the initial ‘off-the-shelf’ collaboration targets and the personalized therapies as development progressed and recognized revenue based on an estimate of the percentage of completion of the project determined based on the costs incurred on the project as a percentage of the total expected costs. The Company expected to satisfy the performance obligations relating to the material rights to designate additional ‘off-the-shelf’ collaboration targets from the point that the options would have been exercised and then as development progressed, in line with the initial ‘off-the-shelf’ collaboration targets, or at the point in time that the rights expired. The Company expected to satisfy the performance obligations relating to the material rights </p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"">to extend the research term from the point that the options would have been exercised and then over the period of the extension, or at the point in time that the rights expired.</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">On April 12, 2024 the Company announced the termination of the collaboration with Genentech in relation to the research, development and commercialization of cancer targeted allogeneic T-cell therapies. See Note 15 for further discussion.</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;""><i style=""font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"">The GSK Termination and Transfer Agreement</i></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">On April 6, 2023, the Company and GSK entered into a Termination and Transfer Agreement (the “Termination and Transfer Agreement”) regarding the return of rights and materials comprised within the PRAME and NY-ESO cell therapy programs. The parties will work collaboratively to ensure continuity for patients in ongoing lete-cel clinical trials forming part of the NY-ESO cell therapy program. </p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">As part of the agreement, sponsorship and responsibility for the ongoing IGNYTE and long-term follow-up (“LTFU”) trials relating to the NY-ESO cell therapy program will transfer to Adaptimmune. In return for this, Adaptimmune received an upfront payment of £7.5 million in June 2023 following the signing of the agreement and milestone payment of £3 million and £12 million in September 2023 and December 2023, respectively. Further milestone payments totalling £7.5 million will be due in relation to successive stages of transfer of the trials of which a milestone of £6 million had been met and accrued, but not billed, at March 31, 2024.</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">The Company determined that GSK is a customer and has accounted for the agreement under ASC 606 <i style=""font-style:italic;"">Revenue from Contracts with Customers</i>. The agreement is accounted for as a separate contract from the original GSK Collaboration and License Agreement. The Company has identified the following performance obligations under the agreement: (i) to take over sponsorship for the IGNYTE trial and (ii) to take over sponsorship for the LTFU trial.</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">The aggregate transaction price at inception of the agreement was $37,335,000 comprising the total £30,000,000 upfront and milestone payments. No value was ascribed to non-cash consideration and there was no variable consideration identified. The aggregate transaction price is allocated to the performance obligations depending on the relative standalone selling price of the performance obligations. In determining the best estimate of the relative standalone selling price, the Company considered the internal pricing objectives it used in negotiating the contract, together with internal data regarding the expected costs and a standard margin on those costs, for completing the trials. The amount of the transaction price allocated to the performance obligation is recognized as or when the Company satisfies the performance obligation. </p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">The Company expects to satisfy the performance obligations over time from the point that sponsorship of the active trials that make up the trial transfers and then over the period that the trial is completed, based on the number of patients transferred and still actively enrolled to date on the trial at a given period-end relative to the total estimated periods of active patient enrollment over the estimated duration of the trial. </p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">The Company considers that this depicts the progress of the completion of the trials under the Termination and Transfer Agreement, as the status of patients on the trial is not directly affected by decisions that the Company might make relating to its own development of the NY-ESO cell therapy program.</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">The amount of the transaction price that is allocated to performance obligations that are unsatisfied or partially satisfied under the agreement as of March 31, 2024 was $34,495,000, of which $18,325,000 is allocated to the IGNYTE performance obligation and $16,170,000 is allocated to the LTFU performance obligation.</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;""><i style=""font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"">The Astellas Collaboration Agreement</i></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">The Company and Universal Cells mutually agreed to terminate the Astellas Collaboration Agreement as of March 6, 2023 (the “Termination Date”). In connection with the termination, all licenses and sublicenses granted to either party pursuant to the Collaboration Agreement ceased as of the Termination Date. There were no termination penalties in connection with the termination; however the Company is still entitled to receive reimbursement for research and development work performed up to and including a period of 30 days after the Termination Date.</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">The termination was accounted for as a contract modification on a cumulative catch-up basis. No performance obligations were identified as a result of the modification as there were no further goods or services to be provided by the Company and the modification resulted in the remaining unsatisfied and partially satisfied performance obligations under the collaboration becoming fully satisfied. The aggregate transaction price of the contract modification was $42,365,000 which included the remaining deferred income that had not been recognized as revenue as of the date of the modification and variable consideration from the remaining reimbursement income to be billed under the collaboration at the end of the 30 day period after the Effective Date. The transaction price of the modification was recognized in full in March 2023 and there is no remaining transaction price allocated to performance obligations that are unsatisfied or partially satisfied under, no remaining deferred income relating to, the agreement as of March 31, 2024 and no revenue was recognized in 2024.</p>",None,None,,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Revenue,Revenue,Disclosures,http://www.adaptimmune.com/role/DisclosureRevenue,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
adap_NumberOfContractsWithCustomer_Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,adap:NumberOfContractsWithCustomer,Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,2,Unit_Standard_contract_auh80WJhTk-_p34nyhWWFA,INF,2.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Number of contracts with customers,Number of contracts with customers,Disclosures,http://www.adaptimmune.com/role/DisclosureRevenueRevenueFromContractsWithCustomersDetails,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
adap_NumberOfCustomers_As_Of_3_31_2023_E8kJdIyzokqSPfzFvPVD9g,adap:NumberOfCustomers,As_Of_3_31_2023_E8kJdIyzokqSPfzFvPVD9g,2,Unit_Standard_customer_-t4rwr78SESfHCWx-BOAUA,INF,2.0,instant,2023-03-31,0001621227,http://www.sec.gov/CIK,instant_2023-03-31,Number of customers,Number of customers,Disclosures,http://www.adaptimmune.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAccountsReceivableDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_DisaggregationOfRevenueTableTextBlock_Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,us-gaap:DisaggregationOfRevenueTableTextBlock,Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,"<p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:33.75pt;margin:0pt;"">Revenue comprises the following categories (in thousands):</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p><table style=""border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;""><tr style=""height:1pt;""><td style=""vertical-align:bottom;width:51.01%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:17.5%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.62%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:17.5%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td></tr><tr><td style=""vertical-align:bottom;width:51.01%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""5"" style=""vertical-align:bottom;white-space:nowrap;width:45.66%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Three months ended </b></p></td></tr><tr><td style=""vertical-align:bottom;width:51.01%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;""> </b></p></td><td colspan=""5"" style=""vertical-align:bottom;white-space:nowrap;width:45.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">March 31, </b></p></td></tr><tr><td style=""vertical-align:bottom;width:51.01%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">     </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:19.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2024</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.62%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">     </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:19.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2023</b></p></td></tr><tr><td style=""vertical-align:bottom;width:51.01%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:17.5%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""font-size:8pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.62%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:17.5%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""font-size:8pt;visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;width:51.01%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Development revenue</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:17.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 5,678</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.62%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:17.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 47,601</p></td></tr><tr><td style=""vertical-align:bottom;width:51.01%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:17.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 5,678</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.62%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:17.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 47,601</b></p></td></tr></table>",None,None,,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Summary of revenue categories,Summary of revenue categories,Disclosures,http://www.adaptimmune.com/role/DisclosureRevenueTables,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_Duration_1_1_2024_To_3_31_2024_srt_ProductOrServiceAxis_adap_DevelopmentRevenueMember_Vh0yiDjxZE6w0_uvzJVwFw,us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax,Duration_1_1_2024_To_3_31_2024_srt_ProductOrServiceAxis_adap_DevelopmentRevenueMember_Vh0yiDjxZE6w0_uvzJVwFw,5678000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,5678000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Revenue,Revenue,IncomeStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations,2024-01-01,2024-03-31,None,None,None,adap:DevelopmentRevenueMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_Duration_1_1_2023_To_3_31_2023_srt_ProductOrServiceAxis_adap_DevelopmentRevenueMember__bpRsfyJn0GQJDCuXarE1A,us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax,Duration_1_1_2023_To_3_31_2023_srt_ProductOrServiceAxis_adap_DevelopmentRevenueMember__bpRsfyJn0GQJDCuXarE1A,47601000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,47601000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Revenue,Revenue,IncomeStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations,2023-01-01,2023-03-31,None,None,None,adap:DevelopmentRevenueMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw_0,us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax,Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,5678000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,5678000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Revenue,Revenue,IncomeStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw_1,us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax,Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,5678000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,5678000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Revenue,Revenue,IncomeStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_Duration_1_1_2023_To_3_31_2023_y-zxPPLZtEmUIwfawHojag_0,us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax,Duration_1_1_2023_To_3_31_2023_y-zxPPLZtEmUIwfawHojag,47601000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,47601000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Revenue,Revenue,IncomeStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations,2023-01-01,2023-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_Duration_1_1_2023_To_3_31_2023_y-zxPPLZtEmUIwfawHojag_1,us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax,Duration_1_1_2023_To_3_31_2023_y-zxPPLZtEmUIwfawHojag,47601000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,47601000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Revenue,Revenue,IncomeStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations,2023-01-01,2023-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
adap_DecreaseInContractWithCustomerLiability_Duration_1_1_2023_To_12_31_2023_ywGyk4hUCkahRa47Ahko7A,adap:DecreaseInContractWithCustomerLiability,Duration_1_1_2023_To_12_31_2023_ywGyk4hUCkahRa47Ahko7A,856000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,0,856000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-12-31,Deferred revenue decrease,Deferred revenue decrease,Disclosures,http://www.adaptimmune.com/role/DisclosureRevenueRevenueFromContractsWithCustomersDetails,2023-01-01,2023-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_ContractWithCustomerLiability_As_Of_12_31_2023_m48jnprDr0mqVxN2-uk6kw,us-gaap:ContractWithCustomerLiability,As_Of_12_31_2023_m48jnprDr0mqVxN2-uk6kw,178033000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,0,178033000.0,instant,2023-12-31,0001621227,http://www.sec.gov/CIK,instant_2023-12-31,Deferred revenue,Deferred revenue,Disclosures,http://www.adaptimmune.com/role/DisclosureRevenueRevenueFromContractsWithCustomersDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_ContractWithCustomerLiability_As_Of_3_31_2024_Ebq-QFBYXEGIOthDpC9wWw,us-gaap:ContractWithCustomerLiability,As_Of_3_31_2024_Ebq-QFBYXEGIOthDpC9wWw,178889000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,178889000.0,instant,2024-03-31,0001621227,http://www.sec.gov/CIK,instant_2024-03-31,Deferred revenue,Deferred revenue,Disclosures,http://www.adaptimmune.com/role/DisclosureRevenueRevenueFromContractsWithCustomersDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_ContractWithCustomerLiabilityRevenueRecognized_Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,us-gaap:ContractWithCustomerLiabilityRevenueRecognized,Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,5678000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,0,5678000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Revenue recognized in the period,Revenue recognized in the period,Disclosures,http://www.adaptimmune.com/role/DisclosureRevenueRevenueFromContractsWithCustomersDetails,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
adap_IncreaseDecreaseInContractWithCustomerChangeInExchangeRateLiability_Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,adap:IncreaseDecreaseInContractWithCustomerChangeInExchangeRateLiability,Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,1507000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,1507000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Amount of increase in deferred income caused by the change in the exchange rate,Amount of increase in deferred income caused by the change in the exchange rate,Disclosures,http://www.adaptimmune.com/role/DisclosureRevenueRevenueFromContractsWithCustomersDetails,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_ForeignCurrencyExchangeRateTranslation1_As_Of_12_31_2023_m48jnprDr0mqVxN2-uk6kw,us-gaap:ForeignCurrencyExchangeRateTranslation1,As_Of_12_31_2023_m48jnprDr0mqVxN2-uk6kw,1.27,Unit_Standard_pure_3r25NCp6WUGW4b-Voo8YTA,2,1.27,instant,2023-12-31,0001621227,http://www.sec.gov/CIK,instant_2023-12-31,Exchange rate,Exchange rate,Disclosures,http://www.adaptimmune.com/role/DisclosureRevenueRevenueFromContractsWithCustomersDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_ForeignCurrencyExchangeRateTranslation1_As_Of_3_31_2024_Ebq-QFBYXEGIOthDpC9wWw,us-gaap:ForeignCurrencyExchangeRateTranslation1,As_Of_3_31_2024_Ebq-QFBYXEGIOthDpC9wWw,1.26,Unit_Standard_pure_3r25NCp6WUGW4b-Voo8YTA,2,1.26,instant,2024-03-31,0001621227,http://www.sec.gov/CIK,instant_2024-03-31,Exchange rate,Exchange rate,Disclosures,http://www.adaptimmune.com/role/DisclosureRevenueRevenueFromContractsWithCustomersDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
adap_LicenseAgreementMilestonePaymentAccruedButNotYetPaid_As_Of_3_31_2024_Ebq-QFBYXEGIOthDpC9wWw,adap:LicenseAgreementMilestonePaymentAccruedButNotYetPaid,As_Of_3_31_2024_Ebq-QFBYXEGIOthDpC9wWw,7574000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,7574000.0,instant,2024-03-31,0001621227,http://www.sec.gov/CIK,instant_2024-03-31,Milestone payment met and accrued,Milestone payment met and accrued,Disclosures,http://www.adaptimmune.com/role/DisclosureRevenueRevenueFromContractsWithCustomersDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_RevenueRemainingPerformanceObligation_As_Of_3_31_2024_Ebq-QFBYXEGIOthDpC9wWw,us-gaap:RevenueRemainingPerformanceObligation,As_Of_3_31_2024_Ebq-QFBYXEGIOthDpC9wWw,305509000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,0,305509000.0,instant,2024-03-31,0001621227,http://www.sec.gov/CIK,instant_2024-03-31,Aggregate amount of the transaction price that is allocated to performance obligations that are unsatisfied or partially satisfied under the agreements,Aggregate amount of the transaction price that is allocated to performance obligations that are unsatisfied or partially satisfied under the agreements,Disclosures,http://www.adaptimmune.com/role/DisclosureRevenueRevenueFromContractsWithCustomersDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_RevenueRemainingPerformanceObligation_As_Of_3_31_2024_us-gaap_TypeOfArrangementAxis_adap_StrategicCollaborationAndLicenseAgreementMember_1oi71HkA4022gzq0QuJNUw,us-gaap:RevenueRemainingPerformanceObligation,As_Of_3_31_2024_us-gaap_TypeOfArrangementAxis_adap_StrategicCollaborationAndLicenseAgreementMember_1oi71HkA4022gzq0QuJNUw,271015000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,0,271015000.0,instant,2024-03-31,0001621227,http://www.sec.gov/CIK,instant_2024-03-31,Aggregate amount of the transaction price that is allocated to performance obligations that are unsatisfied or partially satisfied under the agreements,Aggregate amount of the transaction price that is allocated to performance obligations that are unsatisfied or partially satisfied under the agreements,Disclosures,http://www.adaptimmune.com/role/DisclosureRevenueRevenueFromContractsWithCustomersDetails,None,None,None,None,None,None,adap:StrategicCollaborationAndLicenseAgreementMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_RevenueRemainingPerformanceObligation_As_Of_3_31_2024_srt_ProductOrServiceAxis_adap_ResearchServiceRightsGrantedForInitialOffShelfCollaborationTargetsMember_us-gaap_TypeOfArrangementAxis_adap_StrategicCollaborationAndLicenseAgreementMember_UEDrgA-EZkuStI9RL6PRCA,us-gaap:RevenueRemainingPerformanceObligation,As_Of_3_31_2024_srt_ProductOrServiceAxis_adap_ResearchServiceRightsGrantedForInitialOffShelfCollaborationTargetsMember_us-gaap_TypeOfArrangementAxis_adap_StrategicCollaborationAndLicenseAgreementMember_UEDrgA-EZkuStI9RL6PRCA,165672000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,0,165672000.0,instant,2024-03-31,0001621227,http://www.sec.gov/CIK,instant_2024-03-31,Aggregate amount of the transaction price that is allocated to performance obligations that are unsatisfied or partially satisfied under the agreements,Aggregate amount of the transaction price that is allocated to performance obligations that are unsatisfied or partially satisfied under the agreements,Disclosures,http://www.adaptimmune.com/role/DisclosureRevenueRevenueFromContractsWithCustomersDetails,None,None,None,None,None,adap:ResearchServiceRightsGrantedForInitialOffShelfCollaborationTargetsMember,adap:StrategicCollaborationAndLicenseAgreementMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_RevenueRemainingPerformanceObligation_As_Of_3_31_2024_srt_ProductOrServiceAxis_adap_ResearchServiceRightsGrantedForPersonalizedTherapiesMember_us-gaap_TypeOfArrangementAxis_adap_StrategicCollaborationAndLicenseAgreementMember_5YXi6tz0R0SoZY8ujN5ZqA,us-gaap:RevenueRemainingPerformanceObligation,As_Of_3_31_2024_srt_ProductOrServiceAxis_adap_ResearchServiceRightsGrantedForPersonalizedTherapiesMember_us-gaap_TypeOfArrangementAxis_adap_StrategicCollaborationAndLicenseAgreementMember_5YXi6tz0R0SoZY8ujN5ZqA,85963000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,0,85963000.0,instant,2024-03-31,0001621227,http://www.sec.gov/CIK,instant_2024-03-31,Aggregate amount of the transaction price that is allocated to performance obligations that are unsatisfied or partially satisfied under the agreements,Aggregate amount of the transaction price that is allocated to performance obligations that are unsatisfied or partially satisfied under the agreements,Disclosures,http://www.adaptimmune.com/role/DisclosureRevenueRevenueFromContractsWithCustomersDetails,None,None,None,None,None,adap:ResearchServiceRightsGrantedForPersonalizedTherapiesMember,adap:StrategicCollaborationAndLicenseAgreementMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_RevenueRemainingPerformanceObligation_As_Of_3_31_2024_srt_ProductOrServiceAxis_adap_MaterialRightToDesignateFirstAdditionalOffShelfCollaborationTargetMember_us-gaap_TypeOfArrangementAxis_adap_StrategicCollaborationAndLicenseAgreementMember_A6hI2eLaaUWhVv6yGuG4RA,us-gaap:RevenueRemainingPerformanceObligation,As_Of_3_31_2024_srt_ProductOrServiceAxis_adap_MaterialRightToDesignateFirstAdditionalOffShelfCollaborationTargetMember_us-gaap_TypeOfArrangementAxis_adap_StrategicCollaborationAndLicenseAgreementMember_A6hI2eLaaUWhVv6yGuG4RA,13081000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,0,13081000.0,instant,2024-03-31,0001621227,http://www.sec.gov/CIK,instant_2024-03-31,Aggregate amount of the transaction price that is allocated to performance obligations that are unsatisfied or partially satisfied under the agreements,Aggregate amount of the transaction price that is allocated to performance obligations that are unsatisfied or partially satisfied under the agreements,Disclosures,http://www.adaptimmune.com/role/DisclosureRevenueRevenueFromContractsWithCustomersDetails,None,None,None,None,None,adap:MaterialRightToDesignateFirstAdditionalOffShelfCollaborationTargetMember,adap:StrategicCollaborationAndLicenseAgreementMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_RevenueRemainingPerformanceObligation_As_Of_3_31_2024_srt_ProductOrServiceAxis_adap_MaterialRightForFirstOptionExtendResearchTermMember_us-gaap_TypeOfArrangementAxis_adap_StrategicCollaborationAndLicenseAgreementMember_me49Tvaz2ku6P3NxZdgXGg,us-gaap:RevenueRemainingPerformanceObligation,As_Of_3_31_2024_srt_ProductOrServiceAxis_adap_MaterialRightForFirstOptionExtendResearchTermMember_us-gaap_TypeOfArrangementAxis_adap_StrategicCollaborationAndLicenseAgreementMember_me49Tvaz2ku6P3NxZdgXGg,5039000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,0,5039000.0,instant,2024-03-31,0001621227,http://www.sec.gov/CIK,instant_2024-03-31,Aggregate amount of the transaction price that is allocated to performance obligations that are unsatisfied or partially satisfied under the agreements,Aggregate amount of the transaction price that is allocated to performance obligations that are unsatisfied or partially satisfied under the agreements,Disclosures,http://www.adaptimmune.com/role/DisclosureRevenueRevenueFromContractsWithCustomersDetails,None,None,None,None,None,adap:MaterialRightForFirstOptionExtendResearchTermMember,adap:StrategicCollaborationAndLicenseAgreementMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_RevenueRemainingPerformanceObligation_As_Of_3_31_2024_srt_ProductOrServiceAxis_adap_MaterialRightForSecondOptionExtendResearchTermMember_us-gaap_TypeOfArrangementAxis_adap_StrategicCollaborationAndLicenseAgreementMember_XEiOc9vBkUCjax70V6lTGQ,us-gaap:RevenueRemainingPerformanceObligation,As_Of_3_31_2024_srt_ProductOrServiceAxis_adap_MaterialRightForSecondOptionExtendResearchTermMember_us-gaap_TypeOfArrangementAxis_adap_StrategicCollaborationAndLicenseAgreementMember_XEiOc9vBkUCjax70V6lTGQ,1260000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,0,1260000.0,instant,2024-03-31,0001621227,http://www.sec.gov/CIK,instant_2024-03-31,Aggregate amount of the transaction price that is allocated to performance obligations that are unsatisfied or partially satisfied under the agreements,Aggregate amount of the transaction price that is allocated to performance obligations that are unsatisfied or partially satisfied under the agreements,Disclosures,http://www.adaptimmune.com/role/DisclosureRevenueRevenueFromContractsWithCustomersDetails,None,None,None,None,None,adap:MaterialRightForSecondOptionExtendResearchTermMember,adap:StrategicCollaborationAndLicenseAgreementMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
adap_UpfrontPaymentReceived_Duration_6_1_2023_To_6_30_2023_us-gaap_TypeOfArrangementAxis_adap_GskTerminationAndTransferAgreementMember_Dk0qroKDMUSwoQalvTARQg,adap:UpfrontPaymentReceived,Duration_6_1_2023_To_6_30_2023_us-gaap_TypeOfArrangementAxis_adap_GskTerminationAndTransferAgreementMember_Dk0qroKDMUSwoQalvTARQg,7500000,Unit_Standard_GBP_2X_-HV6bvECVaTZr2BC1zQ,-5,7500000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2023-06-01_2023-06-30,Upfront payment received,Upfront payment received,Disclosures,http://www.adaptimmune.com/role/DisclosureRevenueRevenueFromContractsWithCustomersDetails,2023-06-01,2023-06-30,None,None,None,None,adap:GskTerminationAndTransferAgreementMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
adap_MilestonePayments_Duration_9_1_2023_To_9_30_2023_us-gaap_TypeOfArrangementAxis_adap_GskTerminationAndTransferAgreementMember_PZO2-GPxKEmLf_Omqb_otQ,adap:MilestonePayments,Duration_9_1_2023_To_9_30_2023_us-gaap_TypeOfArrangementAxis_adap_GskTerminationAndTransferAgreementMember_PZO2-GPxKEmLf_Omqb_otQ,3000000,Unit_Standard_GBP_2X_-HV6bvECVaTZr2BC1zQ,-6,3000000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2023-09-01_2023-09-30,Milestone payment,Milestone payment,Disclosures,http://www.adaptimmune.com/role/DisclosureRevenueCollaborationAgreementGskTerminationAndTransferAgreementDetails,2023-09-01,2023-09-30,None,None,None,None,adap:GskTerminationAndTransferAgreementMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
adap_MilestonePayments_Duration_1_1_2023_To_12_31_2023_us-gaap_TypeOfArrangementAxis_adap_GskTerminationAndTransferAgreementMember_ELOz9yigOkK-sraDsWTBFw,adap:MilestonePayments,Duration_1_1_2023_To_12_31_2023_us-gaap_TypeOfArrangementAxis_adap_GskTerminationAndTransferAgreementMember_ELOz9yigOkK-sraDsWTBFw,12000000,Unit_Standard_GBP_2X_-HV6bvECVaTZr2BC1zQ,-6,12000000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-12-31,Milestone payment,Milestone payment,Disclosures,http://www.adaptimmune.com/role/DisclosureRevenueCollaborationAgreementGskTerminationAndTransferAgreementDetails,2023-01-01,2023-12-31,None,None,None,None,adap:GskTerminationAndTransferAgreementMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
adap_PotentialPaymentForAchievementOfSpecifiedMilestones_Duration_1_1_2024_To_3_31_2024_us-gaap_TypeOfArrangementAxis_adap_GskTerminationAndTransferAgreementMember_jQE7A7LRNkK_3EvTBDi9Mg,adap:PotentialPaymentForAchievementOfSpecifiedMilestones,Duration_1_1_2024_To_3_31_2024_us-gaap_TypeOfArrangementAxis_adap_GskTerminationAndTransferAgreementMember_jQE7A7LRNkK_3EvTBDi9Mg,7500000,Unit_Standard_GBP_2X_-HV6bvECVaTZr2BC1zQ,-5,7500000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Potential milestone payments to be received,Potential milestone payments to be received,Disclosures,http://www.adaptimmune.com/role/DisclosureRevenueCollaborationAgreementGskTerminationAndTransferAgreementDetails,2024-01-01,2024-03-31,None,None,None,None,adap:GskTerminationAndTransferAgreementMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
adap_MilestonePaymentMetAndAccrued_Duration_1_1_2024_To_3_31_2024_us-gaap_TypeOfArrangementAxis_adap_GskTerminationAndTransferAgreementMember_jQE7A7LRNkK_3EvTBDi9Mg,adap:MilestonePaymentMetAndAccrued,Duration_1_1_2024_To_3_31_2024_us-gaap_TypeOfArrangementAxis_adap_GskTerminationAndTransferAgreementMember_jQE7A7LRNkK_3EvTBDi9Mg,6000000,Unit_Standard_GBP_2X_-HV6bvECVaTZr2BC1zQ,-6,6000000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Milestone met and accrued,Milestone met and accrued,Disclosures,http://www.adaptimmune.com/role/DisclosureRevenueCollaborationAgreementGskTerminationAndTransferAgreementDetails,2024-01-01,2024-03-31,None,None,None,None,adap:GskTerminationAndTransferAgreementMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
adap_TransactionPrice_As_Of_4_6_2023_us-gaap_TypeOfArrangementAxis_adap_GskTerminationAndTransferAgreementMember_emyZQi-gdEytk1m0nkiIKA,adap:TransactionPrice,As_Of_4_6_2023_us-gaap_TypeOfArrangementAxis_adap_GskTerminationAndTransferAgreementMember_emyZQi-gdEytk1m0nkiIKA,37335000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,0,37335000.0,instant,2023-04-06,0001621227,http://www.sec.gov/CIK,instant_2023-04-06,Amount of transaction price of the agreement at inception,Amount of transaction price of the agreement at inception,Disclosures,http://www.adaptimmune.com/role/DisclosureRevenueCollaborationAgreementGenentechCollaborationAndLicenseAgreementDetails,None,None,None,None,None,None,adap:GskTerminationAndTransferAgreementMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
adap_UpfrontAndMilestonePaymentReceivable_As_Of_4_6_2023_us-gaap_TypeOfArrangementAxis_adap_GskTerminationAndTransferAgreementMember_emyZQi-gdEytk1m0nkiIKA,adap:UpfrontAndMilestonePaymentReceivable,As_Of_4_6_2023_us-gaap_TypeOfArrangementAxis_adap_GskTerminationAndTransferAgreementMember_emyZQi-gdEytk1m0nkiIKA,30000000,Unit_Standard_GBP_2X_-HV6bvECVaTZr2BC1zQ,0,30000000.0,instant,2023-04-06,0001621227,http://www.sec.gov/CIK,instant_2023-04-06,Upfront and milestone payment receivable,Upfront and milestone payment receivable,Disclosures,http://www.adaptimmune.com/role/DisclosureRevenueCollaborationAgreementGskTerminationAndTransferAgreementDetails,None,None,None,None,None,None,adap:GskTerminationAndTransferAgreementMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_RevenueRemainingPerformanceObligation_As_Of_3_31_2024_us-gaap_TypeOfArrangementAxis_adap_GskTerminationAndTransferAgreementMember_7CGfKxfIDkGtB7hZ3_QT8Q,us-gaap:RevenueRemainingPerformanceObligation,As_Of_3_31_2024_us-gaap_TypeOfArrangementAxis_adap_GskTerminationAndTransferAgreementMember_7CGfKxfIDkGtB7hZ3_QT8Q,34495000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,0,34495000.0,instant,2024-03-31,0001621227,http://www.sec.gov/CIK,instant_2024-03-31,Aggregate amount of the transaction price that is allocated to performance obligations that are unsatisfied or partially satisfied under the agreements,Aggregate amount of the transaction price that is allocated to performance obligations that are unsatisfied or partially satisfied under the agreements,Disclosures,http://www.adaptimmune.com/role/DisclosureRevenueRevenueFromContractsWithCustomersDetails,None,None,None,None,None,None,adap:GskTerminationAndTransferAgreementMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_RevenueRemainingPerformanceObligation_As_Of_3_31_2024_us-gaap_TypeOfArrangementAxis_adap_IgnyteMember_GUoNpY31kUKmocM9DLkr3w,us-gaap:RevenueRemainingPerformanceObligation,As_Of_3_31_2024_us-gaap_TypeOfArrangementAxis_adap_IgnyteMember_GUoNpY31kUKmocM9DLkr3w,18325000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,0,18325000.0,instant,2024-03-31,0001621227,http://www.sec.gov/CIK,instant_2024-03-31,Aggregate amount of the transaction price that is allocated to performance obligations that are unsatisfied or partially satisfied under the agreements,Aggregate amount of the transaction price that is allocated to performance obligations that are unsatisfied or partially satisfied under the agreements,Disclosures,http://www.adaptimmune.com/role/DisclosureRevenueRevenueFromContractsWithCustomersDetails,None,None,None,None,None,None,adap:IgnyteMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_RevenueRemainingPerformanceObligation_As_Of_3_31_2024_us-gaap_TypeOfArrangementAxis_adap_LtfuMember_jgVek7Voh0y03vGVMXAOSg,us-gaap:RevenueRemainingPerformanceObligation,As_Of_3_31_2024_us-gaap_TypeOfArrangementAxis_adap_LtfuMember_jgVek7Voh0y03vGVMXAOSg,16170000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,0,16170000.0,instant,2024-03-31,0001621227,http://www.sec.gov/CIK,instant_2024-03-31,Aggregate amount of the transaction price that is allocated to performance obligations that are unsatisfied or partially satisfied under the agreements,Aggregate amount of the transaction price that is allocated to performance obligations that are unsatisfied or partially satisfied under the agreements,Disclosures,http://www.adaptimmune.com/role/DisclosureRevenueRevenueFromContractsWithCustomersDetails,None,None,None,None,None,None,adap:LtfuMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
adap_TransactionPriceContractModification_As_Of_3_31_2024_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_CgXJIZ0lhU6UXi_Ite6ZGw,adap:TransactionPriceContractModification,As_Of_3_31_2024_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_CgXJIZ0lhU6UXi_Ite6ZGw,42365000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,0,42365000.0,instant,2024-03-31,0001621227,http://www.sec.gov/CIK,instant_2024-03-31,Aggregate transaction price of the contract modification,Aggregate transaction price of the contract modification,Disclosures,http://www.adaptimmune.com/role/DisclosureRevenueCollaborationAgreementAstellasCollaborationAgreementDetails,None,None,None,None,None,None,us-gaap:CollaborativeArrangementMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_RevenueRemainingPerformanceObligation_As_Of_3_31_2024_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_CgXJIZ0lhU6UXi_Ite6ZGw_0,us-gaap:RevenueRemainingPerformanceObligation,As_Of_3_31_2024_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_CgXJIZ0lhU6UXi_Ite6ZGw,0,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,0,0.0,instant,2024-03-31,0001621227,http://www.sec.gov/CIK,instant_2024-03-31,Aggregate amount of the transaction price that is allocated to performance obligations that are unsatisfied or partially satisfied under the agreements,Aggregate amount of the transaction price that is allocated to performance obligations that are unsatisfied or partially satisfied under the agreements,Disclosures,http://www.adaptimmune.com/role/DisclosureRevenueRevenueFromContractsWithCustomersDetails,None,None,None,None,None,None,us-gaap:CollaborativeArrangementMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_RevenueRemainingPerformanceObligation_As_Of_3_31_2024_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_CgXJIZ0lhU6UXi_Ite6ZGw_1,us-gaap:RevenueRemainingPerformanceObligation,As_Of_3_31_2024_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_CgXJIZ0lhU6UXi_Ite6ZGw,0,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,0,0.0,instant,2024-03-31,0001621227,http://www.sec.gov/CIK,instant_2024-03-31,Aggregate amount of the transaction price that is allocated to performance obligations that are unsatisfied or partially satisfied under the agreements,Aggregate amount of the transaction price that is allocated to performance obligations that are unsatisfied or partially satisfied under the agreements,Disclosures,http://www.adaptimmune.com/role/DisclosureRevenueRevenueFromContractsWithCustomersDetails,None,None,None,None,None,None,us-gaap:CollaborativeArrangementMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_RevenueRemainingPerformanceObligation_As_Of_3_31_2024_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_CgXJIZ0lhU6UXi_Ite6ZGw_2,us-gaap:RevenueRemainingPerformanceObligation,As_Of_3_31_2024_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_CgXJIZ0lhU6UXi_Ite6ZGw,0,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,0,0.0,instant,2024-03-31,0001621227,http://www.sec.gov/CIK,instant_2024-03-31,Aggregate amount of the transaction price that is allocated to performance obligations that are unsatisfied or partially satisfied under the agreements,Aggregate amount of the transaction price that is allocated to performance obligations that are unsatisfied or partially satisfied under the agreements,Disclosures,http://www.adaptimmune.com/role/DisclosureRevenueRevenueFromContractsWithCustomersDetails,None,None,None,None,None,None,us-gaap:CollaborativeArrangementMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_EarningsPerShareTextBlock_Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,us-gaap:EarningsPerShareTextBlock,Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,"<p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;""><b style=""font-weight:bold;"">Note 4 </b><b style=""font-weight:bold;"">—</b><b style=""font-weight:bold;""> (Loss)/profit per share</b></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"">The following tables reconcile the numerator and denominator in the basic and diluted (loss)/profit per share computation (in thousands):</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p><table style=""border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:97.91%;""><tr style=""height:1pt;""><td style=""vertical-align:bottom;width:74.15%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:normal;width:2.21%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:normal;width:1.35%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:normal;width:10.39%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:normal;width:2.21%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:normal;width:1.35%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:normal;width:8.3%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td></tr><tr><td style=""vertical-align:bottom;width:74.15%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:2.21%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""5"" style=""vertical-align:bottom;white-space:normal;width:23.63%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Three months ended </b></p></td></tr><tr><td style=""vertical-align:bottom;width:74.15%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:2.21%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""5"" style=""vertical-align:bottom;white-space:normal;width:23.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">March 31, </b></p></td></tr><tr><td style=""vertical-align:bottom;width:74.15%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:2.21%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">     </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:normal;width:11.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2024</b></p></td><td style=""vertical-align:bottom;white-space:normal;width:2.21%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">     </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:normal;width:9.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2023</b></p></td></tr><tr><td style=""vertical-align:bottom;width:74.15%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">Numerator for basic and diluted (loss)/profit per share </b></p></td><td style=""vertical-align:bottom;white-space:normal;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:8.3%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;width:74.15%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Net (loss)/profit attributable to ordinary shareholders </p></td><td style=""vertical-align:bottom;white-space:normal;width:2.21%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:normal;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:normal;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (48,503)</p></td><td style=""vertical-align:bottom;white-space:normal;width:2.21%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:normal;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:normal;width:8.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 1,036</p></td></tr><tr><td style=""vertical-align:bottom;width:74.15%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">Net (loss)/profit attributable to ordinary shareholders used for basic and diluted (loss)/profit per share </b></p></td><td style=""vertical-align:bottom;white-space:normal;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""-sec-ix-hidden:Hidden_b0B7Hqu1KEuWrtlWkAguJQ;""><b style=""font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"">$</b></span></p></td><td style=""vertical-align:bottom;white-space:normal;width:10.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><b style=""font-weight:bold;""> (48,503)</b></p></td><td style=""vertical-align:bottom;white-space:normal;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""-sec-ix-hidden:Hidden_rPecj9RftECULLBXu13R1Q;""><b style=""font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"">$</b></span></p></td><td style=""vertical-align:bottom;white-space:normal;width:8.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 1,036</b></p></td></tr></table><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p><table style=""border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:97.91%;""><tr style=""height:1pt;""><td style=""vertical-align:bottom;width:72.58%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.54%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.54%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td></tr><tr><td style=""vertical-align:bottom;width:72.58%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""3"" style=""vertical-align:bottom;white-space:nowrap;width:25.25%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Three months ended </b></p></td></tr><tr><td style=""vertical-align:bottom;width:72.58%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""3"" style=""vertical-align:bottom;white-space:nowrap;width:25.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">March 31, </b></p></td></tr><tr><td style=""vertical-align:bottom;width:72.58%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;""> </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2024</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">    </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2023</b></p></td></tr><tr><td style=""vertical-align:bottom;width:72.58%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Denominator for basic (loss)/profit per share - Weighted average shares outstanding</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.54%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 1,451,241,661</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.54%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 991,330,402</p></td></tr><tr><td style=""vertical-align:bottom;width:72.58%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Effect of dilutive securities:</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.54%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.54%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;width:72.58%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"">Employee stock options </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 8,946,213</p></td></tr><tr><td style=""vertical-align:bottom;width:72.58%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">Denominator for diluted (loss)/profit per share</b> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 1,451,241,661</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 1,000,276,615</b></p></td></tr></table><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"">The dilutive effect of 249,957,127 and 128,614,053 stock options outstanding as of March 31, 2024 and 2023 respectively have been excluded from the diluted (loss)/profit per share calculation for the three months ended March 31, 2024 and 2023 because they would have an antidilutive effect on the (loss)/profit per share for the period.</p>",None,None,,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Loss per share,Loss per share,Disclosures,http://www.adaptimmune.com/role/DisclosureLossPerShare,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock,Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,"<p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"">The following tables reconcile the numerator and denominator in the basic and diluted (loss)/profit per share computation (in thousands):</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p><table style=""border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:97.91%;""><tr style=""height:1pt;""><td style=""vertical-align:bottom;width:74.15%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:normal;width:2.21%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:normal;width:1.35%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:normal;width:10.39%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:normal;width:2.21%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:normal;width:1.35%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:normal;width:8.3%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td></tr><tr><td style=""vertical-align:bottom;width:74.15%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:2.21%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""5"" style=""vertical-align:bottom;white-space:normal;width:23.63%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Three months ended </b></p></td></tr><tr><td style=""vertical-align:bottom;width:74.15%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:2.21%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""5"" style=""vertical-align:bottom;white-space:normal;width:23.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">March 31, </b></p></td></tr><tr><td style=""vertical-align:bottom;width:74.15%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:2.21%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">     </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:normal;width:11.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2024</b></p></td><td style=""vertical-align:bottom;white-space:normal;width:2.21%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">     </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:normal;width:9.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2023</b></p></td></tr><tr><td style=""vertical-align:bottom;width:74.15%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">Numerator for basic and diluted (loss)/profit per share </b></p></td><td style=""vertical-align:bottom;white-space:normal;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:8.3%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;width:74.15%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Net (loss)/profit attributable to ordinary shareholders </p></td><td style=""vertical-align:bottom;white-space:normal;width:2.21%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:normal;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:normal;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (48,503)</p></td><td style=""vertical-align:bottom;white-space:normal;width:2.21%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:normal;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:normal;width:8.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 1,036</p></td></tr><tr><td style=""vertical-align:bottom;width:74.15%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">Net (loss)/profit attributable to ordinary shareholders used for basic and diluted (loss)/profit per share </b></p></td><td style=""vertical-align:bottom;white-space:normal;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""-sec-ix-hidden:Hidden_b0B7Hqu1KEuWrtlWkAguJQ;""><b style=""font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"">$</b></span></p></td><td style=""vertical-align:bottom;white-space:normal;width:10.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><b style=""font-weight:bold;""> (48,503)</b></p></td><td style=""vertical-align:bottom;white-space:normal;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""-sec-ix-hidden:Hidden_rPecj9RftECULLBXu13R1Q;""><b style=""font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"">$</b></span></p></td><td style=""vertical-align:bottom;white-space:normal;width:8.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 1,036</b></p></td></tr></table><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p><table style=""border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:97.91%;""><tr style=""height:1pt;""><td style=""vertical-align:bottom;width:72.58%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.54%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.54%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td></tr><tr><td style=""vertical-align:bottom;width:72.58%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""3"" style=""vertical-align:bottom;white-space:nowrap;width:25.25%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Three months ended </b></p></td></tr><tr><td style=""vertical-align:bottom;width:72.58%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""3"" style=""vertical-align:bottom;white-space:nowrap;width:25.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">March 31, </b></p></td></tr><tr><td style=""vertical-align:bottom;width:72.58%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;""> </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2024</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">    </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2023</b></p></td></tr><tr><td style=""vertical-align:bottom;width:72.58%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Denominator for basic (loss)/profit per share - Weighted average shares outstanding</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.54%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 1,451,241,661</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.54%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 991,330,402</p></td></tr><tr><td style=""vertical-align:bottom;width:72.58%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Effect of dilutive securities:</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.54%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.54%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;width:72.58%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"">Employee stock options </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 8,946,213</p></td></tr><tr><td style=""vertical-align:bottom;width:72.58%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">Denominator for diluted (loss)/profit per share</b> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 1,451,241,661</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 1,000,276,615</b></p></td></tr></table>",None,None,,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Schedule of numerator and denominator in the basic and diluted loss per share computation,Schedule of numerator and denominator in the basic and diluted loss per share computation,Disclosures,http://www.adaptimmune.com/role/DisclosureLossPerShareTables,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_NetIncomeLoss_Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw_3,us-gaap:NetIncomeLoss,Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,-48503000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,-48503000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Net (loss)/profit attributable to ordinary shareholders,Net (loss)/profit attributable to ordinary shareholders,IncomeStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_NetIncomeLoss_Duration_1_1_2023_To_3_31_2023_y-zxPPLZtEmUIwfawHojag_3,us-gaap:NetIncomeLoss,Duration_1_1_2023_To_3_31_2023_y-zxPPLZtEmUIwfawHojag,1036000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,1036000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Net (loss)/profit attributable to ordinary shareholders,Net (loss)/profit attributable to ordinary shareholders,IncomeStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations,2023-01-01,2023-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic,Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,-48503000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,-48503000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Net (loss)/profit attributable to ordinary shareholders used for basic (loss)/profit per share,Net (loss)/profit attributable to ordinary shareholders used for basic (loss)/profit per share,Disclosures,http://www.adaptimmune.com/role/DisclosureLossPerShareBasicAndDilutedLossPerShareDetails,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_Duration_1_1_2023_To_3_31_2023_y-zxPPLZtEmUIwfawHojag,us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic,Duration_1_1_2023_To_3_31_2023_y-zxPPLZtEmUIwfawHojag,1036000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,1036000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Net (loss)/profit attributable to ordinary shareholders used for basic (loss)/profit per share,Net (loss)/profit attributable to ordinary shareholders used for basic (loss)/profit per share,Disclosures,http://www.adaptimmune.com/role/DisclosureLossPerShareBasicAndDilutedLossPerShareDetails,2023-01-01,2023-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw_0,us-gaap:WeightedAverageNumberOfSharesOutstandingBasic,Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,1451241661,Unit_Standard_shares_KIp_HZ7W0kSuHGlx3Wi_-g,0,1451241661.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Weighted average number of shares used to calculate basic loss per share,Weighted average number of shares used to calculate basic loss per share,IncomeStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw_1,us-gaap:WeightedAverageNumberOfSharesOutstandingBasic,Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,1451241661,Unit_Standard_shares_KIp_HZ7W0kSuHGlx3Wi_-g,0,1451241661.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Weighted average number of shares used to calculate basic loss per share,Weighted average number of shares used to calculate basic loss per share,IncomeStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_Duration_1_1_2023_To_3_31_2023_y-zxPPLZtEmUIwfawHojag_0,us-gaap:WeightedAverageNumberOfSharesOutstandingBasic,Duration_1_1_2023_To_3_31_2023_y-zxPPLZtEmUIwfawHojag,991330402,Unit_Standard_shares_KIp_HZ7W0kSuHGlx3Wi_-g,0,991330402.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Weighted average number of shares used to calculate basic loss per share,Weighted average number of shares used to calculate basic loss per share,IncomeStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations,2023-01-01,2023-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_Duration_1_1_2023_To_3_31_2023_y-zxPPLZtEmUIwfawHojag_1,us-gaap:WeightedAverageNumberOfSharesOutstandingBasic,Duration_1_1_2023_To_3_31_2023_y-zxPPLZtEmUIwfawHojag,991330402,Unit_Standard_shares_KIp_HZ7W0kSuHGlx3Wi_-g,0,991330402.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Weighted average number of shares used to calculate basic loss per share,Weighted average number of shares used to calculate basic loss per share,IncomeStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations,2023-01-01,2023-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_Duration_1_1_2023_To_3_31_2023_y-zxPPLZtEmUIwfawHojag,us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements,Duration_1_1_2023_To_3_31_2023_y-zxPPLZtEmUIwfawHojag,8946213,Unit_Standard_shares_KIp_HZ7W0kSuHGlx3Wi_-g,0,8946213.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Employee stock options (in shares),Employee stock options (in shares),Disclosures,http://www.adaptimmune.com/role/DisclosureLossPerShareBasicAndDilutedLossPerShareDetails,2023-01-01,2023-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw_0,us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding,Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,1451241661,Unit_Standard_shares_KIp_HZ7W0kSuHGlx3Wi_-g,0,1451241661.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Denominator for diluted (loss)/profit per share,Denominator for diluted (loss)/profit per share,IncomeStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw_1,us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding,Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,1451241661,Unit_Standard_shares_KIp_HZ7W0kSuHGlx3Wi_-g,0,1451241661.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Denominator for diluted (loss)/profit per share,Denominator for diluted (loss)/profit per share,IncomeStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_Duration_1_1_2023_To_3_31_2023_y-zxPPLZtEmUIwfawHojag_0,us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding,Duration_1_1_2023_To_3_31_2023_y-zxPPLZtEmUIwfawHojag,1000276615,Unit_Standard_shares_KIp_HZ7W0kSuHGlx3Wi_-g,0,1000276615.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Denominator for diluted (loss)/profit per share,Denominator for diluted (loss)/profit per share,IncomeStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations,2023-01-01,2023-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_Duration_1_1_2023_To_3_31_2023_y-zxPPLZtEmUIwfawHojag_1,us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding,Duration_1_1_2023_To_3_31_2023_y-zxPPLZtEmUIwfawHojag,1000276615,Unit_Standard_shares_KIp_HZ7W0kSuHGlx3Wi_-g,0,1000276615.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Denominator for diluted (loss)/profit per share,Denominator for diluted (loss)/profit per share,IncomeStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations,2023-01-01,2023-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_Duration_1_1_2024_To_3_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_adap_EmployeeConsultantsAndDirectorsStockOptionsMember_PpVQ9Ek4eEuRRiP7g1Xalw,us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount,Duration_1_1_2024_To_3_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_adap_EmployeeConsultantsAndDirectorsStockOptionsMember_PpVQ9Ek4eEuRRiP7g1Xalw,249957127,Unit_Standard_shares_KIp_HZ7W0kSuHGlx3Wi_-g,0,249957127.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Potentially dilutive equity instruments excluded from the diluted loss per share (in shares),Potentially dilutive equity instruments excluded from the diluted loss per share (in shares),Disclosures,http://www.adaptimmune.com/role/DisclosureLossPerShareAntidilutiveSharesDetails,2024-01-01,2024-03-31,None,None,None,None,None,adap:EmployeeConsultantsAndDirectorsStockOptionsMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_Duration_1_1_2023_To_3_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_adap_EmployeeConsultantsAndDirectorsStockOptionsMember_mBMGeORrPUmpn-App6XJnA,us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount,Duration_1_1_2023_To_3_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_adap_EmployeeConsultantsAndDirectorsStockOptionsMember_mBMGeORrPUmpn-App6XJnA,128614053,Unit_Standard_shares_KIp_HZ7W0kSuHGlx3Wi_-g,0,128614053.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Potentially dilutive equity instruments excluded from the diluted loss per share (in shares),Potentially dilutive equity instruments excluded from the diluted loss per share (in shares),Disclosures,http://www.adaptimmune.com/role/DisclosureLossPerShareAntidilutiveSharesDetails,2023-01-01,2023-03-31,None,None,None,None,None,adap:EmployeeConsultantsAndDirectorsStockOptionsMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_ComprehensiveIncomeNoteTextBlock_Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,us-gaap:ComprehensiveIncomeNoteTextBlock,Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,"<p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;""><b style=""font-weight:bold;"">Note 5 </b><b style=""font-weight:bold;"">—</b><b style=""font-weight:bold;""> Accumulated other comprehensive (loss)/income</b></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">The Company reports foreign currency translation adjustments and the foreign exchange gain or losses arising on the revaluation of intercompany loans of a long-term investment nature within Other comprehensive (loss) income. Unrealized gains and losses on available-for-sale debt securities are also reported within Other comprehensive (loss) income until a gain or loss is realized, at which point they are reclassified to Other (expense) income, net in the Condensed Consolidated Statement of Operations.</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">The following tables show the changes in Accumulated other comprehensive (loss) income (in thousands):</p><table style=""border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;""><tr style=""height:1pt;""><td style=""vertical-align:bottom;width:63.81%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.8%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:63.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""color:#0563c1;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Accumulated</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Accumulated</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Total</b></p></td></tr><tr><td style=""vertical-align:bottom;width:63.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">foreign</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">unrealized</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">accumulated</b></p></td></tr><tr><td style=""vertical-align:bottom;width:63.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">currency</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">(losses) gains on</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">other</b></p></td></tr><tr><td style=""vertical-align:bottom;width:63.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">    </p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">translation </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">    </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">available-for-sale</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">comprehensive</b></p></td></tr><tr><td style=""vertical-align:bottom;width:63.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">adjustments</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">debt securities</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">(loss) income</b></p></td></tr><tr><td style=""vertical-align:bottom;width:63.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.8%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;width:63.81%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Balance at January 1, 2024</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.8%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (3,754)</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.87%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 6</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.17%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (3,748)</p></td></tr><tr><td style=""vertical-align:bottom;width:63.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"">Foreign currency translation adjustments</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.8%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 6,815</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 6,815</p></td></tr><tr><td style=""vertical-align:bottom;width:63.81%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"">Foreign currency gains on intercompany loan of a long-term investment nature, net of tax of $0</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.8%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (5,782)</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.87%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.17%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (5,782)</p></td></tr><tr><td style=""vertical-align:bottom;width:63.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"">Unrealized holding gains on available-for-sale debt securities, net of tax of $0</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (5)</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (5)</p></td></tr><tr><td style=""vertical-align:bottom;width:63.81%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">Balance at March 31, 2024</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><b style=""font-weight:bold;""> (2,721)</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.87%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 1</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><b style=""font-weight:bold;""> (2,720)</b></p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:63.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.8%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:63.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""color:#0563c1;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Accumulated</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Accumulated</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Total</b></p></td></tr><tr><td style=""vertical-align:bottom;width:63.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">foreign</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">unrealized</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">accumulated</b></p></td></tr><tr><td style=""vertical-align:bottom;width:63.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">currency</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;""> (losses) on</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">other</b></p></td></tr><tr><td style=""vertical-align:bottom;width:63.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">    </p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">translation </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">    </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">available-for-sale</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">comprehensive</b></p></td></tr><tr><td style=""vertical-align:bottom;width:63.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">adjustments</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">debt securities</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">(loss) income</b></p></td></tr><tr><td style=""vertical-align:bottom;width:63.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.8%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;width:63.81%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Balance at January 1, 2023</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;""> </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.8%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 55</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.87%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><b style=""font-weight:bold;""> (930)</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.17%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><b style=""font-weight:bold;""> (875)</b></p></td></tr><tr><td style=""vertical-align:bottom;width:63.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"">Foreign currency translation adjustments</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.8%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (16,908)</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (16,908)</p></td></tr><tr><td style=""vertical-align:bottom;width:63.81%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"">Foreign currency gains on intercompany loan of a long-term investment nature, net of tax of $0</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.8%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 15,526</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.87%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.17%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 15,526</p></td></tr><tr><td style=""vertical-align:bottom;width:63.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"">Unrealized holding gains on available-for-sale debt securities, net of tax of $0</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 472</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 472</p></td></tr><tr><td style=""vertical-align:bottom;width:63.81%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">Balance at March 31, 2023</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><b style=""font-weight:bold;""> (1,327)</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.87%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><b style=""font-weight:bold;""> (458)</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><b style=""font-weight:bold;""> (1,785)</b></p></td></tr></table><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p>",None,None,,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Accumulated other comprehensive loss,Accumulated other comprehensive loss,Disclosures,http://www.adaptimmune.com/role/DisclosureAccumulatedOtherComprehensiveLoss,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock,Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,"<p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">The following tables show the changes in Accumulated other comprehensive (loss) income (in thousands):</p><table style=""border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;""><tr style=""height:1pt;""><td style=""vertical-align:bottom;width:63.81%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.8%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:63.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""color:#0563c1;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Accumulated</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Accumulated</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Total</b></p></td></tr><tr><td style=""vertical-align:bottom;width:63.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">foreign</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">unrealized</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">accumulated</b></p></td></tr><tr><td style=""vertical-align:bottom;width:63.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">currency</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">(losses) gains on</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">other</b></p></td></tr><tr><td style=""vertical-align:bottom;width:63.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">    </p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">translation </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">    </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">available-for-sale</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">comprehensive</b></p></td></tr><tr><td style=""vertical-align:bottom;width:63.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">adjustments</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">debt securities</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">(loss) income</b></p></td></tr><tr><td style=""vertical-align:bottom;width:63.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.8%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;width:63.81%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Balance at January 1, 2024</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.8%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (3,754)</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.87%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 6</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.17%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (3,748)</p></td></tr><tr><td style=""vertical-align:bottom;width:63.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"">Foreign currency translation adjustments</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.8%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 6,815</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 6,815</p></td></tr><tr><td style=""vertical-align:bottom;width:63.81%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"">Foreign currency gains on intercompany loan of a long-term investment nature, net of tax of $0</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.8%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (5,782)</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.87%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.17%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (5,782)</p></td></tr><tr><td style=""vertical-align:bottom;width:63.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"">Unrealized holding gains on available-for-sale debt securities, net of tax of $0</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (5)</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (5)</p></td></tr><tr><td style=""vertical-align:bottom;width:63.81%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">Balance at March 31, 2024</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><b style=""font-weight:bold;""> (2,721)</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.87%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 1</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><b style=""font-weight:bold;""> (2,720)</b></p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:63.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.8%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:63.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""color:#0563c1;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Accumulated</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Accumulated</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Total</b></p></td></tr><tr><td style=""vertical-align:bottom;width:63.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">foreign</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">unrealized</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">accumulated</b></p></td></tr><tr><td style=""vertical-align:bottom;width:63.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">currency</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;""> (losses) on</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">other</b></p></td></tr><tr><td style=""vertical-align:bottom;width:63.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">    </p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">translation </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">    </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">available-for-sale</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">comprehensive</b></p></td></tr><tr><td style=""vertical-align:bottom;width:63.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">adjustments</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">debt securities</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">(loss) income</b></p></td></tr><tr><td style=""vertical-align:bottom;width:63.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.8%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;width:63.81%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Balance at January 1, 2023</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;""> </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.8%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 55</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.87%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><b style=""font-weight:bold;""> (930)</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.17%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><b style=""font-weight:bold;""> (875)</b></p></td></tr><tr><td style=""vertical-align:bottom;width:63.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"">Foreign currency translation adjustments</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.8%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (16,908)</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (16,908)</p></td></tr><tr><td style=""vertical-align:bottom;width:63.81%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"">Foreign currency gains on intercompany loan of a long-term investment nature, net of tax of $0</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.8%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 15,526</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.87%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.17%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 15,526</p></td></tr><tr><td style=""vertical-align:bottom;width:63.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"">Unrealized holding gains on available-for-sale debt securities, net of tax of $0</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 472</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 472</p></td></tr><tr><td style=""vertical-align:bottom;width:63.81%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">Balance at March 31, 2023</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><b style=""font-weight:bold;""> (1,327)</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.87%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><b style=""font-weight:bold;""> (458)</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><b style=""font-weight:bold;""> (1,785)</b></p></td></tr></table><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p>",None,None,,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Schedule of changes in Accumulated other comprehensive (loss) income,Schedule of changes in Accumulated other comprehensive (loss) income,Disclosures,http://www.adaptimmune.com/role/DisclosureAccumulatedOtherComprehensiveLossTables,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember_ERY_XKy5VE6zll4cWuVD-A,us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax,As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember_ERY_XKy5VE6zll4cWuVD-A,-3754000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,-3754000.0,instant,2023-12-31,0001621227,http://www.sec.gov/CIK,instant_2023-12-31,Accumulated other comprehensive loss,Accumulated other comprehensive loss,BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,us-gaap:AccumulatedTranslationAdjustmentMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_fU2gzPHZykiVCi4s7Ma9XQ,us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax,As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_fU2gzPHZykiVCi4s7Ma9XQ,6000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,6000.0,instant,2023-12-31,0001621227,http://www.sec.gov/CIK,instant_2023-12-31,Accumulated other comprehensive loss,Accumulated other comprehensive loss,BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_tkvdGIkNGU63Xe1bah-Tww,us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax,As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_tkvdGIkNGU63Xe1bah-Tww,-3748000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,-3748000.0,instant,2023-12-31,0001621227,http://www.sec.gov/CIK,instant_2023-12-31,Accumulated other comprehensive loss,Accumulated other comprehensive loss,BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,us-gaap:AccumulatedOtherComprehensiveIncomeMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember_tFMOrKFU6EeYJshy4y62Sg,us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent,Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember_tFMOrKFU6EeYJshy4y62Sg,6815000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,6815000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,"Foreign currency translation adjustments, net of tax of $0, and $0","Foreign currency translation adjustments, net of tax of $0, and $0",ComprehensiveIncome,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss,2024-01-01,2024-03-31,us-gaap:AccumulatedTranslationAdjustmentMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ik82ej81LUa-lrat2TUS3A,us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent,Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ik82ej81LUa-lrat2TUS3A,6815000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,6815000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,"Foreign currency translation adjustments, net of tax of $0, and $0","Foreign currency translation adjustments, net of tax of $0, and $0",ComprehensiveIncome,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss,2024-01-01,2024-03-31,us-gaap:AccumulatedOtherComprehensiveIncomeMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw_0,us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax,Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,0,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,0.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,"Foreign currency gains (losses) on intercompany loan of a long-term investment nature, tax","Foreign currency gains (losses) on intercompany loan of a long-term investment nature, tax",ComprehensiveIncomeParenthetical,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLossParenthetical,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw_1,us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax,Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,0,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,0.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,"Foreign currency gains (losses) on intercompany loan of a long-term investment nature, tax","Foreign currency gains (losses) on intercompany loan of a long-term investment nature, tax",ComprehensiveIncomeParenthetical,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLossParenthetical,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember_tFMOrKFU6EeYJshy4y62Sg,us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax,Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember_tFMOrKFU6EeYJshy4y62Sg,-5782000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,-5782000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,"Foreign currency gains (losses) on intercompany loan of a long-term investment nature, net of tax of $0, and $0","Foreign currency gains (losses) on intercompany loan of a long-term investment nature, net of tax of $0, and $0",ComprehensiveIncome,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss,2024-01-01,2024-03-31,us-gaap:AccumulatedTranslationAdjustmentMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ik82ej81LUa-lrat2TUS3A,us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax,Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ik82ej81LUa-lrat2TUS3A,-5782000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,-5782000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,"Foreign currency gains (losses) on intercompany loan of a long-term investment nature, net of tax of $0, and $0","Foreign currency gains (losses) on intercompany loan of a long-term investment nature, net of tax of $0, and $0",ComprehensiveIncome,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss,2024-01-01,2024-03-31,us-gaap:AccumulatedOtherComprehensiveIncomeMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw_0,us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax,Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,0,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,0.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,"Unrealized holding gains (losses) on available-for-sale debt securities, tax","Unrealized holding gains (losses) on available-for-sale debt securities, tax",ComprehensiveIncomeParenthetical,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLossParenthetical,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw_1,us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax,Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,0,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,0.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,"Unrealized holding gains (losses) on available-for-sale debt securities, tax","Unrealized holding gains (losses) on available-for-sale debt securities, tax",ComprehensiveIncomeParenthetical,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLossParenthetical,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_DuxLXSUx20e_EEYRiDmCPw,us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax,Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_DuxLXSUx20e_EEYRiDmCPw,-5000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,-5000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,"Unrealized holding gains (losses) on available-for-sale debt securities, net of tax of $0, and $0","Unrealized holding gains (losses) on available-for-sale debt securities, net of tax of $0, and $0",ComprehensiveIncome,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss,2024-01-01,2024-03-31,us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ik82ej81LUa-lrat2TUS3A,us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax,Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ik82ej81LUa-lrat2TUS3A,-5000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,-5000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,"Unrealized holding gains (losses) on available-for-sale debt securities, net of tax of $0, and $0","Unrealized holding gains (losses) on available-for-sale debt securities, net of tax of $0, and $0",ComprehensiveIncome,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss,2024-01-01,2024-03-31,us-gaap:AccumulatedOtherComprehensiveIncomeMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember_TwELFEUggEqXjeNYWOEsHA,us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax,As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember_TwELFEUggEqXjeNYWOEsHA,-2721000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,-2721000.0,instant,2024-03-31,0001621227,http://www.sec.gov/CIK,instant_2024-03-31,Accumulated other comprehensive loss,Accumulated other comprehensive loss,BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,us-gaap:AccumulatedTranslationAdjustmentMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_FZaoIPB6O0mh4FXGFLfhEA,us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax,As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_FZaoIPB6O0mh4FXGFLfhEA,1000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,1000.0,instant,2024-03-31,0001621227,http://www.sec.gov/CIK,instant_2024-03-31,Accumulated other comprehensive loss,Accumulated other comprehensive loss,BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_v2ut_2fa5ESuyOEeiRPKyg,us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax,As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_v2ut_2fa5ESuyOEeiRPKyg,-2720000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,-2720000.0,instant,2024-03-31,0001621227,http://www.sec.gov/CIK,instant_2024-03-31,Accumulated other comprehensive loss,Accumulated other comprehensive loss,BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,us-gaap:AccumulatedOtherComprehensiveIncomeMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember_Muw5EdBklU-ByLI6TPJkYw,us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax,As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember_Muw5EdBklU-ByLI6TPJkYw,55000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,55000.0,instant,2022-12-31,0001621227,http://www.sec.gov/CIK,instant_2022-12-31,Accumulated other comprehensive loss,Accumulated other comprehensive loss,BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,us-gaap:AccumulatedTranslationAdjustmentMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_OlMwAJWF6kiYQL3KmBDRRA,us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax,As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_OlMwAJWF6kiYQL3KmBDRRA,-930000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,-930000.0,instant,2022-12-31,0001621227,http://www.sec.gov/CIK,instant_2022-12-31,Accumulated other comprehensive loss,Accumulated other comprehensive loss,BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_hME9tfmP2kaZUkIIyxGkiw,us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax,As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_hME9tfmP2kaZUkIIyxGkiw,-875000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,-875000.0,instant,2022-12-31,0001621227,http://www.sec.gov/CIK,instant_2022-12-31,Accumulated other comprehensive loss,Accumulated other comprehensive loss,BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,us-gaap:AccumulatedOtherComprehensiveIncomeMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember_nlZz0irTwUGOGQ_j9R9UvA,us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent,Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember_nlZz0irTwUGOGQ_j9R9UvA,-16908000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,-16908000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,"Foreign currency translation adjustments, net of tax of $0, and $0","Foreign currency translation adjustments, net of tax of $0, and $0",ComprehensiveIncome,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss,2023-01-01,2023-03-31,us-gaap:AccumulatedTranslationAdjustmentMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_brTNdJkkYEGDtW7dPYUueg,us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent,Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_brTNdJkkYEGDtW7dPYUueg,-16908000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,-16908000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,"Foreign currency translation adjustments, net of tax of $0, and $0","Foreign currency translation adjustments, net of tax of $0, and $0",ComprehensiveIncome,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss,2023-01-01,2023-03-31,us-gaap:AccumulatedOtherComprehensiveIncomeMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_Duration_1_1_2023_To_3_31_2023_y-zxPPLZtEmUIwfawHojag_0,us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax,Duration_1_1_2023_To_3_31_2023_y-zxPPLZtEmUIwfawHojag,0,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,0.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,"Foreign currency gains (losses) on intercompany loan of a long-term investment nature, tax","Foreign currency gains (losses) on intercompany loan of a long-term investment nature, tax",ComprehensiveIncomeParenthetical,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLossParenthetical,2023-01-01,2023-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_Duration_1_1_2023_To_3_31_2023_y-zxPPLZtEmUIwfawHojag_1,us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax,Duration_1_1_2023_To_3_31_2023_y-zxPPLZtEmUIwfawHojag,0,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,0.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,"Foreign currency gains (losses) on intercompany loan of a long-term investment nature, tax","Foreign currency gains (losses) on intercompany loan of a long-term investment nature, tax",ComprehensiveIncomeParenthetical,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLossParenthetical,2023-01-01,2023-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember_nlZz0irTwUGOGQ_j9R9UvA,us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax,Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember_nlZz0irTwUGOGQ_j9R9UvA,15526000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,15526000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,"Foreign currency gains (losses) on intercompany loan of a long-term investment nature, net of tax of $0, and $0","Foreign currency gains (losses) on intercompany loan of a long-term investment nature, net of tax of $0, and $0",ComprehensiveIncome,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss,2023-01-01,2023-03-31,us-gaap:AccumulatedTranslationAdjustmentMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_brTNdJkkYEGDtW7dPYUueg,us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax,Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_brTNdJkkYEGDtW7dPYUueg,15526000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,15526000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,"Foreign currency gains (losses) on intercompany loan of a long-term investment nature, net of tax of $0, and $0","Foreign currency gains (losses) on intercompany loan of a long-term investment nature, net of tax of $0, and $0",ComprehensiveIncome,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss,2023-01-01,2023-03-31,us-gaap:AccumulatedOtherComprehensiveIncomeMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_Duration_1_1_2023_To_3_31_2023_y-zxPPLZtEmUIwfawHojag_0,us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax,Duration_1_1_2023_To_3_31_2023_y-zxPPLZtEmUIwfawHojag,0,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,0.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,"Unrealized holding gains (losses) on available-for-sale debt securities, tax","Unrealized holding gains (losses) on available-for-sale debt securities, tax",ComprehensiveIncomeParenthetical,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLossParenthetical,2023-01-01,2023-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_Duration_1_1_2023_To_3_31_2023_y-zxPPLZtEmUIwfawHojag_1,us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax,Duration_1_1_2023_To_3_31_2023_y-zxPPLZtEmUIwfawHojag,0,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,0.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,"Unrealized holding gains (losses) on available-for-sale debt securities, tax","Unrealized holding gains (losses) on available-for-sale debt securities, tax",ComprehensiveIncomeParenthetical,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLossParenthetical,2023-01-01,2023-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_lQGOegoQO0mdRrhVePBtIQ,us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax,Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_lQGOegoQO0mdRrhVePBtIQ,472000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,472000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,"Unrealized holding gains (losses) on available-for-sale debt securities, net of tax of $0, and $0","Unrealized holding gains (losses) on available-for-sale debt securities, net of tax of $0, and $0",ComprehensiveIncome,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss,2023-01-01,2023-03-31,us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_brTNdJkkYEGDtW7dPYUueg,us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax,Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_brTNdJkkYEGDtW7dPYUueg,472000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,472000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,"Unrealized holding gains (losses) on available-for-sale debt securities, net of tax of $0, and $0","Unrealized holding gains (losses) on available-for-sale debt securities, net of tax of $0, and $0",ComprehensiveIncome,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss,2023-01-01,2023-03-31,us-gaap:AccumulatedOtherComprehensiveIncomeMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember_4pN7GNc--kCCrWqrhNMyCw,us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax,As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember_4pN7GNc--kCCrWqrhNMyCw,-1327000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,-1327000.0,instant,2023-03-31,0001621227,http://www.sec.gov/CIK,instant_2023-03-31,Accumulated other comprehensive loss,Accumulated other comprehensive loss,BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,us-gaap:AccumulatedTranslationAdjustmentMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_LNIxv5qQ5UuKBFmMjRxgMg,us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax,As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_LNIxv5qQ5UuKBFmMjRxgMg,-458000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,-458000.0,instant,2023-03-31,0001621227,http://www.sec.gov/CIK,instant_2023-03-31,Accumulated other comprehensive loss,Accumulated other comprehensive loss,BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_eUwaKI6UPUS6nbtSznTejA,us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax,As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_eUwaKI6UPUS6nbtSznTejA,-1785000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,-1785000.0,instant,2023-03-31,0001621227,http://www.sec.gov/CIK,instant_2023-03-31,Accumulated other comprehensive loss,Accumulated other comprehensive loss,BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,us-gaap:AccumulatedOtherComprehensiveIncomeMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_FairValueDisclosuresTextBlock_Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,us-gaap:FairValueDisclosuresTextBlock,Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,"<p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;""><b style=""font-weight:bold;"">Note 6 </b><b style=""font-weight:bold;"">—</b><b style=""font-weight:bold;""> Fair value measurements</b></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">Assets and liabilities measured at fair value on a recurring basis based on Level 1, Level 2, and Level 3 fair value measurement criteria as of March 31, 2024 are as follows (in thousands):</p><table style=""border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;""><tr style=""height:1pt;""><td style=""vertical-align:bottom;width:56.07%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.89%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;width:56.07%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""8"" style=""vertical-align:bottom;white-space:nowrap;width:29.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Fair value measurements using</b></p></td></tr><tr><td style=""vertical-align:bottom;width:56.07%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">March 31, </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Level 1</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Level 2</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:7.92%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Level 3</b></p></td></tr><tr><td style=""vertical-align:bottom;width:56.07%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">     </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2024</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">    </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">    </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">    </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;width:56.07%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">Assets classified as available-for-sale debt securities:</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.17%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.81%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.89%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;width:56.07%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Corporate debt securities </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 2,982</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 2,982</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td></tr><tr><td style=""vertical-align:bottom;width:56.07%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 2,982</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 2,982</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> —</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.89%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> —</b></p></td></tr></table><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"">The Company estimates the fair value of available-for-sale debt securities with the aid of a third party valuation service, which uses actual trade and indicative prices sourced from third-party providers on a daily basis to estimate the fair value. If observed market prices are not available (for example securities with short maturities and infrequent secondary market trades), the securities are priced using a valuation model maximizing observable inputs, including market interest rates.</p>",None,None,,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Fair value measurements,Fair value measurements,Disclosures,http://www.adaptimmune.com/role/DisclosureFairValueMeasurements,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock,Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,"<p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">Assets and liabilities measured at fair value on a recurring basis based on Level 1, Level 2, and Level 3 fair value measurement criteria as of March 31, 2024 are as follows (in thousands):</p><table style=""border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;""><tr style=""height:1pt;""><td style=""vertical-align:bottom;width:56.07%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.89%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;width:56.07%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""8"" style=""vertical-align:bottom;white-space:nowrap;width:29.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Fair value measurements using</b></p></td></tr><tr><td style=""vertical-align:bottom;width:56.07%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">March 31, </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Level 1</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Level 2</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:7.92%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Level 3</b></p></td></tr><tr><td style=""vertical-align:bottom;width:56.07%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">     </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2024</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">    </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">    </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">    </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;width:56.07%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">Assets classified as available-for-sale debt securities:</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.17%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.81%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.89%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;width:56.07%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Corporate debt securities </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 2,982</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 2,982</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td></tr><tr><td style=""vertical-align:bottom;width:56.07%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 2,982</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 2,982</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> —</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.89%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> —</b></p></td></tr></table>",None,None,,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Summary of fair value of assets and liabilities on a recurring basis based on fair value measurement criteria,Summary of fair value of assets and liabilities on a recurring basis based on fair value measurement criteria,Disclosures,http://www.adaptimmune.com/role/DisclosureFairValueMeasurementsTables,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_As_Of_3_31_2024_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryBillSecuritiesMember_aIATOVuTc0m6rZxg09-upw,us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent,As_Of_3_31_2024_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryBillSecuritiesMember_aIATOVuTc0m6rZxg09-upw,2982000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,2982000.0,instant,2024-03-31,0001621227,http://www.sec.gov/CIK,instant_2024-03-31,"Marketable securities - available-for-sale debt securities (amortized cost of $2,981 and $2,940) net of allowance for expected credit losses of $0 and $0","Marketable securities - available-for-sale debt securities (amortized cost of $2,981 and $2,940) net of allowance for expected credit losses of $0 and $0",BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,None,None,None,None,None,us-gaap:FairValueMeasurementsRecurringMember,us-gaap:USTreasuryBillSecuritiesMember,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_As_Of_3_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryBillSecuritiesMember_4DmNRWIxGkKE04hUqeE1vw,us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent,As_Of_3_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryBillSecuritiesMember_4DmNRWIxGkKE04hUqeE1vw,2982000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,2982000.0,instant,2024-03-31,0001621227,http://www.sec.gov/CIK,instant_2024-03-31,"Marketable securities - available-for-sale debt securities (amortized cost of $2,981 and $2,940) net of allowance for expected credit losses of $0 and $0","Marketable securities - available-for-sale debt securities (amortized cost of $2,981 and $2,940) net of allowance for expected credit losses of $0 and $0",BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,None,None,None,None,None,us-gaap:FairValueMeasurementsRecurringMember,us-gaap:USTreasuryBillSecuritiesMember,us-gaap:FairValueInputsLevel1Member,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_As_Of_3_31_2024_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_zixC8N6Xd0-lrjlCvpv58w,us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent,As_Of_3_31_2024_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_zixC8N6Xd0-lrjlCvpv58w,2982000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,2982000.0,instant,2024-03-31,0001621227,http://www.sec.gov/CIK,instant_2024-03-31,"Marketable securities - available-for-sale debt securities (amortized cost of $2,981 and $2,940) net of allowance for expected credit losses of $0 and $0","Marketable securities - available-for-sale debt securities (amortized cost of $2,981 and $2,940) net of allowance for expected credit losses of $0 and $0",BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,None,None,None,None,None,us-gaap:FairValueMeasurementsRecurringMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_As_Of_3_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_EurL6Oo9gEWY30J5qzAZtA,us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent,As_Of_3_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_EurL6Oo9gEWY30J5qzAZtA,2982000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,2982000.0,instant,2024-03-31,0001621227,http://www.sec.gov/CIK,instant_2024-03-31,"Marketable securities - available-for-sale debt securities (amortized cost of $2,981 and $2,940) net of allowance for expected credit losses of $0 and $0","Marketable securities - available-for-sale debt securities (amortized cost of $2,981 and $2,940) net of allowance for expected credit losses of $0 and $0",BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,None,None,None,None,None,us-gaap:FairValueMeasurementsRecurringMember,None,us-gaap:FairValueInputsLevel1Member,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock,Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,"<p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;""><b style=""font-weight:bold;"">Note 7 — Marketable securities – available-for-sale debt securities</b></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">As of March 31, 2024, the Company has the following investments in marketable securities (in thousands):</p><table style=""border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.089717865%;padding-left:0pt;padding-right:0pt;width:100%;""><tr style=""height:1pt;""><td style=""vertical-align:bottom;width:40.63%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:13.34%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.34%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.88%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.6%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.86%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;width:40.63%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:13.34%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.34%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Gross</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Gross</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:7.8%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Aggregate</b></p></td></tr><tr><td style=""vertical-align:bottom;width:40.63%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:13.34%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Remaining</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Amortized</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.34%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">unrealized</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">unrealized</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:7.8%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">estimated</b></p></td></tr><tr><td style=""vertical-align:bottom;width:40.63%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">    </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:13.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">contractual maturity</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">    </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">cost</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.34%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">    </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:9.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">gains</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">    </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:7.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">losses</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">    </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:7.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">fair value</b></p></td></tr><tr><td style=""vertical-align:bottom;width:40.63%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">Available-for-sale debt securities:</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;""> </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:13.34%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><b style=""font-weight:bold;"">  </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"">  </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.34%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.88%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"">  </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.6%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"">  </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.86%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"">  </p></td></tr><tr><td style=""vertical-align:bottom;width:40.63%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Corporate debt securities</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:13.34%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"">3 months to 1 year</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 2,981</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.34%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 1</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 2,982</p></td></tr><tr><td style=""vertical-align:bottom;width:40.63%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:13.34%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"">  </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 2,981</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.34%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 1</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> —</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 2,982</b></p></td></tr></table><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">The aggregate fair value (in thousands) and number of securities held by the Company (including those classified as cash equivalents) in an unrealized loss position as of March 31, 2024 and December 31, 2023 are as follows: </p><table style=""border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;""><tr style=""height:1pt;""><td style=""vertical-align:bottom;width:41.67%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.78%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;width:41.67%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.78%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;width:41.67%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""8"" style=""vertical-align:bottom;white-space:nowrap;width:28.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">March 31, 2024</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""8"" style=""vertical-align:bottom;white-space:nowrap;width:26.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">December 31, 2023</b></p></td></tr><tr><td style=""vertical-align:bottom;width:41.67%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">     </b></p></td><td colspan=""2"" style=""vertical-align:bottom;width:9.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Fair market value of investments in an unrealized loss position</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Number of investments in an unrealized loss position</b></p></td><td style=""vertical-align:bottom;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Unrealized losses</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Fair market value of investments in an unrealized loss position</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Number of investments in an unrealized loss position</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;width:7.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Unrealized losses</b></p></td></tr><tr><td style=""vertical-align:bottom;width:41.67%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">Marketable securities in a continuous loss position for less than 12 months:</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.78%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;width:41.67%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Corporate debt securities </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 1,600</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 1</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (1)</p></td></tr><tr><td style=""vertical-align:bottom;width:41.67%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> —</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> —</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> —</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 1,600</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 1</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><b style=""font-weight:bold;""> (1)</b></p></td></tr></table><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;""><span style=""visibility:hidden;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">As of March 31, 2024, no allowance for expected credit losses has been recognized in relation to securities in an unrealized loss position as there are no securities in an unrealized loss position.</p>",None,None,,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Marketable securities - available-for-sale debt securities,Marketable securities - available-for-sale debt securities,Disclosures,http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecurities,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock,Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,"<p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">As of March 31, 2024, the Company has the following investments in marketable securities (in thousands):</p><table style=""border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.089717865%;padding-left:0pt;padding-right:0pt;width:100%;""><tr style=""height:1pt;""><td style=""vertical-align:bottom;width:40.63%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:13.34%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.34%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.88%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.6%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.86%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;width:40.63%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:13.34%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.34%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Gross</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Gross</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:7.8%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Aggregate</b></p></td></tr><tr><td style=""vertical-align:bottom;width:40.63%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:13.34%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Remaining</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Amortized</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.34%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">unrealized</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">unrealized</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:7.8%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">estimated</b></p></td></tr><tr><td style=""vertical-align:bottom;width:40.63%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">    </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:13.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">contractual maturity</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">    </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">cost</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.34%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">    </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:9.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">gains</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">    </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:7.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">losses</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">    </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:7.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">fair value</b></p></td></tr><tr><td style=""vertical-align:bottom;width:40.63%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">Available-for-sale debt securities:</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;""> </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:13.34%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><b style=""font-weight:bold;"">  </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"">  </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.34%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.88%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"">  </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.6%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"">  </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.86%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"">  </p></td></tr><tr><td style=""vertical-align:bottom;width:40.63%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Corporate debt securities</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:13.34%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"">3 months to 1 year</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 2,981</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.34%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 1</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 2,982</p></td></tr><tr><td style=""vertical-align:bottom;width:40.63%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:13.34%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"">  </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 2,981</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.34%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 1</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> —</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 2,982</b></p></td></tr></table>",None,None,,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Schedule of marketable securities,Schedule of marketable securities,Disclosures,http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesTables,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
adap_AvailableForSaleSecuritiesDebtMaturityPeriod_Duration_1_1_2024_To_3_31_2024_srt_RangeAxis_srt_MinimumMember_us-gaap_FairValueByAssetClassAxis_us-gaap_DebtSecuritiesMember_us-gaap_FinancialInstrumentAxis_adap_CorporateDebtSecuritiesMaturityPeriodThreeMonthsToOneYearMember_bpO2-7SZKkyAqVvvElNeDQ,adap:AvailableForSaleSecuritiesDebtMaturityPeriod,Duration_1_1_2024_To_3_31_2024_srt_RangeAxis_srt_MinimumMember_us-gaap_FairValueByAssetClassAxis_us-gaap_DebtSecuritiesMember_us-gaap_FinancialInstrumentAxis_adap_CorporateDebtSecuritiesMaturityPeriodThreeMonthsToOneYearMember_bpO2-7SZKkyAqVvvElNeDQ,P3M,None,None,,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Available For Sale Securities Debt Maturity Period,Available For Sale Securities Debt Maturity Period,Disclosures,http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesDetails,2024-01-01,2024-03-31,None,None,None,None,None,None,None,adap:CorporateDebtSecuritiesMaturityPeriodThreeMonthsToOneYearMember,None,srt:MinimumMember,us-gaap:DebtSecuritiesMember,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
adap_AvailableForSaleSecuritiesDebtMaturityPeriod_Duration_1_1_2024_To_3_31_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_FairValueByAssetClassAxis_us-gaap_DebtSecuritiesMember_us-gaap_FinancialInstrumentAxis_adap_CorporateDebtSecuritiesMaturityPeriodThreeMonthsToOneYearMember_qUnxz0VzaUqFkQRUzPlVcQ,adap:AvailableForSaleSecuritiesDebtMaturityPeriod,Duration_1_1_2024_To_3_31_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_FairValueByAssetClassAxis_us-gaap_DebtSecuritiesMember_us-gaap_FinancialInstrumentAxis_adap_CorporateDebtSecuritiesMaturityPeriodThreeMonthsToOneYearMember_qUnxz0VzaUqFkQRUzPlVcQ,P1Y,None,None,,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Available For Sale Securities Debt Maturity Period,Available For Sale Securities Debt Maturity Period,Disclosures,http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesDetails,2024-01-01,2024-03-31,None,None,None,None,None,None,None,adap:CorporateDebtSecuritiesMaturityPeriodThreeMonthsToOneYearMember,None,srt:MaximumMember,us-gaap:DebtSecuritiesMember,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_As_Of_3_31_2024_us-gaap_FairValueByAssetClassAxis_us-gaap_DebtSecuritiesMember_us-gaap_FinancialInstrumentAxis_adap_CorporateDebtSecuritiesMaturityPeriodThreeMonthsToOneYearMember_7RuM64U-a0aObQUPJYUozA,us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis,As_Of_3_31_2024_us-gaap_FairValueByAssetClassAxis_us-gaap_DebtSecuritiesMember_us-gaap_FinancialInstrumentAxis_adap_CorporateDebtSecuritiesMaturityPeriodThreeMonthsToOneYearMember_7RuM64U-a0aObQUPJYUozA,2981000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,2981000.0,instant,2024-03-31,0001621227,http://www.sec.gov/CIK,instant_2024-03-31,Amortized cost,Amortized cost,Disclosures,http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesDetails,None,None,None,None,None,None,None,None,None,adap:CorporateDebtSecuritiesMaturityPeriodThreeMonthsToOneYearMember,None,None,us-gaap:DebtSecuritiesMember,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_As_Of_3_31_2024_us-gaap_FairValueByAssetClassAxis_us-gaap_DebtSecuritiesMember_us-gaap_FinancialInstrumentAxis_adap_CorporateDebtSecuritiesMaturityPeriodThreeMonthsToOneYearMember_7RuM64U-a0aObQUPJYUozA,us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax,As_Of_3_31_2024_us-gaap_FairValueByAssetClassAxis_us-gaap_DebtSecuritiesMember_us-gaap_FinancialInstrumentAxis_adap_CorporateDebtSecuritiesMaturityPeriodThreeMonthsToOneYearMember_7RuM64U-a0aObQUPJYUozA,-1000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,-1000.0,instant,2024-03-31,0001621227,http://www.sec.gov/CIK,instant_2024-03-31,Gross unrealized gains,Gross unrealized gains,Disclosures,http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesDetails,None,None,None,None,None,None,None,None,None,adap:CorporateDebtSecuritiesMaturityPeriodThreeMonthsToOneYearMember,None,None,us-gaap:DebtSecuritiesMember,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_AvailableForSaleSecuritiesDebtSecurities_As_Of_3_31_2024_us-gaap_FairValueByAssetClassAxis_us-gaap_DebtSecuritiesMember_us-gaap_FinancialInstrumentAxis_adap_CorporateDebtSecuritiesMaturityPeriodThreeMonthsToOneYearMember_7RuM64U-a0aObQUPJYUozA,us-gaap:AvailableForSaleSecuritiesDebtSecurities,As_Of_3_31_2024_us-gaap_FairValueByAssetClassAxis_us-gaap_DebtSecuritiesMember_us-gaap_FinancialInstrumentAxis_adap_CorporateDebtSecuritiesMaturityPeriodThreeMonthsToOneYearMember_7RuM64U-a0aObQUPJYUozA,2982000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,2982000.0,instant,2024-03-31,0001621227,http://www.sec.gov/CIK,instant_2024-03-31,Aggregate estimated fair value,Aggregate estimated fair value,Disclosures,http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesDetails,None,None,None,None,None,None,None,None,None,adap:CorporateDebtSecuritiesMaturityPeriodThreeMonthsToOneYearMember,None,None,us-gaap:DebtSecuritiesMember,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_As_Of_3_31_2024_us-gaap_FairValueByAssetClassAxis_us-gaap_DebtSecuritiesMember_CJ-X5PNl2U-l5wB80yKa-Q,us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis,As_Of_3_31_2024_us-gaap_FairValueByAssetClassAxis_us-gaap_DebtSecuritiesMember_CJ-X5PNl2U-l5wB80yKa-Q,2981000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,2981000.0,instant,2024-03-31,0001621227,http://www.sec.gov/CIK,instant_2024-03-31,Amortized cost,Amortized cost,Disclosures,http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesDetails,None,None,None,None,None,None,None,None,None,None,None,None,us-gaap:DebtSecuritiesMember,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_As_Of_3_31_2024_us-gaap_FairValueByAssetClassAxis_us-gaap_DebtSecuritiesMember_CJ-X5PNl2U-l5wB80yKa-Q,us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax,As_Of_3_31_2024_us-gaap_FairValueByAssetClassAxis_us-gaap_DebtSecuritiesMember_CJ-X5PNl2U-l5wB80yKa-Q,-1000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,-1000.0,instant,2024-03-31,0001621227,http://www.sec.gov/CIK,instant_2024-03-31,Gross unrealized gains,Gross unrealized gains,Disclosures,http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesDetails,None,None,None,None,None,None,None,None,None,None,None,None,us-gaap:DebtSecuritiesMember,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_AvailableForSaleSecuritiesDebtSecurities_As_Of_3_31_2024_us-gaap_FairValueByAssetClassAxis_us-gaap_DebtSecuritiesMember_CJ-X5PNl2U-l5wB80yKa-Q,us-gaap:AvailableForSaleSecuritiesDebtSecurities,As_Of_3_31_2024_us-gaap_FairValueByAssetClassAxis_us-gaap_DebtSecuritiesMember_CJ-X5PNl2U-l5wB80yKa-Q,2982000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,2982000.0,instant,2024-03-31,0001621227,http://www.sec.gov/CIK,instant_2024-03-31,Aggregate estimated fair value,Aggregate estimated fair value,Disclosures,http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesDetails,None,None,None,None,None,None,None,None,None,None,None,None,us-gaap:DebtSecuritiesMember,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock,Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,"<p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">The aggregate fair value (in thousands) and number of securities held by the Company (including those classified as cash equivalents) in an unrealized loss position as of March 31, 2024 and December 31, 2023 are as follows: </p><table style=""border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;""><tr style=""height:1pt;""><td style=""vertical-align:bottom;width:41.67%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.78%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;width:41.67%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.78%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;width:41.67%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""8"" style=""vertical-align:bottom;white-space:nowrap;width:28.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">March 31, 2024</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""8"" style=""vertical-align:bottom;white-space:nowrap;width:26.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">December 31, 2023</b></p></td></tr><tr><td style=""vertical-align:bottom;width:41.67%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">     </b></p></td><td colspan=""2"" style=""vertical-align:bottom;width:9.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Fair market value of investments in an unrealized loss position</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Number of investments in an unrealized loss position</b></p></td><td style=""vertical-align:bottom;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Unrealized losses</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Fair market value of investments in an unrealized loss position</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Number of investments in an unrealized loss position</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;width:7.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Unrealized losses</b></p></td></tr><tr><td style=""vertical-align:bottom;width:41.67%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">Marketable securities in a continuous loss position for less than 12 months:</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.78%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;width:41.67%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Corporate debt securities </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 1,600</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 1</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (1)</p></td></tr><tr><td style=""vertical-align:bottom;width:41.67%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> —</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> —</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> —</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 1,600</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 1</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><b style=""font-weight:bold;""> (1)</b></p></td></tr></table>",None,None,,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Schedule of aggregate fair value and number of securities held by the Company in an unrealized loss position,Schedule of aggregate fair value and number of securities held by the Company in an unrealized loss position,Disclosures,http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesTables,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_K6A_5dFExEKoxJmaURgF8g,us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months,As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_K6A_5dFExEKoxJmaURgF8g,1600000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,1600000.0,instant,2023-12-31,0001621227,http://www.sec.gov/CIK,instant_2023-12-31,"Fair market value of investments in an unrealized loss position, less than 12 months","Fair market value of investments in an unrealized loss position, less than 12 months",Disclosures,http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesUnrealizedLossPositionDetails,None,None,None,None,None,None,None,None,None,us-gaap:CorporateDebtSecuritiesMember,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions_As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_K6A_5dFExEKoxJmaURgF8g,us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions,As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_K6A_5dFExEKoxJmaURgF8g,-1,Unit_Standard_security_SpBy3ZgSLU6yf0N3c08hUw,INF,-1.0,instant,2023-12-31,0001621227,http://www.sec.gov/CIK,instant_2023-12-31,"Number of available-for-sale securities in an unrealized loss position, less than 12 months","Number of available-for-sale securities in an unrealized loss position, less than 12 months",Disclosures,http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesUnrealizedLossPositionDetails,None,None,None,None,None,None,None,None,None,us-gaap:CorporateDebtSecuritiesMember,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_K6A_5dFExEKoxJmaURgF8g,us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss,As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_K6A_5dFExEKoxJmaURgF8g,1000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,1000.0,instant,2023-12-31,0001621227,http://www.sec.gov/CIK,instant_2023-12-31,"Unrealized losses, less than 12 months","Unrealized losses, less than 12 months",Disclosures,http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesUnrealizedLossPositionDetails,None,None,None,None,None,None,None,None,None,us-gaap:CorporateDebtSecuritiesMember,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_As_Of_12_31_2023_m48jnprDr0mqVxN2-uk6kw,us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition,As_Of_12_31_2023_m48jnprDr0mqVxN2-uk6kw,1600000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,1600000.0,instant,2023-12-31,0001621227,http://www.sec.gov/CIK,instant_2023-12-31,Fair market value of investments in an unrealized loss position,Fair market value of investments in an unrealized loss position,Disclosures,http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesUnrealizedLossPositionDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_As_Of_12_31_2023_m48jnprDr0mqVxN2-uk6kw,us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions,As_Of_12_31_2023_m48jnprDr0mqVxN2-uk6kw,1,Unit_Standard_security_SpBy3ZgSLU6yf0N3c08hUw,INF,1.0,instant,2023-12-31,0001621227,http://www.sec.gov/CIK,instant_2023-12-31,Number of investments in an unrealized loss position,Number of investments in an unrealized loss position,Disclosures,http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesUnrealizedLossPositionDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_As_Of_12_31_2023_m48jnprDr0mqVxN2-uk6kw,us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss,As_Of_12_31_2023_m48jnprDr0mqVxN2-uk6kw,1000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,1000.0,instant,2023-12-31,0001621227,http://www.sec.gov/CIK,instant_2023-12-31,Unrealized losses,Unrealized losses,Disclosures,http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesUnrealizedLossPositionDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_OtherCurrentAssetsTextBlock_Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,us-gaap:OtherCurrentAssetsTextBlock,Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,"<p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;""><b style=""font-weight:bold;"">Note 8 — Other current assets</b></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">Other current assets consisted of the following (in thousands):</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;""><span style=""font-size:0pt;visibility:hidden;"">​</span></p><table style=""border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;""><tr style=""height:1pt;""><td style=""vertical-align:bottom;width:71.12%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.54%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.78%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td></tr><tr><td style=""vertical-align:bottom;width:71.12%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10.1%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">March 31, </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.54%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">December 31, </b></p></td></tr><tr><td style=""vertical-align:bottom;width:71.12%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">    </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2024</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.54%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2023</b></p></td></tr><tr><td style=""vertical-align:bottom;width:71.12%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Research and development credits receivable</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.8%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 18,697</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.54%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.78%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 46,098</p></td></tr><tr><td style=""vertical-align:bottom;width:71.12%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Prepayments</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 9,854</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.54%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.78%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 9,954</p></td></tr><tr><td style=""vertical-align:bottom;width:71.12%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Clinical materials</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.8%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 1,668</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.54%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.78%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 1,329</p></td></tr><tr><td style=""vertical-align:bottom;width:71.12%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">VAT receivable</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 1,791</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.54%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.78%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td></tr><tr><td style=""vertical-align:bottom;width:71.12%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Other current assets</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 2,837</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.54%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 2,412</p></td></tr><tr><td style=""vertical-align:bottom;width:71.12%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 34,847</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.54%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 59,793</b></p></td></tr></table><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;""><span style=""visibility:hidden;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">On January 19, 2024, a receipt of £24.2 million ($30.8 million) was received from HMRC relating to the Research and development credits receivable.</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p>",None,None,,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Other current assets,Other current assets,Disclosures,http://www.adaptimmune.com/role/DisclosureOtherCurrentAssets,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock,Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,"<p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;""><span style=""font-size:0pt;visibility:hidden;"">​</span></p><table style=""border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;""><tr style=""height:1pt;""><td style=""vertical-align:bottom;width:71.12%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.54%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.78%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td></tr><tr><td style=""vertical-align:bottom;width:71.12%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10.1%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">March 31, </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.54%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">December 31, </b></p></td></tr><tr><td style=""vertical-align:bottom;width:71.12%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">    </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2024</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.54%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2023</b></p></td></tr><tr><td style=""vertical-align:bottom;width:71.12%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Research and development credits receivable</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.8%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 18,697</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.54%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.78%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 46,098</p></td></tr><tr><td style=""vertical-align:bottom;width:71.12%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Prepayments</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 9,854</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.54%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.78%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 9,954</p></td></tr><tr><td style=""vertical-align:bottom;width:71.12%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Clinical materials</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.8%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 1,668</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.54%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.78%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 1,329</p></td></tr><tr><td style=""vertical-align:bottom;width:71.12%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">VAT receivable</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 1,791</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.54%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.78%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td></tr><tr><td style=""vertical-align:bottom;width:71.12%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Other current assets</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 2,837</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.54%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 2,412</p></td></tr><tr><td style=""vertical-align:bottom;width:71.12%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 34,847</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.54%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 59,793</b></p></td></tr></table>",None,None,,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Summary of other current assets,Summary of other current assets,Disclosures,http://www.adaptimmune.com/role/DisclosureOtherCurrentAssetsTables,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
adap_TaxCreditReceivableCurrent_As_Of_3_31_2024_Ebq-QFBYXEGIOthDpC9wWw,adap:TaxCreditReceivableCurrent,As_Of_3_31_2024_Ebq-QFBYXEGIOthDpC9wWw,18697000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,18697000.0,instant,2024-03-31,0001621227,http://www.sec.gov/CIK,instant_2024-03-31,Research and development credits receivable,Research and development credits receivable,Disclosures,http://www.adaptimmune.com/role/DisclosureOtherCurrentAssetsDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
adap_TaxCreditReceivableCurrent_As_Of_12_31_2023_m48jnprDr0mqVxN2-uk6kw,adap:TaxCreditReceivableCurrent,As_Of_12_31_2023_m48jnprDr0mqVxN2-uk6kw,46098000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,46098000.0,instant,2023-12-31,0001621227,http://www.sec.gov/CIK,instant_2023-12-31,Research and development credits receivable,Research and development credits receivable,Disclosures,http://www.adaptimmune.com/role/DisclosureOtherCurrentAssetsDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_PrepaidExpenseCurrent_As_Of_3_31_2024_Ebq-QFBYXEGIOthDpC9wWw,us-gaap:PrepaidExpenseCurrent,As_Of_3_31_2024_Ebq-QFBYXEGIOthDpC9wWw,9854000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,9854000.0,instant,2024-03-31,0001621227,http://www.sec.gov/CIK,instant_2024-03-31,Prepayments,Prepayments,Disclosures,http://www.adaptimmune.com/role/DisclosureOtherCurrentAssetsDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_PrepaidExpenseCurrent_As_Of_12_31_2023_m48jnprDr0mqVxN2-uk6kw,us-gaap:PrepaidExpenseCurrent,As_Of_12_31_2023_m48jnprDr0mqVxN2-uk6kw,9954000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,9954000.0,instant,2023-12-31,0001621227,http://www.sec.gov/CIK,instant_2023-12-31,Prepayments,Prepayments,Disclosures,http://www.adaptimmune.com/role/DisclosureOtherCurrentAssetsDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
adap_ClinicalMaterialsCurrent_As_Of_3_31_2024_Ebq-QFBYXEGIOthDpC9wWw,adap:ClinicalMaterialsCurrent,As_Of_3_31_2024_Ebq-QFBYXEGIOthDpC9wWw,1668000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,1668000.0,instant,2024-03-31,0001621227,http://www.sec.gov/CIK,instant_2024-03-31,Clinical materials,Clinical materials,Disclosures,http://www.adaptimmune.com/role/DisclosureOtherCurrentAssetsDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
adap_ClinicalMaterialsCurrent_As_Of_12_31_2023_m48jnprDr0mqVxN2-uk6kw,adap:ClinicalMaterialsCurrent,As_Of_12_31_2023_m48jnprDr0mqVxN2-uk6kw,1329000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,1329000.0,instant,2023-12-31,0001621227,http://www.sec.gov/CIK,instant_2023-12-31,Clinical materials,Clinical materials,Disclosures,http://www.adaptimmune.com/role/DisclosureOtherCurrentAssetsDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_ValueAddedTaxReceivableCurrent_As_Of_3_31_2024_Ebq-QFBYXEGIOthDpC9wWw,us-gaap:ValueAddedTaxReceivableCurrent,As_Of_3_31_2024_Ebq-QFBYXEGIOthDpC9wWw,1791000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,1791000.0,instant,2024-03-31,0001621227,http://www.sec.gov/CIK,instant_2024-03-31,VAT receivable,VAT receivable,Disclosures,http://www.adaptimmune.com/role/DisclosureOtherCurrentAssetsDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_OtherAssetsCurrent_As_Of_3_31_2024_Ebq-QFBYXEGIOthDpC9wWw,us-gaap:OtherAssetsCurrent,As_Of_3_31_2024_Ebq-QFBYXEGIOthDpC9wWw,2837000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,2837000.0,instant,2024-03-31,0001621227,http://www.sec.gov/CIK,instant_2024-03-31,Other current assets,Other current assets,Disclosures,http://www.adaptimmune.com/role/DisclosureOtherCurrentAssetsDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_OtherAssetsCurrent_As_Of_12_31_2023_m48jnprDr0mqVxN2-uk6kw,us-gaap:OtherAssetsCurrent,As_Of_12_31_2023_m48jnprDr0mqVxN2-uk6kw,2412000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,2412000.0,instant,2023-12-31,0001621227,http://www.sec.gov/CIK,instant_2023-12-31,Other current assets,Other current assets,Disclosures,http://www.adaptimmune.com/role/DisclosureOtherCurrentAssetsDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
adap_PrepaidExpenseAndOtherAssetsCurrentIncludingAccountsReceivable_As_Of_3_31_2024_Ebq-QFBYXEGIOthDpC9wWw,adap:PrepaidExpenseAndOtherAssetsCurrentIncludingAccountsReceivable,As_Of_3_31_2024_Ebq-QFBYXEGIOthDpC9wWw,34847000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,34847000.0,instant,2024-03-31,0001621227,http://www.sec.gov/CIK,instant_2024-03-31,Total,Total,Disclosures,http://www.adaptimmune.com/role/DisclosureOtherCurrentAssetsDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
adap_PrepaidExpenseAndOtherAssetsCurrentIncludingAccountsReceivable_As_Of_12_31_2023_m48jnprDr0mqVxN2-uk6kw,adap:PrepaidExpenseAndOtherAssetsCurrentIncludingAccountsReceivable,As_Of_12_31_2023_m48jnprDr0mqVxN2-uk6kw,59793000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,59793000.0,instant,2023-12-31,0001621227,http://www.sec.gov/CIK,instant_2023-12-31,Total,Total,Disclosures,http://www.adaptimmune.com/role/DisclosureOtherCurrentAssetsDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
adap_CashReceiptRelatingToCreditsReceivable_Duration_1_19_2024_To_1_19_2024_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember_zLu4vmo5r0yZvWmkWFmC5Q_0,adap:CashReceiptRelatingToCreditsReceivable,Duration_1_19_2024_To_1_19_2024_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember_zLu4vmo5r0yZvWmkWFmC5Q,24200000,Unit_Standard_GBP_2X_-HV6bvECVaTZr2BC1zQ,-5,24200000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-19_2024-01-19,Amount of receivable from Research and Development credits,Amount of receivable from Research and Development credits,Disclosures,http://www.adaptimmune.com/role/DisclosureOtherCurrentAssetsDetails,2024-01-19,2024-01-19,None,None,None,None,None,None,None,None,None,None,None,us-gaap:ResearchMember,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
adap_CashReceiptRelatingToCreditsReceivable_Duration_1_19_2024_To_1_19_2024_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember_zLu4vmo5r0yZvWmkWFmC5Q_1,adap:CashReceiptRelatingToCreditsReceivable,Duration_1_19_2024_To_1_19_2024_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember_zLu4vmo5r0yZvWmkWFmC5Q,30800000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-5,30800000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-19_2024-01-19,Amount of receivable from Research and Development credits,Amount of receivable from Research and Development credits,Disclosures,http://www.adaptimmune.com/role/DisclosureOtherCurrentAssetsDetails,2024-01-19,2024-01-19,None,None,None,None,None,None,None,None,None,None,None,us-gaap:ResearchMember,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_LesseeOperatingLeasesTextBlock_Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,us-gaap:LesseeOperatingLeasesTextBlock,Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,"<p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;""><b style=""font-weight:bold;"">Note 9 — Operating leases</b></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"">The Company has operating leases in relation to property for office, manufacturing and research facilities<span style=""font-size:12pt;"">. </span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"">The following table shows the lease costs for the three months ended March 31, 2024 and 2023 and the weighted-average remaining lease term and the weighted-average discount rate as at March 31, 2024 and 2023:</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;""><span style=""font-size:0pt;visibility:hidden;"">​</span></p><table style=""border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;""><tr style=""height:1pt;""><td style=""vertical-align:bottom;width:41.65%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:27.67%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.81%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:41.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:27.67%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""5"" style=""vertical-align:bottom;white-space:nowrap;width:23.73%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Three months ended </b></p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:41.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:27.67%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""5"" style=""vertical-align:bottom;white-space:nowrap;width:23.73%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">March 31, </b></p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:41.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:27.67%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">     </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:11.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2024</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">     </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2023</b></p></td></tr><tr><td style=""vertical-align:bottom;width:41.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">Lease cost:</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:27.67%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""font-size:8pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""font-size:8pt;visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;width:41.65%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Operating lease cost</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:27.67%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.93%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.81%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 1,682</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 1,060</p></td></tr><tr><td style=""vertical-align:bottom;width:41.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Short-term lease cost</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:27.67%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 59</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 137</p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:41.65%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:27.67%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.93%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 1,741</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;""> </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 1,197</b></p></td></tr><tr style=""height:0pt;visibility:hidden;""><td colspan=""8"" style=""padding:0pt;""></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:41.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:27.67%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td colspan=""5"" style=""vertical-align:bottom;white-space:nowrap;width:23.73%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">March 31, </b></p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:41.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:27.67%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:11.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2024</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2023</b></p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:41.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:27.67%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:41.65%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Weighted-average remaining lease term - operating leases</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:27.67%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.93%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:11.93%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"">5.3 years</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"">6.7 years</p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:41.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Weighted-average discount rate - operating leases</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:27.67%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:11.93%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><span style=""font-family:'Times';"">8.0%</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><span style=""font-family:'Times';"">6.8%</span></p></td></tr></table><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;""><span style=""font-size:0pt;visibility:hidden;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"">The maturities of operating lease liabilities as of March 31, 2024 are as follows (in thousands):</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;""><span style=""visibility:hidden;"">​</span></p><table style=""border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;""><tr style=""height:1pt;""><td style=""vertical-align:bottom;width:75.52%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:18.41%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:75.52%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""color:#111111;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">     </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:20.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Operating leases</b></p></td></tr><tr><td style=""vertical-align:bottom;width:75.52%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:20.71%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;width:75.52%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">2024</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.75%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:18.41%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 5,189</p></td></tr><tr><td style=""vertical-align:bottom;width:75.52%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">2025</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;""> </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:18.41%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 5,561</p></td></tr><tr><td style=""vertical-align:bottom;width:75.52%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">2026</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.75%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;""> </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:18.41%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 4,362</p></td></tr><tr><td style=""vertical-align:bottom;width:75.52%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">2027</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;""> </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:18.41%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 5,560</p></td></tr><tr><td style=""vertical-align:bottom;width:75.52%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">2028</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.75%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;""> </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:18.41%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 2,141</p></td></tr><tr><td style=""vertical-align:bottom;width:75.52%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">after 2028</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;""> </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:18.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 5,499</p></td></tr><tr><td style=""vertical-align:bottom;width:75.52%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">Total lease payments</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.75%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:18.41%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 28,312</b></p></td></tr><tr><td style=""vertical-align:bottom;width:75.52%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Less: Imputed interest</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:18.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (4,620)</p></td></tr><tr><td style=""vertical-align:bottom;width:75.52%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">Present value of lease liability</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.75%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:18.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 23,692</b></p></td></tr></table><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;""><span style=""visibility:hidden;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">The maximum lease term without activation of termination options is to 2041. </p>",None,None,,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Operating leases,Operating leases,Disclosures,http://www.adaptimmune.com/role/DisclosureOperatingLeases,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock,Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,"<p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;""><span style=""font-size:0pt;visibility:hidden;"">​</span></p><table style=""border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;""><tr style=""height:1pt;""><td style=""vertical-align:bottom;width:41.65%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:27.67%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.81%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:41.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:27.67%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""5"" style=""vertical-align:bottom;white-space:nowrap;width:23.73%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Three months ended </b></p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:41.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:27.67%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""5"" style=""vertical-align:bottom;white-space:nowrap;width:23.73%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">March 31, </b></p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:41.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:27.67%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">     </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:11.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2024</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">     </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2023</b></p></td></tr><tr><td style=""vertical-align:bottom;width:41.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">Lease cost:</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:27.67%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""font-size:8pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""font-size:8pt;visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;width:41.65%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Operating lease cost</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:27.67%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.93%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.81%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 1,682</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 1,060</p></td></tr><tr><td style=""vertical-align:bottom;width:41.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Short-term lease cost</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:27.67%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 59</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 137</p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:41.65%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:27.67%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.93%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 1,741</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;""> </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 1,197</b></p></td></tr><tr style=""height:0pt;visibility:hidden;""><td colspan=""8"" style=""padding:0pt;""></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:41.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:27.67%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td colspan=""5"" style=""vertical-align:bottom;white-space:nowrap;width:23.73%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">March 31, </b></p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:41.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:27.67%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:11.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2024</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2023</b></p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:41.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:27.67%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:41.65%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Weighted-average remaining lease term - operating leases</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:27.67%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.93%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:11.93%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"">5.3 years</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"">6.7 years</p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:41.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Weighted-average discount rate - operating leases</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:27.67%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:11.93%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><span style=""font-family:'Times';"">8.0%</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><span style=""font-family:'Times';"">6.8%</span></p></td></tr></table><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;""><span style=""font-size:0pt;visibility:hidden;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"">The maturities of operating lease liabilities as of March 31, 2024 are as follows (in thousands):</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;""><span style=""visibility:hidden;"">​</span></p><table style=""border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;""><tr style=""height:1pt;""><td style=""vertical-align:bottom;width:75.52%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:18.41%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:75.52%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""color:#111111;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">     </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:20.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Operating leases</b></p></td></tr><tr><td style=""vertical-align:bottom;width:75.52%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:20.71%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;width:75.52%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">2024</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.75%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:18.41%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 5,189</p></td></tr><tr><td style=""vertical-align:bottom;width:75.52%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">2025</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;""> </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:18.41%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 5,561</p></td></tr><tr><td style=""vertical-align:bottom;width:75.52%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">2026</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.75%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;""> </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:18.41%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 4,362</p></td></tr><tr><td style=""vertical-align:bottom;width:75.52%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">2027</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;""> </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:18.41%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 5,560</p></td></tr><tr><td style=""vertical-align:bottom;width:75.52%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">2028</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.75%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;""> </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:18.41%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 2,141</p></td></tr><tr><td style=""vertical-align:bottom;width:75.52%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">after 2028</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;""> </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:18.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 5,499</p></td></tr><tr><td style=""vertical-align:bottom;width:75.52%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">Total lease payments</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.75%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:18.41%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 28,312</b></p></td></tr><tr><td style=""vertical-align:bottom;width:75.52%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Less: Imputed interest</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:18.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (4,620)</p></td></tr><tr><td style=""vertical-align:bottom;width:75.52%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">Present value of lease liability</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.75%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:18.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 23,692</b></p></td></tr></table>",None,None,,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Schedule of maturities of operating lease liabilities,Schedule of maturities of operating lease liabilities,Disclosures,http://www.adaptimmune.com/role/DisclosureOperatingLeasesTables,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
adap_WeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateTableTextBlock_Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,adap:WeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateTableTextBlock,Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,"<p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;""><span style=""font-size:0pt;visibility:hidden;"">​</span></p><table style=""border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;""><tr style=""height:1pt;""><td style=""vertical-align:bottom;width:41.65%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:27.67%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.81%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:41.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:27.67%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""5"" style=""vertical-align:bottom;white-space:nowrap;width:23.73%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Three months ended </b></p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:41.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:27.67%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""5"" style=""vertical-align:bottom;white-space:nowrap;width:23.73%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">March 31, </b></p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:41.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:27.67%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">     </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:11.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2024</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">     </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2023</b></p></td></tr><tr><td style=""vertical-align:bottom;width:41.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">Lease cost:</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:27.67%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""font-size:8pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""font-size:8pt;visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;width:41.65%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Operating lease cost</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:27.67%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.93%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.81%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 1,682</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 1,060</p></td></tr><tr><td style=""vertical-align:bottom;width:41.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Short-term lease cost</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:27.67%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 59</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 137</p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:41.65%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:27.67%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.93%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 1,741</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;""> </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 1,197</b></p></td></tr><tr style=""height:0pt;visibility:hidden;""><td colspan=""8"" style=""padding:0pt;""></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:41.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:27.67%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td colspan=""5"" style=""vertical-align:bottom;white-space:nowrap;width:23.73%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">March 31, </b></p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:41.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:27.67%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:11.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2024</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2023</b></p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:41.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:27.67%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:41.65%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Weighted-average remaining lease term - operating leases</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:27.67%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.93%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:11.93%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"">5.3 years</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"">6.7 years</p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:41.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Weighted-average discount rate - operating leases</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:27.67%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:11.93%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><span style=""font-family:'Times';"">8.0%</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><span style=""font-family:'Times';"">6.8%</span></p></td></tr></table>",None,None,,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Schedule of weighted-average remaining lease term and the weighted-average discount rate,Schedule of weighted-average remaining lease term and the weighted-average discount rate,Disclosures,http://www.adaptimmune.com/role/DisclosureOperatingLeasesTables,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_OperatingLeaseCost_Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,us-gaap:OperatingLeaseCost,Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,1682000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,1682000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Operating lease cost,Operating lease cost,Disclosures,http://www.adaptimmune.com/role/DisclosureOperatingLeasesDetails,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_OperatingLeaseCost_Duration_1_1_2023_To_3_31_2023_y-zxPPLZtEmUIwfawHojag,us-gaap:OperatingLeaseCost,Duration_1_1_2023_To_3_31_2023_y-zxPPLZtEmUIwfawHojag,1060000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,1060000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Operating lease cost,Operating lease cost,Disclosures,http://www.adaptimmune.com/role/DisclosureOperatingLeasesDetails,2023-01-01,2023-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_ShortTermLeaseCost_Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,us-gaap:ShortTermLeaseCost,Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,59000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,59000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Short-term lease cost,Short-term lease cost,Disclosures,http://www.adaptimmune.com/role/DisclosureOperatingLeasesDetails,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_ShortTermLeaseCost_Duration_1_1_2023_To_3_31_2023_y-zxPPLZtEmUIwfawHojag,us-gaap:ShortTermLeaseCost,Duration_1_1_2023_To_3_31_2023_y-zxPPLZtEmUIwfawHojag,137000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,137000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Short-term lease cost,Short-term lease cost,Disclosures,http://www.adaptimmune.com/role/DisclosureOperatingLeasesDetails,2023-01-01,2023-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_LeaseCost_Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,us-gaap:LeaseCost,Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,1741000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,1741000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Total,Total,Disclosures,http://www.adaptimmune.com/role/DisclosureOperatingLeasesDetails,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_LeaseCost_Duration_1_1_2023_To_3_31_2023_y-zxPPLZtEmUIwfawHojag,us-gaap:LeaseCost,Duration_1_1_2023_To_3_31_2023_y-zxPPLZtEmUIwfawHojag,1197000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,1197000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Total,Total,Disclosures,http://www.adaptimmune.com/role/DisclosureOperatingLeasesDetails,2023-01-01,2023-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_As_Of_3_31_2024_Ebq-QFBYXEGIOthDpC9wWw,us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1,As_Of_3_31_2024_Ebq-QFBYXEGIOthDpC9wWw,P5Y3M18D,None,None,,instant,2024-03-31,0001621227,http://www.sec.gov/CIK,instant_2024-03-31,Weighted-average remaining lease term - operating leases,Weighted-average remaining lease term - operating leases,Disclosures,http://www.adaptimmune.com/role/DisclosureOperatingLeasesDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_As_Of_3_31_2023_E8kJdIyzokqSPfzFvPVD9g,us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1,As_Of_3_31_2023_E8kJdIyzokqSPfzFvPVD9g,P6Y8M12D,None,None,,instant,2023-03-31,0001621227,http://www.sec.gov/CIK,instant_2023-03-31,Weighted-average remaining lease term - operating leases,Weighted-average remaining lease term - operating leases,Disclosures,http://www.adaptimmune.com/role/DisclosureOperatingLeasesDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_As_Of_3_31_2024_Ebq-QFBYXEGIOthDpC9wWw,us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent,As_Of_3_31_2024_Ebq-QFBYXEGIOthDpC9wWw,0.080,Unit_Standard_pure_3r25NCp6WUGW4b-Voo8YTA,3,0.08,instant,2024-03-31,0001621227,http://www.sec.gov/CIK,instant_2024-03-31,Weighted-average discount rate - operating leases,Weighted-average discount rate - operating leases,Disclosures,http://www.adaptimmune.com/role/DisclosureOperatingLeasesDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_As_Of_3_31_2023_E8kJdIyzokqSPfzFvPVD9g,us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent,As_Of_3_31_2023_E8kJdIyzokqSPfzFvPVD9g,0.068,Unit_Standard_pure_3r25NCp6WUGW4b-Voo8YTA,3,0.068,instant,2023-03-31,0001621227,http://www.sec.gov/CIK,instant_2023-03-31,Weighted-average discount rate - operating leases,Weighted-average discount rate - operating leases,Disclosures,http://www.adaptimmune.com/role/DisclosureOperatingLeasesDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_As_Of_3_31_2024_Ebq-QFBYXEGIOthDpC9wWw,us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths,As_Of_3_31_2024_Ebq-QFBYXEGIOthDpC9wWw,5189000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,5189000.0,instant,2024-03-31,0001621227,http://www.sec.gov/CIK,instant_2024-03-31,2024,2024,Disclosures,http://www.adaptimmune.com/role/DisclosureOperatingLeasesMaturitiesDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_As_Of_3_31_2024_Ebq-QFBYXEGIOthDpC9wWw,us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo,As_Of_3_31_2024_Ebq-QFBYXEGIOthDpC9wWw,5561000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,5561000.0,instant,2024-03-31,0001621227,http://www.sec.gov/CIK,instant_2024-03-31,2025,2025,Disclosures,http://www.adaptimmune.com/role/DisclosureOperatingLeasesMaturitiesDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_As_Of_3_31_2024_Ebq-QFBYXEGIOthDpC9wWw,us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree,As_Of_3_31_2024_Ebq-QFBYXEGIOthDpC9wWw,4362000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,4362000.0,instant,2024-03-31,0001621227,http://www.sec.gov/CIK,instant_2024-03-31,2026,2026,Disclosures,http://www.adaptimmune.com/role/DisclosureOperatingLeasesMaturitiesDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_As_Of_3_31_2024_Ebq-QFBYXEGIOthDpC9wWw,us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour,As_Of_3_31_2024_Ebq-QFBYXEGIOthDpC9wWw,5560000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,5560000.0,instant,2024-03-31,0001621227,http://www.sec.gov/CIK,instant_2024-03-31,2027,2027,Disclosures,http://www.adaptimmune.com/role/DisclosureOperatingLeasesMaturitiesDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_As_Of_3_31_2024_Ebq-QFBYXEGIOthDpC9wWw,us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive,As_Of_3_31_2024_Ebq-QFBYXEGIOthDpC9wWw,2141000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,2141000.0,instant,2024-03-31,0001621227,http://www.sec.gov/CIK,instant_2024-03-31,2028,2028,Disclosures,http://www.adaptimmune.com/role/DisclosureOperatingLeasesMaturitiesDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_As_Of_3_31_2024_Ebq-QFBYXEGIOthDpC9wWw,us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive,As_Of_3_31_2024_Ebq-QFBYXEGIOthDpC9wWw,5499000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,5499000.0,instant,2024-03-31,0001621227,http://www.sec.gov/CIK,instant_2024-03-31,after 2028,after 2028,Disclosures,http://www.adaptimmune.com/role/DisclosureOperatingLeasesMaturitiesDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_As_Of_3_31_2024_Ebq-QFBYXEGIOthDpC9wWw,us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue,As_Of_3_31_2024_Ebq-QFBYXEGIOthDpC9wWw,28312000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,28312000.0,instant,2024-03-31,0001621227,http://www.sec.gov/CIK,instant_2024-03-31,Total lease payments,Total lease payments,Disclosures,http://www.adaptimmune.com/role/DisclosureOperatingLeasesMaturitiesDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_As_Of_3_31_2024_Ebq-QFBYXEGIOthDpC9wWw,us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount,As_Of_3_31_2024_Ebq-QFBYXEGIOthDpC9wWw,4620000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,4620000.0,instant,2024-03-31,0001621227,http://www.sec.gov/CIK,instant_2024-03-31,Less: Imputed interest,Less: Imputed interest,Disclosures,http://www.adaptimmune.com/role/DisclosureOperatingLeasesMaturitiesDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_OperatingLeaseLiability_As_Of_3_31_2024_Ebq-QFBYXEGIOthDpC9wWw,us-gaap:OperatingLeaseLiability,As_Of_3_31_2024_Ebq-QFBYXEGIOthDpC9wWw,23692000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,23692000.0,instant,2024-03-31,0001621227,http://www.sec.gov/CIK,instant_2024-03-31,Present value of lease liability,Present value of lease liability,Disclosures,http://www.adaptimmune.com/role/DisclosureOperatingLeasesMaturitiesDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock,Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,"<p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;""><b style=""font-weight:bold;"">Note 10 </b><b style=""font-weight:bold;"">—</b><b style=""font-weight:bold;""> Accrued expenses and other current liabilities</b></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">Accrued expenses and other current liabilities consisted of the following (in thousands):</p><table style=""border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;""><tr style=""height:1pt;""><td style=""vertical-align:bottom;width:64.55%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:12.49%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:4.1%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:13.14%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td></tr><tr><td style=""vertical-align:bottom;width:64.55%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:13.68%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">March 31, </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:17.24%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">December 31, </b></p></td></tr><tr><td style=""vertical-align:bottom;width:64.55%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">    </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:13.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2024</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">    </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:17.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2023</b></p></td></tr><tr><td style=""vertical-align:bottom;width:64.55%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Accrued clinical and development expenditure</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:12.49%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 12,049</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:4.1%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:13.14%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 12,351</p></td></tr><tr><td style=""vertical-align:bottom;width:64.55%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Accrued employee expenses</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:12.49%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 6,248</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:4.1%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:13.14%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 13,226</p></td></tr><tr><td style=""vertical-align:bottom;width:64.55%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">VAT payable</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:12.49%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:4.1%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:13.14%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 1,398</p></td></tr><tr><td style=""vertical-align:bottom;width:64.55%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Other accrued expenditure</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:12.49%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 4,113</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:4.1%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:13.14%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 3,277</p></td></tr><tr><td style=""vertical-align:bottom;width:64.55%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Other</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:12.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 640</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:4.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:13.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 51</p></td></tr><tr><td style=""vertical-align:bottom;width:64.55%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:12.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 23,050</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:4.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:13.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 30,303</b></p></td></tr></table><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p>",None,None,,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Accrued expenses and other current liabilities,Accrued expenses and other current liabilities,Disclosures,http://www.adaptimmune.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock,Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,"<p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">Accrued expenses and other current liabilities consisted of the following (in thousands):</p><table style=""border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;""><tr style=""height:1pt;""><td style=""vertical-align:bottom;width:64.55%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:12.49%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:4.1%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:13.14%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td></tr><tr><td style=""vertical-align:bottom;width:64.55%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:13.68%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">March 31, </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:17.24%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">December 31, </b></p></td></tr><tr><td style=""vertical-align:bottom;width:64.55%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">    </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:13.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2024</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">    </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:17.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2023</b></p></td></tr><tr><td style=""vertical-align:bottom;width:64.55%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Accrued clinical and development expenditure</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:12.49%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 12,049</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:4.1%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:13.14%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 12,351</p></td></tr><tr><td style=""vertical-align:bottom;width:64.55%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Accrued employee expenses</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:12.49%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 6,248</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:4.1%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:13.14%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 13,226</p></td></tr><tr><td style=""vertical-align:bottom;width:64.55%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">VAT payable</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:12.49%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:4.1%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:13.14%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 1,398</p></td></tr><tr><td style=""vertical-align:bottom;width:64.55%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Other accrued expenditure</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:12.49%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 4,113</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:4.1%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:13.14%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 3,277</p></td></tr><tr><td style=""vertical-align:bottom;width:64.55%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Other</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:12.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 640</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:4.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:13.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 51</p></td></tr><tr><td style=""vertical-align:bottom;width:64.55%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:12.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 23,050</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:4.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:13.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 30,303</b></p></td></tr></table><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p>",None,None,,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Schedule of accrued expenses and other current liabilities,Schedule of accrued expenses and other current liabilities,Disclosures,http://www.adaptimmune.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
adap_AccruedLiabilitiesForPurchasesCurrent_As_Of_3_31_2024_Ebq-QFBYXEGIOthDpC9wWw,adap:AccruedLiabilitiesForPurchasesCurrent,As_Of_3_31_2024_Ebq-QFBYXEGIOthDpC9wWw,12049000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,12049000.0,instant,2024-03-31,0001621227,http://www.sec.gov/CIK,instant_2024-03-31,Accrued clinical and development expenditure,Accrued clinical and development expenditure,Disclosures,http://www.adaptimmune.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
adap_AccruedLiabilitiesForPurchasesCurrent_As_Of_12_31_2023_m48jnprDr0mqVxN2-uk6kw,adap:AccruedLiabilitiesForPurchasesCurrent,As_Of_12_31_2023_m48jnprDr0mqVxN2-uk6kw,12351000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,12351000.0,instant,2023-12-31,0001621227,http://www.sec.gov/CIK,instant_2023-12-31,Accrued clinical and development expenditure,Accrued clinical and development expenditure,Disclosures,http://www.adaptimmune.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_EmployeeRelatedLiabilitiesCurrent_As_Of_3_31_2024_Ebq-QFBYXEGIOthDpC9wWw,us-gaap:EmployeeRelatedLiabilitiesCurrent,As_Of_3_31_2024_Ebq-QFBYXEGIOthDpC9wWw,6248000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,6248000.0,instant,2024-03-31,0001621227,http://www.sec.gov/CIK,instant_2024-03-31,Accrued employee expenses,Accrued employee expenses,Disclosures,http://www.adaptimmune.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_EmployeeRelatedLiabilitiesCurrent_As_Of_12_31_2023_m48jnprDr0mqVxN2-uk6kw,us-gaap:EmployeeRelatedLiabilitiesCurrent,As_Of_12_31_2023_m48jnprDr0mqVxN2-uk6kw,13226000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,13226000.0,instant,2023-12-31,0001621227,http://www.sec.gov/CIK,instant_2023-12-31,Accrued employee expenses,Accrued employee expenses,Disclosures,http://www.adaptimmune.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
adap_ValueAddedTaxPayable_As_Of_12_31_2023_m48jnprDr0mqVxN2-uk6kw,adap:ValueAddedTaxPayable,As_Of_12_31_2023_m48jnprDr0mqVxN2-uk6kw,1398000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,1398000.0,instant,2023-12-31,0001621227,http://www.sec.gov/CIK,instant_2023-12-31,VAT Payable,VAT Payable,Disclosures,http://www.adaptimmune.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_OtherAccruedLiabilitiesCurrent_As_Of_3_31_2024_Ebq-QFBYXEGIOthDpC9wWw,us-gaap:OtherAccruedLiabilitiesCurrent,As_Of_3_31_2024_Ebq-QFBYXEGIOthDpC9wWw,4113000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,4113000.0,instant,2024-03-31,0001621227,http://www.sec.gov/CIK,instant_2024-03-31,Other accrued expenditure,Other accrued expenditure,Disclosures,http://www.adaptimmune.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_OtherAccruedLiabilitiesCurrent_As_Of_12_31_2023_m48jnprDr0mqVxN2-uk6kw,us-gaap:OtherAccruedLiabilitiesCurrent,As_Of_12_31_2023_m48jnprDr0mqVxN2-uk6kw,3277000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,3277000.0,instant,2023-12-31,0001621227,http://www.sec.gov/CIK,instant_2023-12-31,Other accrued expenditure,Other accrued expenditure,Disclosures,http://www.adaptimmune.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_OtherLiabilitiesCurrent_As_Of_3_31_2024_Ebq-QFBYXEGIOthDpC9wWw,us-gaap:OtherLiabilitiesCurrent,As_Of_3_31_2024_Ebq-QFBYXEGIOthDpC9wWw,640000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,640000.0,instant,2024-03-31,0001621227,http://www.sec.gov/CIK,instant_2024-03-31,Other,Other,Disclosures,http://www.adaptimmune.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_OtherLiabilitiesCurrent_As_Of_12_31_2023_m48jnprDr0mqVxN2-uk6kw,us-gaap:OtherLiabilitiesCurrent,As_Of_12_31_2023_m48jnprDr0mqVxN2-uk6kw,51000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,51000.0,instant,2023-12-31,0001621227,http://www.sec.gov/CIK,instant_2023-12-31,Other,Other,Disclosures,http://www.adaptimmune.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_AccruedLiabilitiesCurrent_As_Of_3_31_2024_Ebq-QFBYXEGIOthDpC9wWw_0,us-gaap:AccruedLiabilitiesCurrent,As_Of_3_31_2024_Ebq-QFBYXEGIOthDpC9wWw,23050000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,23050000.0,instant,2024-03-31,0001621227,http://www.sec.gov/CIK,instant_2024-03-31,Accrued expenses and other current liabilities,Accrued expenses and other current liabilities,BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_AccruedLiabilitiesCurrent_As_Of_3_31_2024_Ebq-QFBYXEGIOthDpC9wWw_1,us-gaap:AccruedLiabilitiesCurrent,As_Of_3_31_2024_Ebq-QFBYXEGIOthDpC9wWw,23050000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,23050000.0,instant,2024-03-31,0001621227,http://www.sec.gov/CIK,instant_2024-03-31,Accrued expenses and other current liabilities,Accrued expenses and other current liabilities,BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_AccruedLiabilitiesCurrent_As_Of_12_31_2023_m48jnprDr0mqVxN2-uk6kw_0,us-gaap:AccruedLiabilitiesCurrent,As_Of_12_31_2023_m48jnprDr0mqVxN2-uk6kw,30303000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,30303000.0,instant,2023-12-31,0001621227,http://www.sec.gov/CIK,instant_2023-12-31,Accrued expenses and other current liabilities,Accrued expenses and other current liabilities,BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_AccruedLiabilitiesCurrent_As_Of_12_31_2023_m48jnprDr0mqVxN2-uk6kw_1,us-gaap:AccruedLiabilitiesCurrent,As_Of_12_31_2023_m48jnprDr0mqVxN2-uk6kw,30303000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,30303000.0,instant,2023-12-31,0001621227,http://www.sec.gov/CIK,instant_2023-12-31,Accrued expenses and other current liabilities,Accrued expenses and other current liabilities,BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock,Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,"<p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;""><b style=""font-weight:bold;"">Note 11 </b><b style=""font-weight:bold;"">—</b><b style=""font-weight:bold;""> Share-based compensation</b></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">The following table shows the total share-based compensation expense included in the unaudited consolidated statements of operations (in thousands):</p><table style=""border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;""><tr style=""height:1pt;""><td style=""vertical-align:bottom;width:66.37%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.06%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td></tr><tr><td style=""vertical-align:bottom;width:66.37%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""4"" style=""vertical-align:bottom;white-space:nowrap;width:28.4%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Three months ended </b></p></td></tr><tr><td style=""vertical-align:bottom;width:66.37%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""4"" style=""vertical-align:bottom;white-space:nowrap;width:28.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">March 31, </b></p></td></tr><tr><td style=""vertical-align:bottom;width:66.37%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">    </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:12.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2024</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">    </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:14.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2023</b></p></td></tr><tr><td style=""vertical-align:bottom;width:66.37%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Research and development</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.57%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.06%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 813</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 116</p></td></tr><tr><td style=""vertical-align:bottom;width:66.37%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">General and administrative</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 2,289</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 1,560</p></td></tr><tr><td style=""vertical-align:bottom;width:66.37%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.57%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 3,102</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 1,676</b></p></td></tr></table><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;""><span style=""visibility:hidden;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">The following table shows information about share options and options which have a nominal exercise price (similar to restricted stock units (RSUs)) granted:</p><table style=""border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;""><tr style=""height:1pt;""><td style=""vertical-align:bottom;white-space:nowrap;width:66.37%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.06%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:66.37%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""4"" style=""vertical-align:bottom;white-space:nowrap;width:28.4%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Three months ended </b></p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:66.37%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""4"" style=""vertical-align:bottom;white-space:nowrap;width:28.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">March 31, </b></p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:66.37%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:12.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2024</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">    </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:14.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2023</b></p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:66.37%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Number of options over ordinary shares granted</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.57%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.06%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"">37,097,688</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"">21,755,328</p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:66.37%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Weighted average fair value of ordinary shares options</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.06%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"">0.12</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"">0.25</p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:66.37%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Number of additional options with a nominal exercise price granted</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.57%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.06%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"">26,984,352</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"">19,866,912</p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:66.37%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Weighted average fair value of options with a nominal exercise price </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.06%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"">0.14</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"">0.32</p></td></tr></table><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;""><span style=""visibility:hidden;"">​</span></p>",None,None,,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Share-based compensation,Share-based compensation,Disclosures,http://www.adaptimmune.com/role/DisclosureShareBasedCompensation,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock,Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,"<p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">The following table shows the total share-based compensation expense included in the unaudited consolidated statements of operations (in thousands):</p><table style=""border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;""><tr style=""height:1pt;""><td style=""vertical-align:bottom;width:66.37%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.06%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td></tr><tr><td style=""vertical-align:bottom;width:66.37%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""4"" style=""vertical-align:bottom;white-space:nowrap;width:28.4%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Three months ended </b></p></td></tr><tr><td style=""vertical-align:bottom;width:66.37%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""4"" style=""vertical-align:bottom;white-space:nowrap;width:28.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">March 31, </b></p></td></tr><tr><td style=""vertical-align:bottom;width:66.37%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">    </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:12.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2024</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">    </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:14.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2023</b></p></td></tr><tr><td style=""vertical-align:bottom;width:66.37%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Research and development</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.57%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.06%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 813</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 116</p></td></tr><tr><td style=""vertical-align:bottom;width:66.37%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">General and administrative</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 2,289</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 1,560</p></td></tr><tr><td style=""vertical-align:bottom;width:66.37%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.57%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 3,102</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 1,676</b></p></td></tr></table>",None,None,,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Summary of share-based compensation expense included in the consolidated statements of operations,Summary of share-based compensation expense included in the consolidated statements of operations,Disclosures,http://www.adaptimmune.com/role/DisclosureShareBasedCompensationTables,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_AllocatedShareBasedCompensationExpense_Duration_1_1_2024_To_3_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_Zy2AGf0A0UaOuFBKhTLWTA,us-gaap:AllocatedShareBasedCompensationExpense,Duration_1_1_2024_To_3_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_Zy2AGf0A0UaOuFBKhTLWTA,813000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,813000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Total share-based compensation expense,Total share-based compensation expense,Disclosures,http://www.adaptimmune.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,us-gaap:ResearchAndDevelopmentExpenseMember,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_AllocatedShareBasedCompensationExpense_Duration_1_1_2023_To_3_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_-EKBX1d1M0eys50YN5-Vug,us-gaap:AllocatedShareBasedCompensationExpense,Duration_1_1_2023_To_3_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_-EKBX1d1M0eys50YN5-Vug,116000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,116000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Total share-based compensation expense,Total share-based compensation expense,Disclosures,http://www.adaptimmune.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails,2023-01-01,2023-03-31,None,None,None,None,None,None,None,None,None,None,None,None,us-gaap:ResearchAndDevelopmentExpenseMember,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_AllocatedShareBasedCompensationExpense_Duration_1_1_2024_To_3_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_03bLJHPoqUSlv23OjwrZTA,us-gaap:AllocatedShareBasedCompensationExpense,Duration_1_1_2024_To_3_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_03bLJHPoqUSlv23OjwrZTA,2289000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,2289000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Total share-based compensation expense,Total share-based compensation expense,Disclosures,http://www.adaptimmune.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,us-gaap:GeneralAndAdministrativeExpenseMember,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_AllocatedShareBasedCompensationExpense_Duration_1_1_2023_To_3_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_mkTJVywO6UeWNGyHV5HX6Q,us-gaap:AllocatedShareBasedCompensationExpense,Duration_1_1_2023_To_3_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_mkTJVywO6UeWNGyHV5HX6Q,1560000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,1560000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Total share-based compensation expense,Total share-based compensation expense,Disclosures,http://www.adaptimmune.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails,2023-01-01,2023-03-31,None,None,None,None,None,None,None,None,None,None,None,None,us-gaap:GeneralAndAdministrativeExpenseMember,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_AllocatedShareBasedCompensationExpense_Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,us-gaap:AllocatedShareBasedCompensationExpense,Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,3102000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,3102000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Total share-based compensation expense,Total share-based compensation expense,Disclosures,http://www.adaptimmune.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_AllocatedShareBasedCompensationExpense_Duration_1_1_2023_To_3_31_2023_y-zxPPLZtEmUIwfawHojag,us-gaap:AllocatedShareBasedCompensationExpense,Duration_1_1_2023_To_3_31_2023_y-zxPPLZtEmUIwfawHojag,1676000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,1676000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Total share-based compensation expense,Total share-based compensation expense,Disclosures,http://www.adaptimmune.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails,2023-01-01,2023-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock,Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,"<p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">The following table shows information about share options and options which have a nominal exercise price (similar to restricted stock units (RSUs)) granted:</p><table style=""border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;""><tr style=""height:1pt;""><td style=""vertical-align:bottom;white-space:nowrap;width:66.37%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.06%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:66.37%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""4"" style=""vertical-align:bottom;white-space:nowrap;width:28.4%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Three months ended </b></p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:66.37%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""4"" style=""vertical-align:bottom;white-space:nowrap;width:28.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">March 31, </b></p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:66.37%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:12.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2024</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">    </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:14.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2023</b></p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:66.37%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Number of options over ordinary shares granted</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.57%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.06%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"">37,097,688</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"">21,755,328</p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:66.37%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Weighted average fair value of ordinary shares options</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.06%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"">0.12</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"">0.25</p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:66.37%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Number of additional options with a nominal exercise price granted</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.57%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.06%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"">26,984,352</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"">19,866,912</p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:66.37%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Weighted average fair value of options with a nominal exercise price </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.06%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"">0.14</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"">0.32</p></td></tr></table><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;""><span style=""visibility:hidden;"">​</span></p>",None,None,,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Summary of all stock option activity,Summary of all stock option activity,Disclosures,http://www.adaptimmune.com/role/DisclosureShareBasedCompensationTables,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross,Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,37097688,Unit_Standard_shares_KIp_HZ7W0kSuHGlx3Wi_-g,INF,37097688.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Number of options over ordinary shares granted (in shares),Number of options over ordinary shares granted (in shares),Disclosures,http://www.adaptimmune.com/role/DisclosureShareBasedCompensationOptionsDetails,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_Duration_1_1_2023_To_3_31_2023_y-zxPPLZtEmUIwfawHojag,us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross,Duration_1_1_2023_To_3_31_2023_y-zxPPLZtEmUIwfawHojag,21755328,Unit_Standard_shares_KIp_HZ7W0kSuHGlx3Wi_-g,INF,21755328.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Number of options over ordinary shares granted (in shares),Number of options over ordinary shares granted (in shares),Disclosures,http://www.adaptimmune.com/role/DisclosureShareBasedCompensationOptionsDetails,2023-01-01,2023-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue,Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,0.12,Unit_Divide_USD_shares_xtly01YGSEyZ3gCwnLlqCg,2,0.12,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Weighted average fair value of ordinary shares options (in dollars per share),Weighted average fair value of ordinary shares options (in dollars per share),Disclosures,http://www.adaptimmune.com/role/DisclosureShareBasedCompensationOptionsDetails,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_Duration_1_1_2023_To_3_31_2023_y-zxPPLZtEmUIwfawHojag,us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue,Duration_1_1_2023_To_3_31_2023_y-zxPPLZtEmUIwfawHojag,0.25,Unit_Divide_USD_shares_xtly01YGSEyZ3gCwnLlqCg,2,0.25,duration,None,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Weighted average fair value of ordinary shares options (in dollars per share),Weighted average fair value of ordinary shares options (in dollars per share),Disclosures,http://www.adaptimmune.com/role/DisclosureShareBasedCompensationOptionsDetails,2023-01-01,2023-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
adap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWithNominalExercisePriceGrantsInPeriodGross_Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,adap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWithNominalExercisePriceGrantsInPeriodGross,Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,26984352,Unit_Standard_shares_KIp_HZ7W0kSuHGlx3Wi_-g,INF,26984352.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Number of additional options with a nominal exercise price granted,Number of additional options with a nominal exercise price granted,Disclosures,http://www.adaptimmune.com/role/DisclosureShareBasedCompensationOptionsDetails,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
adap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWithNominalExercisePriceGrantsInPeriodGross_Duration_1_1_2023_To_3_31_2023_y-zxPPLZtEmUIwfawHojag,adap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWithNominalExercisePriceGrantsInPeriodGross,Duration_1_1_2023_To_3_31_2023_y-zxPPLZtEmUIwfawHojag,19866912,Unit_Standard_shares_KIp_HZ7W0kSuHGlx3Wi_-g,INF,19866912.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Number of additional options with a nominal exercise price granted,Number of additional options with a nominal exercise price granted,Disclosures,http://www.adaptimmune.com/role/DisclosureShareBasedCompensationOptionsDetails,2023-01-01,2023-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
adap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueWithNominalExercisePrice_Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,adap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueWithNominalExercisePrice,Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,0.14,Unit_Divide_USD_shares_xtly01YGSEyZ3gCwnLlqCg,2,0.14,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Weighted average fair value of options with a nominal exercise price,Weighted average fair value of options with a nominal exercise price,Disclosures,http://www.adaptimmune.com/role/DisclosureShareBasedCompensationOptionsDetails,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
adap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueWithNominalExercisePrice_Duration_1_1_2023_To_3_31_2023_y-zxPPLZtEmUIwfawHojag,adap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueWithNominalExercisePrice,Duration_1_1_2023_To_3_31_2023_y-zxPPLZtEmUIwfawHojag,0.32,Unit_Divide_USD_shares_xtly01YGSEyZ3gCwnLlqCg,2,0.32,duration,None,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Weighted average fair value of options with a nominal exercise price,Weighted average fair value of options with a nominal exercise price,Disclosures,http://www.adaptimmune.com/role/DisclosureShareBasedCompensationOptionsDetails,2023-01-01,2023-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_StockholdersEquityNoteDisclosureTextBlock_Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,us-gaap:StockholdersEquityNoteDisclosureTextBlock,Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,"<p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;""><b style=""font-weight:bold;"">Note 12 </b><b style=""font-weight:bold;"">—</b><b style=""font-weight:bold;""> Stockholders’ equity</b></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"">On April 8, 2022 the Company entered into a sales agreement with Cowen (the “Sales Agreement”) under which we may from time to time issue and sell ADSs representing our ordinary shares through Cowen in ATM offerings for an aggregate offering price of up to $200 million. In the three months ended March 31, 2024 the Company sold 27,278,176 ADSs under the agreement representing 163,669,056 ordinary shares resulting in net proceeds to the Company of $29,149,648 after deducting commissions payable under the Sales Agreement and estimated issuance costs. As of March 31, 2024, approximately $156,228,841<span style=""white-space:pre-wrap;""> remained available for sale under the Sales Agreement.  </span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p>",None,None,,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Stockholders' equity,Stockholders' equity,Disclosures,http://www.adaptimmune.com/role/DisclosureStockholdersEquity,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
adap_StockIssuedDuringPeriodValueSalesAgreement_Duration_4_8_2022_To_4_8_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_SubsidiarySaleOfStockAxis_adap_SalesAgreement2022Member_bYRuGiDGN06E5ppH6MZd4Q,adap:StockIssuedDuringPeriodValueSalesAgreement,Duration_4_8_2022_To_4_8_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_SubsidiarySaleOfStockAxis_adap_SalesAgreement2022Member_bYRuGiDGN06E5ppH6MZd4Q,200000000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-6,200000000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2022-04-08_2022-04-08,Aggregate offering price of ADS shares under At The Market sales agreement,Aggregate offering price of ADS shares under At The Market sales agreement,Disclosures,http://www.adaptimmune.com/role/DisclosureStockholdersEquityOfferingsDetails,2022-04-08,2022-04-08,None,None,None,None,None,None,None,None,None,srt:MaximumMember,None,None,None,adap:SalesAgreement2022Member,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
adap_StockSoldDuringPeriodRepresentedByAmericanDepositarySharesNewIssues_Duration_1_1_2024_To_3_31_2024_us-gaap_SubsidiarySaleOfStockAxis_adap_SalesAgreement2022Member_fkMYiqacXkyEk5LsybZgCA,adap:StockSoldDuringPeriodRepresentedByAmericanDepositarySharesNewIssues,Duration_1_1_2024_To_3_31_2024_us-gaap_SubsidiarySaleOfStockAxis_adap_SalesAgreement2022Member_fkMYiqacXkyEk5LsybZgCA,27278176,Unit_Standard_shares_KIp_HZ7W0kSuHGlx3Wi_-g,INF,27278176.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Sold shares represented by American Depositary Shares (in shares),Sold shares represented by American Depositary Shares (in shares),Disclosures,http://www.adaptimmune.com/role/DisclosureStockholdersEquityOfferingsDetails,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,adap:SalesAgreement2022Member,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_StockIssuedDuringPeriodSharesNewIssues_Duration_1_1_2024_To_3_31_2024_us-gaap_SubsidiarySaleOfStockAxis_adap_SalesAgreement2022Member_fkMYiqacXkyEk5LsybZgCA,us-gaap:StockIssuedDuringPeriodSharesNewIssues,Duration_1_1_2024_To_3_31_2024_us-gaap_SubsidiarySaleOfStockAxis_adap_SalesAgreement2022Member_fkMYiqacXkyEk5LsybZgCA,163669056,Unit_Standard_shares_KIp_HZ7W0kSuHGlx3Wi_-g,INF,163669056.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,"Issuance of shares upon completion of public offering, net of issuance costs (in shares)","Issuance of shares upon completion of public offering, net of issuance costs (in shares)",StatementOfEquity,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfChangeInEquity,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,adap:SalesAgreement2022Member,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_ProceedsFromIssuanceOrSaleOfEquity_Duration_1_1_2024_To_3_31_2024_us-gaap_SubsidiarySaleOfStockAxis_adap_SalesAgreement2022Member_fkMYiqacXkyEk5LsybZgCA,us-gaap:ProceedsFromIssuanceOrSaleOfEquity,Duration_1_1_2024_To_3_31_2024_us-gaap_SubsidiarySaleOfStockAxis_adap_SalesAgreement2022Member_fkMYiqacXkyEk5LsybZgCA,29149648,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,0,29149648.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Net proceeds,Net proceeds,Disclosures,http://www.adaptimmune.com/role/DisclosureStockholdersEquityOfferingsDetails,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,adap:SalesAgreement2022Member,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
adap_StockIssuedSalesAgreementRemainingAmountAvailableForSale_Duration_1_1_2024_To_3_31_2024_us-gaap_SubsidiarySaleOfStockAxis_adap_SalesAgreement2022Member_fkMYiqacXkyEk5LsybZgCA,adap:StockIssuedSalesAgreementRemainingAmountAvailableForSale,Duration_1_1_2024_To_3_31_2024_us-gaap_SubsidiarySaleOfStockAxis_adap_SalesAgreement2022Member_fkMYiqacXkyEk5LsybZgCA,156228841,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,0,156228841.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Remaining amount under the Sales Agreement,Remaining amount under the Sales Agreement,Disclosures,http://www.adaptimmune.com/role/DisclosureStockholdersEquityOfferingsDetails,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,adap:SalesAgreement2022Member,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_BusinessCombinationDisclosureTextBlock_Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,us-gaap:BusinessCombinationDisclosureTextBlock,Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,"<p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">Note 13 – Business combinations</b></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"">On March 6, 2023 the Company announced entry into a definitive agreement under which it would combine with TCR<sup style=""font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"">2</sup> Therapeutics Inc. (“TCR<sup style=""font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"">2</sup>”) in an all-stock transaction to create a preeminent cell therapy company focused on treating solid tumors. TCR<sup style=""font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"">2</sup> is a Boston, Massachusetts-based T-cell therapy company focused on treating solid tumours, with clinical franchises undergoing trials and a preclinical pipeline. The combination provides extensive benefits for clinical development and product delivery supported by complementary technology platforms.</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"">The transaction was approved by the Company’s shareholders and TCR<sup style=""font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"">2</sup> stockholders on May 30, 2023 and the merger became effective on June 1, 2023. The Company issued 357,429,306 shares to TCR<sup style=""font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"">2 </sup>stockholders in return for 100% of TCR<sup style=""font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"">2</sup>’s stock. As a result, TCR<sup style=""font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"">2</sup> and all entities within the TCR<sup style=""font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"">2</sup> group, became wholly owned by the Company. Following the completion of the transaction, the former TCR<sup style=""font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"">2</sup> stockholders held approximately 25% of the Company, whereas the Company’s pre-existing shareholders held approximately 75%.</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;""><span style=""visibility:hidden;background:#ffff00;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"">The Company was identified as the acquirer, with TCR<sup style=""font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"">2</sup> as the acquiree, and June 1, 2023 was determined to be the acquisition date. </p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"">The consideration transferred for TCR<sup style=""font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"">2</sup> includes the shares issued by the Company to former TCR<sup style=""font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"">2</sup> shareholders, plus the fair value of replacement awards of the Company granted to TCR<sup style=""font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"">2</sup> grantholders attributable to pre-combination vesting. The table below summarizes the consideration transferred and the amounts of the assets acquired and liabilities assumed recognized at the acquisition date:</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p><table style=""border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;""><tr style=""height:1pt;""><td style=""vertical-align:bottom;white-space:nowrap;width:75.41%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:19.72%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:75.41%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">Consideration transferred:</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:19.72%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:75.41%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Fair value of 357,429,306 ordinary shares issued</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:19.72%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 60,763</p></td></tr><tr><td style=""vertical-align:bottom;width:75.41%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Fair value of replacement options and RSU-style options granted attributable to pre-combination service:</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:19.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 963</p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:75.41%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">Purchase consideration</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:19.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 61,726</b></p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:75.41%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:19.72%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:75.41%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">Identifiable assets acquired and liabilities assumed:</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:19.72%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:75.41%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:19.72%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:75.41%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><i style=""font-style:italic;"">Assets acquired</i></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:19.72%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:75.41%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Cash and cash equivalents</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:19.72%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 43,610</p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:75.41%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Restricted cash</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:19.72%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 1,654</p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:75.41%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Marketable securities - available-for-sale debt securities</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:19.72%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 39,532</p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:75.41%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Other current assets and prepaid expenses</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:19.72%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 6,029</p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:75.41%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Property, plant and equipment</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:19.72%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 2,712</p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:75.41%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Operating lease right-of-use assets</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:19.72%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 5,145</p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:75.41%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Intangible assets</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:19.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 58</p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:75.41%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">Total assets acquired</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:19.72%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 98,740</b></p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:75.41%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:19.72%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:75.41%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><i style=""font-style:italic;"">Liabilities assumed</i></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:19.72%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:75.41%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Accounts payable</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:19.72%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (6,210)</p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:75.41%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Accrued expenses and other current liabilities</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:19.72%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (4,537)</p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:75.41%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Operating lease liabilities, current</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:19.72%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (1,974)</p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:75.41%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Operating lease liabilities, non-current</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:19.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (2,244)</p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:75.41%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">Total liabilities assumed</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:19.72%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><b style=""font-weight:bold;""> (14,965)</b></p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:75.41%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:19.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:75.41%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">Net assets acquired and liabilities assumed</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.83%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:19.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 83,775</b></p></td></tr></table><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"">The fair value of the 357,429,306 ordinary shares issued to TCR<sup style=""font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"">2</sup> stockholders of $60,763,000 was determined on the basis of the closing market price of $1.02 ($0.17 per ordinary share) of the Company’s ADSs as of May 31, 2023. </p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"">The assets acquired and liabilities assumed were measured based on management’s estimates of the fair value as of the acquisition date, excluding leases.</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;""><span style=""visibility:hidden;background:#ffff00;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"">The lease contracts acquired by the Company relate to the rental of office and manufacturing spaces in which TCR<sup style=""font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"">2</sup> was the lessee. The Company retained TCR<sup style=""font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"">2</sup>’s previous classification of acquired leases as operating leases as there were no lease modifications as a result of the combination, with the exception of leases with a remaining lease term of 12 months or less at the acquisition date, for which no assets or liabilities were recognized at the acquisition date. The lease liabilities were measured at the present value of the remaining lease payments as if the leases were a new lease as of June 1, 2023, discounted using the incremental borrowing rate. The right-of-use assets were measured at the same amount as the lease liabilities, with adjustments to reflect favorable or unfavorable terms compared to market terms. No intangible assets were identified in relation to lease contracts acquired.</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"">The table below summarises the calculation for the gain on bargain purchase, recognized in the Gain on bargain purchase line in the Consolidated Statement of Operations:</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p><table style=""border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;""><tr style=""height:1pt;""><td style=""vertical-align:bottom;white-space:nowrap;width:75.41%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:19.72%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:75.41%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">Gain on bargain purchase</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:19.72%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:75.41%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:19.72%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-style:italic;visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:75.41%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Purchase consideration </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:19.72%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (61,726)</p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:75.41%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Net assets acquired and liabilities assumed</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:19.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 83,775</p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:75.41%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">Gain on bargain purchase</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:19.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 22,049</b></p></td></tr></table><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"">The transaction resulted in a gain on bargain purchase as the purchase consideration included in the agreement on March 6, 2023 comprising Company ADSs was based on a fixed ratio of 1.5117 of the Company’s ADSs to be issued for each TCR<sup style=""font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"">2</sup> stock acquired. As the transaction was an all-stock transaction, the value of the consideration was highly sensitive to changes in the Company’s ADS price. The price of a Company ADS fell from a closing price of $1.32 on March 6, 2023 compared to a closing price of $1.02 on May 31, 2023. </p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;""><span style=""visibility:hidden;background:#ffff00;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""display:inline-block;text-indent:0pt;width:36pt;""></span>The amount of revenue and earnings of the combined entity for the three months ended March 31, 2023, had the acquisition date been January 1, 2022, would be as follows:</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""display:inline-block;text-indent:0pt;width:36pt;""></span><span style=""visibility:hidden;"">​</span></p><table style=""border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;""><tr style=""height:1pt;""><td style=""vertical-align:bottom;white-space:nowrap;width:75.41%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:19.72%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td></tr><tr><td style=""vertical-align:bottom;width:75.41%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:21.55%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Three months ended</b></p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:75.41%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:21.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">March 31, 2023</b></p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:75.41%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Revenue</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:19.72%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 47,601</p></td></tr><tr><td style=""vertical-align:bottom;width:75.41%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Net loss</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:19.72%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (31,325)</p></td></tr></table><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"">The supplemental pro forma earnings for the three months ended March 31, 2023 were adjusted to exclude the $3.8 million of acquisition-related costs recognized by the Company and the $3.7 million of acquisition-related costs incurred by TCR<sup style=""font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"">2</sup> during that period. The supplemental pro forma earnings was adjusted to include the impact of replacement options issued, as if these had been issued as of January 1, 2022. Accordingly, the share-based compensation expense recognized by TCR<sup style=""font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"">2</sup> in the three months ended March 31, 2023 of $0.6 million was excluded from the pro forma earnings.</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;""><span style=""visibility:hidden;background:#ffff00;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"">TCR<sup style=""font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"">2</sup> did not generate revenue in the period from January 1, 2023 to March 31, 2023, as it has no contracts with customers, so there was no impact on the revenue included in the Company’s Consolidated Statement of Operations or in the supplemental pro forma revenue and earnings presented above. </p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;""><span style=""visibility:hidden;background:#ffff00;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"">The Company incurred the following acquisition-related costs that were recognized as an expense in 2023: </p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p><table style=""border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;""><tr style=""height:1pt;""><td style=""vertical-align:bottom;white-space:nowrap;width:60.53%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:15.84%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:15.81%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:60.53%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:17.32%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Three months ended </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:17.29%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Total </b></p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:60.53%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:17.32%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">March 31, </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:17.29%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">acquisition-related</b></p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:60.53%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:17.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2023</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:17.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">costs</b></p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:60.53%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Legal, professional and accounting fees</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:15.84%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 3,323</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:15.81%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 5,174</p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:60.53%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Bankers' fees</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:15.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 750</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:15.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 2,172</p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:60.53%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">Total acquisition-related costs</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:15.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 4,073</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:15.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 7,346</b></p></td></tr></table><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"">All acquisition-related costs that were recognized as an expense were recognized in General and administrative expenses in the Consolidated Statement of Operations. No issuance costs were incurred relating to the issuance of shares to TCR<sup style=""font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"">2</sup> stockholders.</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""display:inline-block;text-indent:0pt;width:36pt;""></span><span style=""visibility:hidden;"">​</span></p>",None,None,,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Business combinations,Business combinations,Disclosures,http://www.adaptimmune.com/role/DisclosureBusinessCombinations,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_As_Of_6_1_2023_us-gaap_BusinessAcquisitionAxis_adap_Tcr2TherapeuticsMember_xrD4N9RX10CoQJzSi9gLfA,us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired,As_Of_6_1_2023_us-gaap_BusinessAcquisitionAxis_adap_Tcr2TherapeuticsMember_xrD4N9RX10CoQJzSi9gLfA,1,Unit_Standard_pure_3r25NCp6WUGW4b-Voo8YTA,2,1.0,instant,2023-06-01,0001621227,http://www.sec.gov/CIK,instant_2023-06-01,Percentage of ownership,Percentage of ownership,Disclosures,http://www.adaptimmune.com/role/DisclosureBusinessCombinationsDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,adap:Tcr2TherapeuticsMember,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
adap_BusinessCombinationPercentageOfOwnershipFollowingCompletionOfTransaction_As_Of_6_1_2023_srt_OwnershipAxis_adap_Tcr2TherapeuticsMember_xXGyWHVEwEOnpRjWLKpYKg,adap:BusinessCombinationPercentageOfOwnershipFollowingCompletionOfTransaction,As_Of_6_1_2023_srt_OwnershipAxis_adap_Tcr2TherapeuticsMember_xXGyWHVEwEOnpRjWLKpYKg,0.25,Unit_Standard_pure_3r25NCp6WUGW4b-Voo8YTA,2,0.25,instant,2023-06-01,0001621227,http://www.sec.gov/CIK,instant_2023-06-01,Percentage held following the transaction,Percentage held following the transaction,Disclosures,http://www.adaptimmune.com/role/DisclosureBusinessCombinationsDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,adap:Tcr2TherapeuticsMember,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
adap_BusinessCombinationPercentageOfOwnershipFollowingCompletionOfTransaction_As_Of_6_1_2023_srt_OwnershipAxis_adap_AdaptimmuneMember_PMg38QUn4kWI92M0mzEksg,adap:BusinessCombinationPercentageOfOwnershipFollowingCompletionOfTransaction,As_Of_6_1_2023_srt_OwnershipAxis_adap_AdaptimmuneMember_PMg38QUn4kWI92M0mzEksg,0.75,Unit_Standard_pure_3r25NCp6WUGW4b-Voo8YTA,2,0.75,instant,2023-06-01,0001621227,http://www.sec.gov/CIK,instant_2023-06-01,Percentage held following the transaction,Percentage held following the transaction,Disclosures,http://www.adaptimmune.com/role/DisclosureBusinessCombinationsDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,adap:AdaptimmuneMember,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
adap_ScheduleOfAssetsAcquiredAndLiabilitiesAssumedRecognizedIncludingConsiderationAtAcquisitionDate_Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,adap:ScheduleOfAssetsAcquiredAndLiabilitiesAssumedRecognizedIncludingConsiderationAtAcquisitionDate,Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,"<p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p><table style=""border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;""><tr style=""height:1pt;""><td style=""vertical-align:bottom;white-space:nowrap;width:75.41%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:19.72%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:75.41%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">Consideration transferred:</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:19.72%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:75.41%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Fair value of 357,429,306 ordinary shares issued</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:19.72%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 60,763</p></td></tr><tr><td style=""vertical-align:bottom;width:75.41%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Fair value of replacement options and RSU-style options granted attributable to pre-combination service:</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:19.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 963</p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:75.41%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">Purchase consideration</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:19.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 61,726</b></p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:75.41%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:19.72%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:75.41%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">Identifiable assets acquired and liabilities assumed:</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:19.72%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:75.41%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:19.72%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:75.41%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><i style=""font-style:italic;"">Assets acquired</i></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:19.72%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:75.41%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Cash and cash equivalents</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:19.72%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 43,610</p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:75.41%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Restricted cash</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:19.72%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 1,654</p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:75.41%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Marketable securities - available-for-sale debt securities</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:19.72%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 39,532</p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:75.41%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Other current assets and prepaid expenses</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:19.72%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 6,029</p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:75.41%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Property, plant and equipment</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:19.72%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 2,712</p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:75.41%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Operating lease right-of-use assets</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:19.72%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 5,145</p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:75.41%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Intangible assets</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:19.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 58</p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:75.41%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">Total assets acquired</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:19.72%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 98,740</b></p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:75.41%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:19.72%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:75.41%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><i style=""font-style:italic;"">Liabilities assumed</i></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:19.72%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:75.41%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Accounts payable</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:19.72%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (6,210)</p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:75.41%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Accrued expenses and other current liabilities</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:19.72%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (4,537)</p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:75.41%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Operating lease liabilities, current</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:19.72%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (1,974)</p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:75.41%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Operating lease liabilities, non-current</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:19.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (2,244)</p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:75.41%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">Total liabilities assumed</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:19.72%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><b style=""font-weight:bold;""> (14,965)</b></p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:75.41%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:19.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:75.41%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">Net assets acquired and liabilities assumed</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.83%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:19.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 83,775</b></p></td></tr></table>",None,None,,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Summary of the consideration transferred and the amounts of the assets acquired and liabilities assumed recognized at the acquisition date,Summary of the consideration transferred and the amounts of the assets acquired and liabilities assumed recognized at the acquisition date,Disclosures,http://www.adaptimmune.com/role/DisclosureBusinessCombinationsTables,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_Duration_6_1_2023_To_6_1_2023_us-gaap_BusinessAcquisitionAxis_adap_Tcr2TherapeuticsMember_bWuT8n9w8k6Q8yKux5Ip8Q_0,us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued,Duration_6_1_2023_To_6_1_2023_us-gaap_BusinessAcquisitionAxis_adap_Tcr2TherapeuticsMember_bWuT8n9w8k6Q8yKux5Ip8Q,357429306,Unit_Standard_shares_KIp_HZ7W0kSuHGlx3Wi_-g,INF,357429306.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2023-06-01_2023-06-01,Shares issued,Shares issued,Disclosures,http://www.adaptimmune.com/role/DisclosureBusinessCombinationsDetails,2023-06-01,2023-06-01,None,None,None,None,None,None,None,None,None,None,None,None,None,None,adap:Tcr2TherapeuticsMember,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_Duration_6_1_2023_To_6_1_2023_us-gaap_BusinessAcquisitionAxis_adap_Tcr2TherapeuticsMember_bWuT8n9w8k6Q8yKux5Ip8Q_1,us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued,Duration_6_1_2023_To_6_1_2023_us-gaap_BusinessAcquisitionAxis_adap_Tcr2TherapeuticsMember_bWuT8n9w8k6Q8yKux5Ip8Q,357429306,Unit_Standard_shares_KIp_HZ7W0kSuHGlx3Wi_-g,INF,357429306.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2023-06-01_2023-06-01,Shares issued,Shares issued,Disclosures,http://www.adaptimmune.com/role/DisclosureBusinessCombinationsDetails,2023-06-01,2023-06-01,None,None,None,None,None,None,None,None,None,None,None,None,None,None,adap:Tcr2TherapeuticsMember,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_Duration_6_1_2023_To_6_1_2023_us-gaap_BusinessAcquisitionAxis_adap_Tcr2TherapeuticsMember_bWuT8n9w8k6Q8yKux5Ip8Q,us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable,Duration_6_1_2023_To_6_1_2023_us-gaap_BusinessAcquisitionAxis_adap_Tcr2TherapeuticsMember_bWuT8n9w8k6Q8yKux5Ip8Q,60763000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,60763000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2023-06-01_2023-06-01,Fair value of shares issued,Fair value of shares issued,Disclosures,http://www.adaptimmune.com/role/DisclosureBusinessCombinationsDetails,2023-06-01,2023-06-01,None,None,None,None,None,None,None,None,None,None,None,None,None,None,adap:Tcr2TherapeuticsMember,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
adap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableFairValueOfReplacementShareOptions_Duration_6_1_2023_To_6_1_2023_us-gaap_BusinessAcquisitionAxis_adap_Tcr2TherapeuticsMember_bWuT8n9w8k6Q8yKux5Ip8Q,adap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableFairValueOfReplacementShareOptions,Duration_6_1_2023_To_6_1_2023_us-gaap_BusinessAcquisitionAxis_adap_Tcr2TherapeuticsMember_bWuT8n9w8k6Q8yKux5Ip8Q,963000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,963000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2023-06-01_2023-06-01,Fair value of replacement share options issued,Fair value of replacement share options issued,Disclosures,http://www.adaptimmune.com/role/DisclosureBusinessCombinationsDetails,2023-06-01,2023-06-01,None,None,None,None,None,None,None,None,None,None,None,None,None,None,adap:Tcr2TherapeuticsMember,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_As_Of_6_1_2023_us-gaap_BusinessAcquisitionAxis_adap_Tcr2TherapeuticsMember_xrD4N9RX10CoQJzSi9gLfA,us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents,As_Of_6_1_2023_us-gaap_BusinessAcquisitionAxis_adap_Tcr2TherapeuticsMember_xrD4N9RX10CoQJzSi9gLfA,43610000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,43610000.0,instant,2023-06-01,0001621227,http://www.sec.gov/CIK,instant_2023-06-01,Cash and cash equivalents,Cash and cash equivalents,Disclosures,http://www.adaptimmune.com/role/DisclosureBusinessCombinationsDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,adap:Tcr2TherapeuticsMember,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
adap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash_As_Of_6_1_2023_us-gaap_BusinessAcquisitionAxis_adap_Tcr2TherapeuticsMember_xrD4N9RX10CoQJzSi9gLfA,adap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash,As_Of_6_1_2023_us-gaap_BusinessAcquisitionAxis_adap_Tcr2TherapeuticsMember_xrD4N9RX10CoQJzSi9gLfA,1654000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,1654000.0,instant,2023-06-01,0001621227,http://www.sec.gov/CIK,instant_2023-06-01,Restricted cash,Restricted cash,Disclosures,http://www.adaptimmune.com/role/DisclosureBusinessCombinationsDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,adap:Tcr2TherapeuticsMember,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_As_Of_6_1_2023_us-gaap_BusinessAcquisitionAxis_adap_Tcr2TherapeuticsMember_xrD4N9RX10CoQJzSi9gLfA,us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities,As_Of_6_1_2023_us-gaap_BusinessAcquisitionAxis_adap_Tcr2TherapeuticsMember_xrD4N9RX10CoQJzSi9gLfA,39532000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,39532000.0,instant,2023-06-01,0001621227,http://www.sec.gov/CIK,instant_2023-06-01,Marketable securities - available-for-sale debt securities,Marketable securities - available-for-sale debt securities,Disclosures,http://www.adaptimmune.com/role/DisclosureBusinessCombinationsDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,adap:Tcr2TherapeuticsMember,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_As_Of_6_1_2023_us-gaap_BusinessAcquisitionAxis_adap_Tcr2TherapeuticsMember_xrD4N9RX10CoQJzSi9gLfA,us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets,As_Of_6_1_2023_us-gaap_BusinessAcquisitionAxis_adap_Tcr2TherapeuticsMember_xrD4N9RX10CoQJzSi9gLfA,6029000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,6029000.0,instant,2023-06-01,0001621227,http://www.sec.gov/CIK,instant_2023-06-01,Other current assets and prepaid expenses,Other current assets and prepaid expenses,Disclosures,http://www.adaptimmune.com/role/DisclosureBusinessCombinationsDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,adap:Tcr2TherapeuticsMember,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_As_Of_6_1_2023_us-gaap_BusinessAcquisitionAxis_adap_Tcr2TherapeuticsMember_xrD4N9RX10CoQJzSi9gLfA,us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment,As_Of_6_1_2023_us-gaap_BusinessAcquisitionAxis_adap_Tcr2TherapeuticsMember_xrD4N9RX10CoQJzSi9gLfA,2712000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,2712000.0,instant,2023-06-01,0001621227,http://www.sec.gov/CIK,instant_2023-06-01,"Property, plant and equipment","Property, plant and equipment",Disclosures,http://www.adaptimmune.com/role/DisclosureBusinessCombinationsDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,adap:Tcr2TherapeuticsMember,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_OperatingLeaseRightOfUseAsset_As_Of_6_1_2023_us-gaap_BusinessAcquisitionAxis_adap_Tcr2TherapeuticsMember_xrD4N9RX10CoQJzSi9gLfA,us-gaap:OperatingLeaseRightOfUseAsset,As_Of_6_1_2023_us-gaap_BusinessAcquisitionAxis_adap_Tcr2TherapeuticsMember_xrD4N9RX10CoQJzSi9gLfA,5145000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,5145000.0,instant,2023-06-01,0001621227,http://www.sec.gov/CIK,instant_2023-06-01,"Operating lease right-of-use assets, net of accumulated amortization of $14,381 and $13,220","Operating lease right-of-use assets, net of accumulated amortization of $14,381 and $13,220",BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,adap:Tcr2TherapeuticsMember,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_As_Of_6_1_2023_us-gaap_BusinessAcquisitionAxis_adap_Tcr2TherapeuticsMember_xrD4N9RX10CoQJzSi9gLfA,us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill,As_Of_6_1_2023_us-gaap_BusinessAcquisitionAxis_adap_Tcr2TherapeuticsMember_xrD4N9RX10CoQJzSi9gLfA,58000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,58000.0,instant,2023-06-01,0001621227,http://www.sec.gov/CIK,instant_2023-06-01,Intangible assets,Intangible assets,Disclosures,http://www.adaptimmune.com/role/DisclosureBusinessCombinationsDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,adap:Tcr2TherapeuticsMember,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_As_Of_6_1_2023_us-gaap_BusinessAcquisitionAxis_adap_Tcr2TherapeuticsMember_xrD4N9RX10CoQJzSi9gLfA,us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets,As_Of_6_1_2023_us-gaap_BusinessAcquisitionAxis_adap_Tcr2TherapeuticsMember_xrD4N9RX10CoQJzSi9gLfA,98740000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,98740000.0,instant,2023-06-01,0001621227,http://www.sec.gov/CIK,instant_2023-06-01,Total assets acquired,Total assets acquired,Disclosures,http://www.adaptimmune.com/role/DisclosureBusinessCombinationsDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,adap:Tcr2TherapeuticsMember,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_As_Of_6_1_2023_us-gaap_BusinessAcquisitionAxis_adap_Tcr2TherapeuticsMember_xrD4N9RX10CoQJzSi9gLfA,us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable,As_Of_6_1_2023_us-gaap_BusinessAcquisitionAxis_adap_Tcr2TherapeuticsMember_xrD4N9RX10CoQJzSi9gLfA,6210000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,6210000.0,instant,2023-06-01,0001621227,http://www.sec.gov/CIK,instant_2023-06-01,Accounts payable,Accounts payable,Disclosures,http://www.adaptimmune.com/role/DisclosureBusinessCombinationsDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,adap:Tcr2TherapeuticsMember,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
adap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpensesAndOtherCurrentLiabilities_As_Of_6_1_2023_us-gaap_BusinessAcquisitionAxis_adap_Tcr2TherapeuticsMember_xrD4N9RX10CoQJzSi9gLfA,adap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpensesAndOtherCurrentLiabilities,As_Of_6_1_2023_us-gaap_BusinessAcquisitionAxis_adap_Tcr2TherapeuticsMember_xrD4N9RX10CoQJzSi9gLfA,4537000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,4537000.0,instant,2023-06-01,0001621227,http://www.sec.gov/CIK,instant_2023-06-01,Accrued expenses and other current liabilities,Accrued expenses and other current liabilities,Disclosures,http://www.adaptimmune.com/role/DisclosureBusinessCombinationsDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,adap:Tcr2TherapeuticsMember,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_OperatingLeaseLiabilityCurrent_As_Of_6_1_2023_us-gaap_BusinessAcquisitionAxis_adap_Tcr2TherapeuticsMember_xrD4N9RX10CoQJzSi9gLfA,us-gaap:OperatingLeaseLiabilityCurrent,As_Of_6_1_2023_us-gaap_BusinessAcquisitionAxis_adap_Tcr2TherapeuticsMember_xrD4N9RX10CoQJzSi9gLfA,1974000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,1974000.0,instant,2023-06-01,0001621227,http://www.sec.gov/CIK,instant_2023-06-01,"Operating lease liabilities, current","Operating lease liabilities, current",BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,adap:Tcr2TherapeuticsMember,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_OperatingLeaseLiabilityNoncurrent_As_Of_6_1_2023_us-gaap_BusinessAcquisitionAxis_adap_Tcr2TherapeuticsMember_xrD4N9RX10CoQJzSi9gLfA,us-gaap:OperatingLeaseLiabilityNoncurrent,As_Of_6_1_2023_us-gaap_BusinessAcquisitionAxis_adap_Tcr2TherapeuticsMember_xrD4N9RX10CoQJzSi9gLfA,2244000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,2244000.0,instant,2023-06-01,0001621227,http://www.sec.gov/CIK,instant_2023-06-01,"Operating lease liabilities, non-current","Operating lease liabilities, non-current",BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,adap:Tcr2TherapeuticsMember,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_As_Of_6_1_2023_us-gaap_BusinessAcquisitionAxis_adap_Tcr2TherapeuticsMember_xrD4N9RX10CoQJzSi9gLfA,us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities,As_Of_6_1_2023_us-gaap_BusinessAcquisitionAxis_adap_Tcr2TherapeuticsMember_xrD4N9RX10CoQJzSi9gLfA,-14965000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,-14965000.0,instant,2023-06-01,0001621227,http://www.sec.gov/CIK,instant_2023-06-01,Total liabilities assumed,Total liabilities assumed,Disclosures,http://www.adaptimmune.com/role/DisclosureBusinessCombinationsDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,adap:Tcr2TherapeuticsMember,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_Duration_5_31_2023_To_5_31_2023_us-gaap_BusinessAcquisitionAxis_adap_Tcr2TherapeuticsMember_TZwCTXC9kU6Z4RNcZ1PghA,us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued,Duration_5_31_2023_To_5_31_2023_us-gaap_BusinessAcquisitionAxis_adap_Tcr2TherapeuticsMember_TZwCTXC9kU6Z4RNcZ1PghA,357429306,Unit_Standard_shares_KIp_HZ7W0kSuHGlx3Wi_-g,INF,357429306.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2023-05-31_2023-05-31,Shares issued,Shares issued,Disclosures,http://www.adaptimmune.com/role/DisclosureBusinessCombinationsDetails,2023-05-31,2023-05-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,adap:Tcr2TherapeuticsMember,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_Duration_5_31_2023_To_5_31_2023_us-gaap_BusinessAcquisitionAxis_adap_Tcr2TherapeuticsMember_TZwCTXC9kU6Z4RNcZ1PghA,us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable,Duration_5_31_2023_To_5_31_2023_us-gaap_BusinessAcquisitionAxis_adap_Tcr2TherapeuticsMember_TZwCTXC9kU6Z4RNcZ1PghA,60763000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,0,60763000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2023-05-31_2023-05-31,Fair value of shares issued,Fair value of shares issued,Disclosures,http://www.adaptimmune.com/role/DisclosureBusinessCombinationsDetails,2023-05-31,2023-05-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,adap:Tcr2TherapeuticsMember,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_BusinessAcquisitionSharePrice_As_Of_5_31_2023_us-gaap_BusinessAcquisitionAxis_adap_Tcr2TherapeuticsMember_RAEMsfqwuE-y96-zm0QHFQ,us-gaap:BusinessAcquisitionSharePrice,As_Of_5_31_2023_us-gaap_BusinessAcquisitionAxis_adap_Tcr2TherapeuticsMember_RAEMsfqwuE-y96-zm0QHFQ,1.02,Unit_Divide_USD_shares_xtly01YGSEyZ3gCwnLlqCg,2,1.02,instant,2023-05-31,0001621227,http://www.sec.gov/CIK,instant_2023-05-31,Market price,Market price,Disclosures,http://www.adaptimmune.com/role/DisclosureBusinessCombinationsDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,adap:Tcr2TherapeuticsMember,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_SharesIssuedPricePerShare_As_Of_5_31_2023_us-gaap_BusinessAcquisitionAxis_adap_Tcr2TherapeuticsMember_RAEMsfqwuE-y96-zm0QHFQ,us-gaap:SharesIssuedPricePerShare,As_Of_5_31_2023_us-gaap_BusinessAcquisitionAxis_adap_Tcr2TherapeuticsMember_RAEMsfqwuE-y96-zm0QHFQ,0.17,Unit_Divide_USD_shares_xtly01YGSEyZ3gCwnLlqCg,2,0.17,instant,2023-05-31,0001621227,http://www.sec.gov/CIK,instant_2023-05-31,Ordinary share price per share,Ordinary share price per share,Disclosures,http://www.adaptimmune.com/role/DisclosureBusinessCombinationsDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,adap:Tcr2TherapeuticsMember,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
adap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsInRelationToLeaseContracts_As_Of_6_1_2023_us-gaap_BusinessAcquisitionAxis_adap_Tcr2TherapeuticsMember_xrD4N9RX10CoQJzSi9gLfA,adap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsInRelationToLeaseContracts,As_Of_6_1_2023_us-gaap_BusinessAcquisitionAxis_adap_Tcr2TherapeuticsMember_xrD4N9RX10CoQJzSi9gLfA,0,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,0,0.0,instant,2023-06-01,0001621227,http://www.sec.gov/CIK,instant_2023-06-01,Intangible assets relation to lease contracts acquired,Intangible assets relation to lease contracts acquired,Disclosures,http://www.adaptimmune.com/role/DisclosureBusinessCombinationsDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,adap:Tcr2TherapeuticsMember,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
adap_DisclosureOfCalculationForGainOnBargainPurchaseTableTextBlock_Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,adap:DisclosureOfCalculationForGainOnBargainPurchaseTableTextBlock,Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,"<p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p><table style=""border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;""><tr style=""height:1pt;""><td style=""vertical-align:bottom;white-space:nowrap;width:75.41%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:19.72%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:75.41%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">Gain on bargain purchase</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:19.72%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:75.41%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:19.72%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-style:italic;visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:75.41%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Purchase consideration </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:19.72%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (61,726)</p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:75.41%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Net assets acquired and liabilities assumed</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:19.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 83,775</p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:75.41%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">Gain on bargain purchase</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:19.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 22,049</b></p></td></tr></table>",None,None,,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Schedule of calculation for the gain on bargain purchase,Schedule of calculation for the gain on bargain purchase,Disclosures,http://www.adaptimmune.com/role/DisclosureBusinessCombinationsTables,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_BusinessCombinationConsiderationTransferred1_Duration_6_1_2023_To_6_1_2023_us-gaap_BusinessAcquisitionAxis_adap_Tcr2TherapeuticsMember_bWuT8n9w8k6Q8yKux5Ip8Q_0,us-gaap:BusinessCombinationConsiderationTransferred1,Duration_6_1_2023_To_6_1_2023_us-gaap_BusinessAcquisitionAxis_adap_Tcr2TherapeuticsMember_bWuT8n9w8k6Q8yKux5Ip8Q,61726000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,61726000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2023-06-01_2023-06-01,Purchase consideration,Purchase consideration,Disclosures,http://www.adaptimmune.com/role/DisclosureBusinessCombinationsDetails,2023-06-01,2023-06-01,None,None,None,None,None,None,None,None,None,None,None,None,None,None,adap:Tcr2TherapeuticsMember,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_BusinessCombinationConsiderationTransferred1_Duration_6_1_2023_To_6_1_2023_us-gaap_BusinessAcquisitionAxis_adap_Tcr2TherapeuticsMember_bWuT8n9w8k6Q8yKux5Ip8Q_1,us-gaap:BusinessCombinationConsiderationTransferred1,Duration_6_1_2023_To_6_1_2023_us-gaap_BusinessAcquisitionAxis_adap_Tcr2TherapeuticsMember_bWuT8n9w8k6Q8yKux5Ip8Q,61726000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,61726000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2023-06-01_2023-06-01,Purchase consideration,Purchase consideration,Disclosures,http://www.adaptimmune.com/role/DisclosureBusinessCombinationsDetails,2023-06-01,2023-06-01,None,None,None,None,None,None,None,None,None,None,None,None,None,None,adap:Tcr2TherapeuticsMember,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_As_Of_6_1_2023_us-gaap_BusinessAcquisitionAxis_adap_Tcr2TherapeuticsMember_xrD4N9RX10CoQJzSi9gLfA_0,us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet,As_Of_6_1_2023_us-gaap_BusinessAcquisitionAxis_adap_Tcr2TherapeuticsMember_xrD4N9RX10CoQJzSi9gLfA,83775000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,83775000.0,instant,2023-06-01,0001621227,http://www.sec.gov/CIK,instant_2023-06-01,Net assets acquired and liabilities assumed,Net assets acquired and liabilities assumed,Disclosures,http://www.adaptimmune.com/role/DisclosureBusinessCombinationsDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,adap:Tcr2TherapeuticsMember,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_As_Of_6_1_2023_us-gaap_BusinessAcquisitionAxis_adap_Tcr2TherapeuticsMember_xrD4N9RX10CoQJzSi9gLfA_1,us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet,As_Of_6_1_2023_us-gaap_BusinessAcquisitionAxis_adap_Tcr2TherapeuticsMember_xrD4N9RX10CoQJzSi9gLfA,83775000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,83775000.0,instant,2023-06-01,0001621227,http://www.sec.gov/CIK,instant_2023-06-01,Net assets acquired and liabilities assumed,Net assets acquired and liabilities assumed,Disclosures,http://www.adaptimmune.com/role/DisclosureBusinessCombinationsDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,adap:Tcr2TherapeuticsMember,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_BusinessCombinationBargainPurchaseGainRecognizedAmount_Duration_6_1_2023_To_6_1_2023_us-gaap_BusinessAcquisitionAxis_adap_Tcr2TherapeuticsMember_bWuT8n9w8k6Q8yKux5Ip8Q,us-gaap:BusinessCombinationBargainPurchaseGainRecognizedAmount,Duration_6_1_2023_To_6_1_2023_us-gaap_BusinessAcquisitionAxis_adap_Tcr2TherapeuticsMember_bWuT8n9w8k6Q8yKux5Ip8Q,22049000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,22049000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2023-06-01_2023-06-01,Gain on bargain purchase,Gain on bargain purchase,IncomeStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations,2023-06-01,2023-06-01,None,None,None,None,None,None,None,None,None,None,None,None,None,None,adap:Tcr2TherapeuticsMember,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
adap_RatioForIssuanceOfCompanySAmericanDepositorySharesForEachOfAcquireeSStockAcquired_As_Of_3_6_2023_us-gaap_BusinessAcquisitionAxis_adap_Tcr2TherapeuticsMember_1ZpzKi6fEUa6BYy5gA_zhQ,adap:RatioForIssuanceOfCompanySAmericanDepositorySharesForEachOfAcquireeSStockAcquired,As_Of_3_6_2023_us-gaap_BusinessAcquisitionAxis_adap_Tcr2TherapeuticsMember_1ZpzKi6fEUa6BYy5gA_zhQ,1.5117,Unit_Standard_pure_3r25NCp6WUGW4b-Voo8YTA,4,1.5117,instant,2023-03-06,0001621227,http://www.sec.gov/CIK,instant_2023-03-06,Ratio for issuance of Company's ADSs for each TCR2 stock acquired,Ratio for issuance of Company's ADSs for each TCR2 stock acquired,Disclosures,http://www.adaptimmune.com/role/DisclosureBusinessCombinationsGainOnBargainPurchaseDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,adap:Tcr2TherapeuticsMember,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_SharePrice_As_Of_3_6_2023_us-gaap_BusinessAcquisitionAxis_adap_Tcr2TherapeuticsMember_1ZpzKi6fEUa6BYy5gA_zhQ,us-gaap:SharePrice,As_Of_3_6_2023_us-gaap_BusinessAcquisitionAxis_adap_Tcr2TherapeuticsMember_1ZpzKi6fEUa6BYy5gA_zhQ,1.32,Unit_Divide_USD_shares_xtly01YGSEyZ3gCwnLlqCg,2,1.32,instant,2023-03-06,0001621227,http://www.sec.gov/CIK,instant_2023-03-06,Closing price of Company's ADS,Closing price of Company's ADS,Disclosures,http://www.adaptimmune.com/role/DisclosureBusinessCombinationsGainOnBargainPurchaseDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,adap:Tcr2TherapeuticsMember,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_SharePrice_As_Of_5_31_2023_us-gaap_BusinessAcquisitionAxis_adap_Tcr2TherapeuticsMember_RAEMsfqwuE-y96-zm0QHFQ,us-gaap:SharePrice,As_Of_5_31_2023_us-gaap_BusinessAcquisitionAxis_adap_Tcr2TherapeuticsMember_RAEMsfqwuE-y96-zm0QHFQ,1.02,Unit_Divide_USD_shares_xtly01YGSEyZ3gCwnLlqCg,2,1.02,instant,2023-05-31,0001621227,http://www.sec.gov/CIK,instant_2023-05-31,Closing price of Company's ADS,Closing price of Company's ADS,Disclosures,http://www.adaptimmune.com/role/DisclosureBusinessCombinationsGainOnBargainPurchaseDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,adap:Tcr2TherapeuticsMember,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_BusinessAcquisitionProFormaInformationTextBlock_Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,us-gaap:BusinessAcquisitionProFormaInformationTextBlock,Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,"<p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""display:inline-block;text-indent:0pt;width:36pt;""></span><span style=""visibility:hidden;"">​</span></p><table style=""border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;""><tr style=""height:1pt;""><td style=""vertical-align:bottom;white-space:nowrap;width:75.41%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:19.72%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td></tr><tr><td style=""vertical-align:bottom;width:75.41%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:21.55%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Three months ended</b></p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:75.41%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:21.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">March 31, 2023</b></p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:75.41%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Revenue</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:19.72%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 47,601</p></td></tr><tr><td style=""vertical-align:bottom;width:75.41%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Net loss</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:19.72%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (31,325)</p></td></tr></table>",None,None,,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Schedule of amount of revenue and earnings of the combined entity,Schedule of amount of revenue and earnings of the combined entity,Disclosures,http://www.adaptimmune.com/role/DisclosureBusinessCombinationsTables,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_BusinessAcquisitionsProFormaRevenue_Duration_1_1_2024_To_3_31_2024_us-gaap_BusinessAcquisitionAxis_adap_Tcr2TherapeuticsMember_YaLzWVsA_kmY_1UHs1dX0Q,us-gaap:BusinessAcquisitionsProFormaRevenue,Duration_1_1_2024_To_3_31_2024_us-gaap_BusinessAcquisitionAxis_adap_Tcr2TherapeuticsMember_YaLzWVsA_kmY_1UHs1dX0Q,47601,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,0,47601.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Revenue,Revenue,Disclosures,http://www.adaptimmune.com/role/DisclosureBusinessCombinationsProformaInformationDetails,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,adap:Tcr2TherapeuticsMember,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_Duration_1_1_2024_To_3_31_2024_us-gaap_BusinessAcquisitionAxis_adap_Tcr2TherapeuticsMember_YaLzWVsA_kmY_1UHs1dX0Q,us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss,Duration_1_1_2024_To_3_31_2024_us-gaap_BusinessAcquisitionAxis_adap_Tcr2TherapeuticsMember_YaLzWVsA_kmY_1UHs1dX0Q,-31325,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,0,-31325.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Net loss,Net loss,Disclosures,http://www.adaptimmune.com/role/DisclosureBusinessCombinationsProformaInformationDetails,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,adap:Tcr2TherapeuticsMember,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_BusinessCombinationAcquisitionRelatedCosts_Duration_1_1_2023_To_3_31_2023_us-gaap_BusinessAcquisitionAxis_adap_Tcr2TherapeuticsMember_LN8rSRKM50yY-MD76U6VdA,us-gaap:BusinessCombinationAcquisitionRelatedCosts,Duration_1_1_2023_To_3_31_2023_us-gaap_BusinessAcquisitionAxis_adap_Tcr2TherapeuticsMember_LN8rSRKM50yY-MD76U6VdA,3800000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-5,3800000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Acquisition-related costs,Acquisition-related costs,Disclosures,http://www.adaptimmune.com/role/DisclosureBusinessCombinationsProformaInformationDetails,2023-01-01,2023-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,adap:Tcr2TherapeuticsMember,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
adap_BusinessCombinationAcquisitionRelatedCostsIncurredByAcquiree_Duration_1_1_2024_To_3_31_2024_us-gaap_BusinessAcquisitionAxis_adap_Tcr2TherapeuticsMember_YaLzWVsA_kmY_1UHs1dX0Q,adap:BusinessCombinationAcquisitionRelatedCostsIncurredByAcquiree,Duration_1_1_2024_To_3_31_2024_us-gaap_BusinessAcquisitionAxis_adap_Tcr2TherapeuticsMember_YaLzWVsA_kmY_1UHs1dX0Q,3700000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-5,3700000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Acquisition-related costs incurred by TCR2,Acquisition-related costs incurred by TCR2,Disclosures,http://www.adaptimmune.com/role/DisclosureBusinessCombinationsProformaInformationDetails,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,adap:Tcr2TherapeuticsMember,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_AllocatedShareBasedCompensationExpense_Duration_1_1_2023_To_3_31_2023_us-gaap_BusinessAcquisitionAxis_adap_Tcr2TherapeuticsMember_LN8rSRKM50yY-MD76U6VdA,us-gaap:AllocatedShareBasedCompensationExpense,Duration_1_1_2023_To_3_31_2023_us-gaap_BusinessAcquisitionAxis_adap_Tcr2TherapeuticsMember_LN8rSRKM50yY-MD76U6VdA,600000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-5,600000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Total share-based compensation expense,Total share-based compensation expense,Disclosures,http://www.adaptimmune.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails,2023-01-01,2023-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,adap:Tcr2TherapeuticsMember,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
adap_DisclosureOfAcquisitionRelatedCostsThatWereRecognizedAsExpenseTableTextBlock_Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,adap:DisclosureOfAcquisitionRelatedCostsThatWereRecognizedAsExpenseTableTextBlock,Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,"<p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"">The Company incurred the following acquisition-related costs that were recognized as an expense in 2023: </p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p><table style=""border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;""><tr style=""height:1pt;""><td style=""vertical-align:bottom;white-space:nowrap;width:60.53%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:15.84%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:15.81%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:60.53%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:17.32%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Three months ended </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:17.29%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Total </b></p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:60.53%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:17.32%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">March 31, </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:17.29%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">acquisition-related</b></p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:60.53%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:17.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2023</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:17.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">costs</b></p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:60.53%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Legal, professional and accounting fees</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:15.84%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 3,323</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:15.81%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 5,174</p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:60.53%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Bankers' fees</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:15.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 750</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:15.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 2,172</p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:60.53%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">Total acquisition-related costs</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:15.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 4,073</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:15.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 7,346</b></p></td></tr></table>",None,None,,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Schedule of acquisition-related costs that were recognized as an expense,Schedule of acquisition-related costs that were recognized as an expense,Disclosures,http://www.adaptimmune.com/role/DisclosureBusinessCombinationsTables,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
adap_BusinessCombinationAcquisitionRelatedCostsLegalProfessionalAndAccountingFees_Duration_1_1_2024_To_3_31_2024_us-gaap_BusinessAcquisitionAxis_adap_Tcr2TherapeuticsMember_YaLzWVsA_kmY_1UHs1dX0Q,adap:BusinessCombinationAcquisitionRelatedCostsLegalProfessionalAndAccountingFees,Duration_1_1_2024_To_3_31_2024_us-gaap_BusinessAcquisitionAxis_adap_Tcr2TherapeuticsMember_YaLzWVsA_kmY_1UHs1dX0Q,3323000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,3323000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,"Legal, professional and accounting fees","Legal, professional and accounting fees",Disclosures,http://www.adaptimmune.com/role/DisclosureBusinessCombinationsAcquisitionRelatedCostsDetails,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,adap:Tcr2TherapeuticsMember,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
adap_BusinessCombinationAcquisitionRelatedCostsLegalProfessionalAndAccountingFees_Duration_1_1_2023_To_12_31_2023_us-gaap_BusinessAcquisitionAxis_adap_Tcr2TherapeuticsMember_lWAm9aaXQ0evvG9S0X_EiA,adap:BusinessCombinationAcquisitionRelatedCostsLegalProfessionalAndAccountingFees,Duration_1_1_2023_To_12_31_2023_us-gaap_BusinessAcquisitionAxis_adap_Tcr2TherapeuticsMember_lWAm9aaXQ0evvG9S0X_EiA,5174000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,5174000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-12-31,"Legal, professional and accounting fees","Legal, professional and accounting fees",Disclosures,http://www.adaptimmune.com/role/DisclosureBusinessCombinationsAcquisitionRelatedCostsDetails,2023-01-01,2023-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,adap:Tcr2TherapeuticsMember,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
adap_BusinessCombinationAcquisitionRelatedCostsBankersFees_Duration_1_1_2024_To_3_31_2024_us-gaap_BusinessAcquisitionAxis_adap_Tcr2TherapeuticsMember_YaLzWVsA_kmY_1UHs1dX0Q,adap:BusinessCombinationAcquisitionRelatedCostsBankersFees,Duration_1_1_2024_To_3_31_2024_us-gaap_BusinessAcquisitionAxis_adap_Tcr2TherapeuticsMember_YaLzWVsA_kmY_1UHs1dX0Q,750000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,750000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Bankers' fees,Bankers' fees,Disclosures,http://www.adaptimmune.com/role/DisclosureBusinessCombinationsAcquisitionRelatedCostsDetails,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,adap:Tcr2TherapeuticsMember,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
adap_BusinessCombinationAcquisitionRelatedCostsBankersFees_Duration_1_1_2023_To_12_31_2023_us-gaap_BusinessAcquisitionAxis_adap_Tcr2TherapeuticsMember_lWAm9aaXQ0evvG9S0X_EiA,adap:BusinessCombinationAcquisitionRelatedCostsBankersFees,Duration_1_1_2023_To_12_31_2023_us-gaap_BusinessAcquisitionAxis_adap_Tcr2TherapeuticsMember_lWAm9aaXQ0evvG9S0X_EiA,2172000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,2172000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-12-31,Bankers' fees,Bankers' fees,Disclosures,http://www.adaptimmune.com/role/DisclosureBusinessCombinationsAcquisitionRelatedCostsDetails,2023-01-01,2023-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,adap:Tcr2TherapeuticsMember,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_BusinessCombinationAcquisitionRelatedCosts_Duration_1_1_2024_To_3_31_2024_us-gaap_BusinessAcquisitionAxis_adap_Tcr2TherapeuticsMember_YaLzWVsA_kmY_1UHs1dX0Q,us-gaap:BusinessCombinationAcquisitionRelatedCosts,Duration_1_1_2024_To_3_31_2024_us-gaap_BusinessAcquisitionAxis_adap_Tcr2TherapeuticsMember_YaLzWVsA_kmY_1UHs1dX0Q,4073000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,4073000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Acquisition-related costs,Acquisition-related costs,Disclosures,http://www.adaptimmune.com/role/DisclosureBusinessCombinationsProformaInformationDetails,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,adap:Tcr2TherapeuticsMember,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_BusinessCombinationAcquisitionRelatedCosts_Duration_1_1_2023_To_12_31_2023_us-gaap_BusinessAcquisitionAxis_adap_Tcr2TherapeuticsMember_lWAm9aaXQ0evvG9S0X_EiA,us-gaap:BusinessCombinationAcquisitionRelatedCosts,Duration_1_1_2023_To_12_31_2023_us-gaap_BusinessAcquisitionAxis_adap_Tcr2TherapeuticsMember_lWAm9aaXQ0evvG9S0X_EiA,7346000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,7346000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-12-31,Acquisition-related costs,Acquisition-related costs,Disclosures,http://www.adaptimmune.com/role/DisclosureBusinessCombinationsProformaInformationDetails,2023-01-01,2023-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,adap:Tcr2TherapeuticsMember,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
adap_BusinessCombinationAcquisitionRelatedCostsStockIssuanceCosts_Duration_1_1_2024_To_3_31_2024_us-gaap_BusinessAcquisitionAxis_adap_Tcr2TherapeuticsMember_YaLzWVsA_kmY_1UHs1dX0Q,adap:BusinessCombinationAcquisitionRelatedCostsStockIssuanceCosts,Duration_1_1_2024_To_3_31_2024_us-gaap_BusinessAcquisitionAxis_adap_Tcr2TherapeuticsMember_YaLzWVsA_kmY_1UHs1dX0Q,0,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,0.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Issuance costs incurred relating to the issuance of shares to TCR2 stockholders,Issuance costs incurred relating to the issuance of shares to TCR2 stockholders,Disclosures,http://www.adaptimmune.com/role/DisclosureBusinessCombinationsAcquisitionRelatedCostsDetails,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,adap:Tcr2TherapeuticsMember,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_SegmentReportingDisclosureTextBlock_Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,us-gaap:SegmentReportingDisclosureTextBlock,Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,"<p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">Note 14 – Segment reporting</b></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""display:inline-block;text-indent:0pt;width:36pt;""></span>The Company has one reportable segment relating to the research, development and planned commercialization of its novel cell therapies. The segment derives its current revenues from research and development collaborations.</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""display:inline-block;text-indent:0pt;width:36pt;""></span>The Company’s chief operating decision maker (the “CODM”), its Chief Executive Officer and the senior leadership team (comprising the Executive Team members and three senior vice presidents), manages the Company’s operations on an integrated basis for the purposes of allocating resources. When evaluating the Company’s financial performance, the CODM reviews total revenues, total expenses and expenses by function and the CODM makes decisions using this information on a global basis.</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""display:inline-block;text-indent:0pt;width:36pt;""></span>The table below is a summary of the segment profit or loss, including significant segment expenses (in thousands):</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p><table style=""border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;""><tr style=""height:1pt;""><td style=""vertical-align:bottom;width:74.4%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td></tr><tr><td style=""vertical-align:bottom;width:74.4%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td colspan=""5"" style=""vertical-align:bottom;white-space:nowrap;width:23.35%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Three months ended </b></p></td></tr><tr><td style=""vertical-align:bottom;width:74.4%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td colspan=""5"" style=""vertical-align:bottom;white-space:nowrap;width:23.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">March 31, </b></p></td></tr><tr><td style=""vertical-align:bottom;width:74.4%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2024</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">    </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2023</b></p></td></tr><tr><td style=""vertical-align:bottom;width:74.4%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Revenue</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 5,678</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 47,601</p></td></tr><tr><td style=""vertical-align:bottom;width:74.4%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Less:</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;width:74.4%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"">Research</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (3,800)</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (3,500)</p></td></tr><tr><td style=""vertical-align:bottom;width:74.4%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"">CMC and Quality</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (14,200)</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (14,300)</p></td></tr><tr><td style=""vertical-align:bottom;width:74.4%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"">Biomarkers</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (2,500)</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (1,200)</p></td></tr><tr><td style=""vertical-align:bottom;width:74.4%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"">Development and Compliance</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (12,600)</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (9,200)</p></td></tr><tr><td style=""vertical-align:bottom;width:74.4%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"">Infrastructure management and Facilities</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (7,700)</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (6,200)</p></td></tr><tr><td style=""vertical-align:bottom;width:74.4%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"">Commercial planning</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (2,600)</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (1,100)</p></td></tr><tr><td style=""vertical-align:bottom;width:74.4%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"">Support functions</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (9,000)</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (13,600)</p></td></tr><tr><td style=""vertical-align:bottom;width:74.4%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"">Other segment expenses<sup style=""font-family:'Calibri','Helvetica','sans-serif';font-size:8.25pt;line-height:100%;top:0pt;vertical-align:top;"">(a)</sup></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (2,539)</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 3,155</p></td></tr><tr><td style=""vertical-align:bottom;width:74.4%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">Total operating expenses</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><b style=""font-weight:bold;""> (54,939)</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><b style=""font-weight:bold;""> (45,945)</b></p></td></tr><tr><td style=""vertical-align:bottom;width:74.4%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">Operating (loss)/profit</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><b style=""font-weight:bold;""> (49,261)</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 1,656</b></p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:74.4%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;width:74.4%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Interest income</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 1,345</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 676</p></td></tr><tr><td style=""vertical-align:bottom;width:74.4%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Other income (expense), net</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (61)</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (671)</p></td></tr><tr><td style=""vertical-align:bottom;width:74.4%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Income tax expense</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (526)</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (625)</p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:74.4%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">Segment and consolidated net (loss)/profit</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><b style=""font-weight:bold;""> (48,503)</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 1,036</b></p></td></tr></table><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><sup style=""font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"">(a)</sup>Other segment expenses includes reimbursements receivable for research and development tax and expenditure credits, depreciation, amortization and share-based compensation expenses.</p>",None,None,,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Segment Reporting,Segment Reporting,Disclosures,http://www.adaptimmune.com/role/DisclosureSegmentReporting,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_NumberOfOperatingSegments_Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,us-gaap:NumberOfOperatingSegments,Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,1,Unit_Standard_segment_GYQAkkfurEG5xv7YEoQJ0g,INF,1.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Number of Operating Segments,Number of Operating Segments,Disclosures,http://www.adaptimmune.com/role/DisclosureSegmentReportingDetails,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock,Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,"<p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p><table style=""border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;""><tr style=""height:1pt;""><td style=""vertical-align:bottom;width:74.4%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td></tr><tr><td style=""vertical-align:bottom;width:74.4%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td colspan=""5"" style=""vertical-align:bottom;white-space:nowrap;width:23.35%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Three months ended </b></p></td></tr><tr><td style=""vertical-align:bottom;width:74.4%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td colspan=""5"" style=""vertical-align:bottom;white-space:nowrap;width:23.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">March 31, </b></p></td></tr><tr><td style=""vertical-align:bottom;width:74.4%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2024</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">    </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2023</b></p></td></tr><tr><td style=""vertical-align:bottom;width:74.4%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Revenue</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 5,678</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 47,601</p></td></tr><tr><td style=""vertical-align:bottom;width:74.4%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Less:</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;width:74.4%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"">Research</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (3,800)</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (3,500)</p></td></tr><tr><td style=""vertical-align:bottom;width:74.4%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"">CMC and Quality</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (14,200)</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (14,300)</p></td></tr><tr><td style=""vertical-align:bottom;width:74.4%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"">Biomarkers</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (2,500)</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (1,200)</p></td></tr><tr><td style=""vertical-align:bottom;width:74.4%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"">Development and Compliance</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (12,600)</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (9,200)</p></td></tr><tr><td style=""vertical-align:bottom;width:74.4%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"">Infrastructure management and Facilities</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (7,700)</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (6,200)</p></td></tr><tr><td style=""vertical-align:bottom;width:74.4%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"">Commercial planning</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (2,600)</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (1,100)</p></td></tr><tr><td style=""vertical-align:bottom;width:74.4%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"">Support functions</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (9,000)</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (13,600)</p></td></tr><tr><td style=""vertical-align:bottom;width:74.4%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"">Other segment expenses<sup style=""font-family:'Calibri','Helvetica','sans-serif';font-size:8.25pt;line-height:100%;top:0pt;vertical-align:top;"">(a)</sup></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (2,539)</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 3,155</p></td></tr><tr><td style=""vertical-align:bottom;width:74.4%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">Total operating expenses</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><b style=""font-weight:bold;""> (54,939)</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><b style=""font-weight:bold;""> (45,945)</b></p></td></tr><tr><td style=""vertical-align:bottom;width:74.4%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">Operating (loss)/profit</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><b style=""font-weight:bold;""> (49,261)</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 1,656</b></p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:74.4%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;width:74.4%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Interest income</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 1,345</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 676</p></td></tr><tr><td style=""vertical-align:bottom;width:74.4%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Other income (expense), net</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (61)</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (671)</p></td></tr><tr><td style=""vertical-align:bottom;width:74.4%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Income tax expense</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (526)</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (625)</p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:74.4%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">Segment and consolidated net (loss)/profit</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><b style=""font-weight:bold;""> (48,503)</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 1,036</b></p></td></tr></table>",None,None,,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Summary of the segment profit or loss,Summary of the segment profit or loss,Disclosures,http://www.adaptimmune.com/role/DisclosureSegmentReportingTables,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_Revenues_Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,us-gaap:Revenues,Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,5678000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,5678000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Revenues,Revenues,Disclosures,http://www.adaptimmune.com/role/DisclosureSegmentReportingDetails,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_Revenues_Duration_1_1_2023_To_3_31_2023_y-zxPPLZtEmUIwfawHojag,us-gaap:Revenues,Duration_1_1_2023_To_3_31_2023_y-zxPPLZtEmUIwfawHojag,47601000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,47601000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Revenues,Revenues,Disclosures,http://www.adaptimmune.com/role/DisclosureSegmentReportingDetails,2023-01-01,2023-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_CostsAndExpenses_Duration_1_1_2024_To_3_31_2024_us-gaap_StatementBusinessSegmentsAxis_adap_ResearchSegmentMember_QmTE5AA_lkWfOL57wNbzow,us-gaap:CostsAndExpenses,Duration_1_1_2024_To_3_31_2024_us-gaap_StatementBusinessSegmentsAxis_adap_ResearchSegmentMember_QmTE5AA_lkWfOL57wNbzow,-3800000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,-3800000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Total operating expenses,Total operating expenses,IncomeStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,adap:ResearchSegmentMember,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_CostsAndExpenses_Duration_1_1_2023_To_3_31_2023_us-gaap_StatementBusinessSegmentsAxis_adap_ResearchSegmentMember_RZ-aI-qBHECxirX1321q4Q,us-gaap:CostsAndExpenses,Duration_1_1_2023_To_3_31_2023_us-gaap_StatementBusinessSegmentsAxis_adap_ResearchSegmentMember_RZ-aI-qBHECxirX1321q4Q,-3500000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,-3500000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Total operating expenses,Total operating expenses,IncomeStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations,2023-01-01,2023-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,adap:ResearchSegmentMember,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_CostsAndExpenses_Duration_1_1_2024_To_3_31_2024_us-gaap_StatementBusinessSegmentsAxis_adap_CmcAndQualitySegmentMember_63sASZiYbEiN80iPOniuPg,us-gaap:CostsAndExpenses,Duration_1_1_2024_To_3_31_2024_us-gaap_StatementBusinessSegmentsAxis_adap_CmcAndQualitySegmentMember_63sASZiYbEiN80iPOniuPg,-14200000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,-14200000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Total operating expenses,Total operating expenses,IncomeStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,adap:CmcAndQualitySegmentMember,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_CostsAndExpenses_Duration_1_1_2023_To_3_31_2023_us-gaap_StatementBusinessSegmentsAxis_adap_CmcAndQualitySegmentMember_K6d1-WE25EWs-m9gyuiciw,us-gaap:CostsAndExpenses,Duration_1_1_2023_To_3_31_2023_us-gaap_StatementBusinessSegmentsAxis_adap_CmcAndQualitySegmentMember_K6d1-WE25EWs-m9gyuiciw,-14300000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,-14300000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Total operating expenses,Total operating expenses,IncomeStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations,2023-01-01,2023-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,adap:CmcAndQualitySegmentMember,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_CostsAndExpenses_Duration_1_1_2024_To_3_31_2024_us-gaap_StatementBusinessSegmentsAxis_adap_BiomarkersSegmentMember_xAT3lLK-9kmXg5GCHotxnw,us-gaap:CostsAndExpenses,Duration_1_1_2024_To_3_31_2024_us-gaap_StatementBusinessSegmentsAxis_adap_BiomarkersSegmentMember_xAT3lLK-9kmXg5GCHotxnw,-2500000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,-2500000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Total operating expenses,Total operating expenses,IncomeStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,adap:BiomarkersSegmentMember,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_CostsAndExpenses_Duration_1_1_2023_To_3_31_2023_us-gaap_StatementBusinessSegmentsAxis_adap_BiomarkersSegmentMember_DQ51yLbpxkyTkBGpXcCENA,us-gaap:CostsAndExpenses,Duration_1_1_2023_To_3_31_2023_us-gaap_StatementBusinessSegmentsAxis_adap_BiomarkersSegmentMember_DQ51yLbpxkyTkBGpXcCENA,-1200000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,-1200000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Total operating expenses,Total operating expenses,IncomeStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations,2023-01-01,2023-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,adap:BiomarkersSegmentMember,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_CostsAndExpenses_Duration_1_1_2024_To_3_31_2024_us-gaap_StatementBusinessSegmentsAxis_adap_DevelopmentAndComplianceSegmentMember_X5VNIKu3X0q--gxBAvC_3A,us-gaap:CostsAndExpenses,Duration_1_1_2024_To_3_31_2024_us-gaap_StatementBusinessSegmentsAxis_adap_DevelopmentAndComplianceSegmentMember_X5VNIKu3X0q--gxBAvC_3A,-12600000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,-12600000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Total operating expenses,Total operating expenses,IncomeStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,adap:DevelopmentAndComplianceSegmentMember,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_CostsAndExpenses_Duration_1_1_2023_To_3_31_2023_us-gaap_StatementBusinessSegmentsAxis_adap_DevelopmentAndComplianceSegmentMember_DfNJeNK7LEeKxeZq9_VR1Q,us-gaap:CostsAndExpenses,Duration_1_1_2023_To_3_31_2023_us-gaap_StatementBusinessSegmentsAxis_adap_DevelopmentAndComplianceSegmentMember_DfNJeNK7LEeKxeZq9_VR1Q,-9200000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,-9200000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Total operating expenses,Total operating expenses,IncomeStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations,2023-01-01,2023-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,adap:DevelopmentAndComplianceSegmentMember,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_CostsAndExpenses_Duration_1_1_2024_To_3_31_2024_us-gaap_StatementBusinessSegmentsAxis_adap_InfrastructureManagementAndFacilitiesSegmentMember_TEpxPjtNLEKUFetvlXRRpA,us-gaap:CostsAndExpenses,Duration_1_1_2024_To_3_31_2024_us-gaap_StatementBusinessSegmentsAxis_adap_InfrastructureManagementAndFacilitiesSegmentMember_TEpxPjtNLEKUFetvlXRRpA,-7700000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,-7700000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Total operating expenses,Total operating expenses,IncomeStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,adap:InfrastructureManagementAndFacilitiesSegmentMember,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_CostsAndExpenses_Duration_1_1_2023_To_3_31_2023_us-gaap_StatementBusinessSegmentsAxis_adap_InfrastructureManagementAndFacilitiesSegmentMember_yrCws-GU_0mZr_0oFn5Hgw,us-gaap:CostsAndExpenses,Duration_1_1_2023_To_3_31_2023_us-gaap_StatementBusinessSegmentsAxis_adap_InfrastructureManagementAndFacilitiesSegmentMember_yrCws-GU_0mZr_0oFn5Hgw,-6200000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,-6200000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Total operating expenses,Total operating expenses,IncomeStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations,2023-01-01,2023-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,adap:InfrastructureManagementAndFacilitiesSegmentMember,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_CostsAndExpenses_Duration_1_1_2024_To_3_31_2024_us-gaap_StatementBusinessSegmentsAxis_adap_CommercialPlanningSegmentMember_oZ_gPDEy7EefZWxljhwvHA,us-gaap:CostsAndExpenses,Duration_1_1_2024_To_3_31_2024_us-gaap_StatementBusinessSegmentsAxis_adap_CommercialPlanningSegmentMember_oZ_gPDEy7EefZWxljhwvHA,-2600000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,-2600000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Total operating expenses,Total operating expenses,IncomeStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,adap:CommercialPlanningSegmentMember,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_CostsAndExpenses_Duration_1_1_2023_To_3_31_2023_us-gaap_StatementBusinessSegmentsAxis_adap_CommercialPlanningSegmentMember_aR2SmD_GLUWUjEXPArcnGA,us-gaap:CostsAndExpenses,Duration_1_1_2023_To_3_31_2023_us-gaap_StatementBusinessSegmentsAxis_adap_CommercialPlanningSegmentMember_aR2SmD_GLUWUjEXPArcnGA,-1100000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,-1100000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Total operating expenses,Total operating expenses,IncomeStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations,2023-01-01,2023-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,adap:CommercialPlanningSegmentMember,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_CostsAndExpenses_Duration_1_1_2024_To_3_31_2024_us-gaap_StatementBusinessSegmentsAxis_adap_SupportFunctionsSegmentMember_uproLdLCS0a0tYa4g9bU8w,us-gaap:CostsAndExpenses,Duration_1_1_2024_To_3_31_2024_us-gaap_StatementBusinessSegmentsAxis_adap_SupportFunctionsSegmentMember_uproLdLCS0a0tYa4g9bU8w,-9000000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,-9000000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Total operating expenses,Total operating expenses,IncomeStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,adap:SupportFunctionsSegmentMember,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_CostsAndExpenses_Duration_1_1_2023_To_3_31_2023_us-gaap_StatementBusinessSegmentsAxis_adap_SupportFunctionsSegmentMember_cEUl5jCGfkewfSbVrYbANA,us-gaap:CostsAndExpenses,Duration_1_1_2023_To_3_31_2023_us-gaap_StatementBusinessSegmentsAxis_adap_SupportFunctionsSegmentMember_cEUl5jCGfkewfSbVrYbANA,-13600000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,-13600000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Total operating expenses,Total operating expenses,IncomeStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations,2023-01-01,2023-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,adap:SupportFunctionsSegmentMember,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_CostsAndExpenses_Duration_1_1_2024_To_3_31_2024_us-gaap_StatementBusinessSegmentsAxis_adap_OtherSegmentMember_WFJhCnIQSEynXxuaU5yWDA,us-gaap:CostsAndExpenses,Duration_1_1_2024_To_3_31_2024_us-gaap_StatementBusinessSegmentsAxis_adap_OtherSegmentMember_WFJhCnIQSEynXxuaU5yWDA,-2539000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,-2539000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Total operating expenses,Total operating expenses,IncomeStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,adap:OtherSegmentMember,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_CostsAndExpenses_Duration_1_1_2023_To_3_31_2023_us-gaap_StatementBusinessSegmentsAxis_adap_OtherSegmentMember_Nps66ZGXt0aE0GedluFrNw,us-gaap:CostsAndExpenses,Duration_1_1_2023_To_3_31_2023_us-gaap_StatementBusinessSegmentsAxis_adap_OtherSegmentMember_Nps66ZGXt0aE0GedluFrNw,3155000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,3155000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Total operating expenses,Total operating expenses,IncomeStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations,2023-01-01,2023-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,adap:OtherSegmentMember,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_CostsAndExpenses_Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw_0,us-gaap:CostsAndExpenses,Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,-54939000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,-54939000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Total operating expenses,Total operating expenses,IncomeStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_CostsAndExpenses_Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw_1,us-gaap:CostsAndExpenses,Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,-54939000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,-54939000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Total operating expenses,Total operating expenses,IncomeStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_CostsAndExpenses_Duration_1_1_2023_To_3_31_2023_y-zxPPLZtEmUIwfawHojag_0,us-gaap:CostsAndExpenses,Duration_1_1_2023_To_3_31_2023_y-zxPPLZtEmUIwfawHojag,-45945000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,-45945000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Total operating expenses,Total operating expenses,IncomeStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations,2023-01-01,2023-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_CostsAndExpenses_Duration_1_1_2023_To_3_31_2023_y-zxPPLZtEmUIwfawHojag_1,us-gaap:CostsAndExpenses,Duration_1_1_2023_To_3_31_2023_y-zxPPLZtEmUIwfawHojag,-45945000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,-45945000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Total operating expenses,Total operating expenses,IncomeStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations,2023-01-01,2023-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_OperatingIncomeLoss_Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw_0,us-gaap:OperatingIncomeLoss,Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,-49261000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,-49261000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Operating (loss)/profit,Operating (loss)/profit,IncomeStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_OperatingIncomeLoss_Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw_1,us-gaap:OperatingIncomeLoss,Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,-49261000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,-49261000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Operating (loss)/profit,Operating (loss)/profit,IncomeStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_OperatingIncomeLoss_Duration_1_1_2023_To_3_31_2023_y-zxPPLZtEmUIwfawHojag_0,us-gaap:OperatingIncomeLoss,Duration_1_1_2023_To_3_31_2023_y-zxPPLZtEmUIwfawHojag,1656000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,1656000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Operating (loss)/profit,Operating (loss)/profit,IncomeStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations,2023-01-01,2023-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_OperatingIncomeLoss_Duration_1_1_2023_To_3_31_2023_y-zxPPLZtEmUIwfawHojag_1,us-gaap:OperatingIncomeLoss,Duration_1_1_2023_To_3_31_2023_y-zxPPLZtEmUIwfawHojag,1656000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,1656000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Operating (loss)/profit,Operating (loss)/profit,IncomeStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations,2023-01-01,2023-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_InterestIncomeDebtSecuritiesAvailableForSaleOperating_Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw_0,us-gaap:InterestIncomeDebtSecuritiesAvailableForSaleOperating,Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,1345000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,1345000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Interest income,Interest income,IncomeStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_InterestIncomeDebtSecuritiesAvailableForSaleOperating_Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw_1,us-gaap:InterestIncomeDebtSecuritiesAvailableForSaleOperating,Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,1345000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,1345000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Interest income,Interest income,IncomeStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_InterestIncomeDebtSecuritiesAvailableForSaleOperating_Duration_1_1_2023_To_3_31_2023_y-zxPPLZtEmUIwfawHojag_0,us-gaap:InterestIncomeDebtSecuritiesAvailableForSaleOperating,Duration_1_1_2023_To_3_31_2023_y-zxPPLZtEmUIwfawHojag,676000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,676000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Interest income,Interest income,IncomeStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations,2023-01-01,2023-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_InterestIncomeDebtSecuritiesAvailableForSaleOperating_Duration_1_1_2023_To_3_31_2023_y-zxPPLZtEmUIwfawHojag_1,us-gaap:InterestIncomeDebtSecuritiesAvailableForSaleOperating,Duration_1_1_2023_To_3_31_2023_y-zxPPLZtEmUIwfawHojag,676000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,676000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Interest income,Interest income,IncomeStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations,2023-01-01,2023-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_OtherNonoperatingIncomeExpense_Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw_0,us-gaap:OtherNonoperatingIncomeExpense,Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,-61000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,-61000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,"Other income (expense), net","Other income (expense), net",IncomeStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_OtherNonoperatingIncomeExpense_Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw_1,us-gaap:OtherNonoperatingIncomeExpense,Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,-61000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,-61000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,"Other income (expense), net","Other income (expense), net",IncomeStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_OtherNonoperatingIncomeExpense_Duration_1_1_2023_To_3_31_2023_y-zxPPLZtEmUIwfawHojag_0,us-gaap:OtherNonoperatingIncomeExpense,Duration_1_1_2023_To_3_31_2023_y-zxPPLZtEmUIwfawHojag,-671000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,-671000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,"Other income (expense), net","Other income (expense), net",IncomeStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations,2023-01-01,2023-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_OtherNonoperatingIncomeExpense_Duration_1_1_2023_To_3_31_2023_y-zxPPLZtEmUIwfawHojag_1,us-gaap:OtherNonoperatingIncomeExpense,Duration_1_1_2023_To_3_31_2023_y-zxPPLZtEmUIwfawHojag,-671000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,-671000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,"Other income (expense), net","Other income (expense), net",IncomeStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations,2023-01-01,2023-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_IncomeTaxExpenseBenefit_Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw_0,us-gaap:IncomeTaxExpenseBenefit,Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,-526000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,-526000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Income tax expense,Income tax expense,IncomeStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_IncomeTaxExpenseBenefit_Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw_1,us-gaap:IncomeTaxExpenseBenefit,Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,-526000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,-526000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Income tax expense,Income tax expense,IncomeStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_IncomeTaxExpenseBenefit_Duration_1_1_2023_To_3_31_2023_y-zxPPLZtEmUIwfawHojag_0,us-gaap:IncomeTaxExpenseBenefit,Duration_1_1_2023_To_3_31_2023_y-zxPPLZtEmUIwfawHojag,-625000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,-625000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Income tax expense,Income tax expense,IncomeStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations,2023-01-01,2023-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_IncomeTaxExpenseBenefit_Duration_1_1_2023_To_3_31_2023_y-zxPPLZtEmUIwfawHojag_1,us-gaap:IncomeTaxExpenseBenefit,Duration_1_1_2023_To_3_31_2023_y-zxPPLZtEmUIwfawHojag,-625000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,-625000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Income tax expense,Income tax expense,IncomeStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations,2023-01-01,2023-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_NetIncomeLoss_Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw_4,us-gaap:NetIncomeLoss,Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,-48503000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,-48503000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Net (loss)/profit attributable to ordinary shareholders,Net (loss)/profit attributable to ordinary shareholders,IncomeStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_NetIncomeLoss_Duration_1_1_2023_To_3_31_2023_y-zxPPLZtEmUIwfawHojag_4,us-gaap:NetIncomeLoss,Duration_1_1_2023_To_3_31_2023_y-zxPPLZtEmUIwfawHojag,1036000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-3,1036000.0,duration,None,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Net (loss)/profit attributable to ordinary shareholders,Net (loss)/profit attributable to ordinary shareholders,IncomeStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations,2023-01-01,2023-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_SubsequentEventsTextBlock_Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,us-gaap:SubsequentEventsTextBlock,Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,"<p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">Note 15 – Subsequent events</b></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">On April 12, 2024 we announced the termination of the strategic collaboration between us and Genentech in relation to the research, development and commercialization of cancer targeted allogeneic T-cell therapies. The termination becomes effective 180 days after the date of receipt of the notice of termination (the “Genentech Termination Date”). As a result of the termination of the Agreement, Adaptimmune will not be entitled to receive any further milestones or other payments that become due after the Genentech Termination Date. We will also cease to have any development obligations after the Genentech Termination Date and all licenses granted to Genentech pursuant to the Agreement will cease to be in effect as of the Genentech Termination Date. The termination is expected to result in the deferred revenue associated with the agreement of $146,287,000 as of March 31, 2024, being recognised as revenue in the remainder of 2024. However, the Company is still evaluating the terms of the termination and therefore an estimate of the other financial effects of this event on the Company cannot yet be made.</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">On February 27, 2024 we announced the return of Cintia Piccina as our Chief Commercial Officer, effective March 18, 2024.</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 0pt 0pt;"">On May 14, 2024 (the “Closing Date”), we entered into a Loan and Security Agreement (the “Loan Agreement”), with several banks and other financial institutions or entities (each, a “Lender”, and collectively “Lenders”) and Hercules Capital, Inc. (the “Agent”), for a term loan facility of up to $125.0 million (the “Term Loan”), consisting of a term loan advance in the aggregate principal amount equal to $25.0 million on the Closing Date (the “Tranche 1 Advance”), a term loan advance available to the Company subject to certain terms and conditions in the aggregate principal amount of $25.0 million (the “Tranche 2 Advance’), a term loan advance available subject to certain terms and conditions in the aggregate amount of $5.0 million (the “Tranche 3 Advance”), a term loan advance available subject to certain terms and conditions in the aggregate principal amount of $30.0 million (the “Tranche 4 Advance”) and a term loan advance available in the sole discretion of the Lenders and subject to certain terms and conditions in the aggregate principal amount of $40.0 million (the “Tranche 5 Advance” and together with each Tranche Advance, the “Term Loan Advances”). The proceeds of the Term Loan will be used solely to repay related fees and expenses in connection with the Loan Agreement and for working capital and general corporate purposes. </p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p>",None,None,,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Subsequent events,Subsequent events,Disclosures,http://www.adaptimmune.com/role/DisclosureSubsequentEvents,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_ContractWithCustomerLiability_As_Of_3_31_2024_srt_MajorCustomersAxis_adap_GenentechInc.Member_OGjK6MHb-kmjYnnOrTepgg,us-gaap:ContractWithCustomerLiability,As_Of_3_31_2024_srt_MajorCustomersAxis_adap_GenentechInc.Member_OGjK6MHb-kmjYnnOrTepgg,146287000,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,0,146287000.0,instant,2024-03-31,0001621227,http://www.sec.gov/CIK,instant_2024-03-31,Deferred revenue,Deferred revenue,Disclosures,http://www.adaptimmune.com/role/DisclosureRevenueRevenueFromContractsWithCustomersDetails,None,None,None,adap:GenentechInc.Member,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_DebtInstrumentFaceAmount_As_Of_5_14_2024_us-gaap_DebtInstrumentAxis_adap_LoanAndSecurityAgreementMember_us-gaap_LongtermDebtTypeAxis_us-gaap_NotesPayableToBanksMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_2q5Wib7qjEG6-H4E8XizJQ,us-gaap:DebtInstrumentFaceAmount,As_Of_5_14_2024_us-gaap_DebtInstrumentAxis_adap_LoanAndSecurityAgreementMember_us-gaap_LongtermDebtTypeAxis_us-gaap_NotesPayableToBanksMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_2q5Wib7qjEG6-H4E8XizJQ,125000000.0,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-5,125000000.0,instant,2024-05-14,0001621227,http://www.sec.gov/CIK,instant_2024-05-14,Amount of term loan facility,Amount of term loan facility,Disclosures,http://www.adaptimmune.com/role/DisclosureSubsequentEventsDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,adap:LoanAndSecurityAgreementMember,us-gaap:NotesPayableToBanksMember,us-gaap:SubsequentEventMember,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_DebtInstrumentFaceAmount_As_Of_5_14_2024_us-gaap_DebtInstrumentAxis_adap_LoanAndSecurityAgreementMember_us-gaap_DebtInstrumentRedemptionPeriodAxis_us-gaap_DebtInstrumentRedemptionPeriodOneMember_us-gaap_LongtermDebtTypeAxis_us-gaap_NotesPayableToBanksMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_OF8ORSjeCEyqZKxlcmAQ-g,us-gaap:DebtInstrumentFaceAmount,As_Of_5_14_2024_us-gaap_DebtInstrumentAxis_adap_LoanAndSecurityAgreementMember_us-gaap_DebtInstrumentRedemptionPeriodAxis_us-gaap_DebtInstrumentRedemptionPeriodOneMember_us-gaap_LongtermDebtTypeAxis_us-gaap_NotesPayableToBanksMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_OF8ORSjeCEyqZKxlcmAQ-g,25000000.0,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-5,25000000.0,instant,2024-05-14,0001621227,http://www.sec.gov/CIK,instant_2024-05-14,Amount of term loan facility,Amount of term loan facility,Disclosures,http://www.adaptimmune.com/role/DisclosureSubsequentEventsDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,adap:LoanAndSecurityAgreementMember,us-gaap:NotesPayableToBanksMember,us-gaap:SubsequentEventMember,us-gaap:DebtInstrumentRedemptionPeriodOneMember,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_DebtInstrumentFaceAmount_As_Of_5_14_2024_us-gaap_DebtInstrumentAxis_adap_LoanAndSecurityAgreementMember_us-gaap_DebtInstrumentRedemptionPeriodAxis_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_us-gaap_LongtermDebtTypeAxis_us-gaap_NotesPayableToBanksMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_FlunAmftq0GsZ2n-Z5WIsQ,us-gaap:DebtInstrumentFaceAmount,As_Of_5_14_2024_us-gaap_DebtInstrumentAxis_adap_LoanAndSecurityAgreementMember_us-gaap_DebtInstrumentRedemptionPeriodAxis_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_us-gaap_LongtermDebtTypeAxis_us-gaap_NotesPayableToBanksMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_FlunAmftq0GsZ2n-Z5WIsQ,25000000.0,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-5,25000000.0,instant,2024-05-14,0001621227,http://www.sec.gov/CIK,instant_2024-05-14,Amount of term loan facility,Amount of term loan facility,Disclosures,http://www.adaptimmune.com/role/DisclosureSubsequentEventsDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,adap:LoanAndSecurityAgreementMember,us-gaap:NotesPayableToBanksMember,us-gaap:SubsequentEventMember,us-gaap:DebtInstrumentRedemptionPeriodTwoMember,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_DebtInstrumentFaceAmount_As_Of_5_14_2024_us-gaap_DebtInstrumentAxis_adap_LoanAndSecurityAgreementMember_us-gaap_DebtInstrumentRedemptionPeriodAxis_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_us-gaap_LongtermDebtTypeAxis_us-gaap_NotesPayableToBanksMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_rvoZHQIYDkmn4niSjxyooQ,us-gaap:DebtInstrumentFaceAmount,As_Of_5_14_2024_us-gaap_DebtInstrumentAxis_adap_LoanAndSecurityAgreementMember_us-gaap_DebtInstrumentRedemptionPeriodAxis_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_us-gaap_LongtermDebtTypeAxis_us-gaap_NotesPayableToBanksMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_rvoZHQIYDkmn4niSjxyooQ,5000000.0,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-5,5000000.0,instant,2024-05-14,0001621227,http://www.sec.gov/CIK,instant_2024-05-14,Amount of term loan facility,Amount of term loan facility,Disclosures,http://www.adaptimmune.com/role/DisclosureSubsequentEventsDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,adap:LoanAndSecurityAgreementMember,us-gaap:NotesPayableToBanksMember,us-gaap:SubsequentEventMember,us-gaap:DebtInstrumentRedemptionPeriodThreeMember,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_DebtInstrumentFaceAmount_As_Of_5_14_2024_us-gaap_DebtInstrumentAxis_adap_LoanAndSecurityAgreementMember_us-gaap_DebtInstrumentRedemptionPeriodAxis_us-gaap_DebtInstrumentRedemptionPeriodFourMember_us-gaap_LongtermDebtTypeAxis_us-gaap_NotesPayableToBanksMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_HN_LRj3xv0y0eXKmMVoDeg,us-gaap:DebtInstrumentFaceAmount,As_Of_5_14_2024_us-gaap_DebtInstrumentAxis_adap_LoanAndSecurityAgreementMember_us-gaap_DebtInstrumentRedemptionPeriodAxis_us-gaap_DebtInstrumentRedemptionPeriodFourMember_us-gaap_LongtermDebtTypeAxis_us-gaap_NotesPayableToBanksMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_HN_LRj3xv0y0eXKmMVoDeg,30000000.0,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-5,30000000.0,instant,2024-05-14,0001621227,http://www.sec.gov/CIK,instant_2024-05-14,Amount of term loan facility,Amount of term loan facility,Disclosures,http://www.adaptimmune.com/role/DisclosureSubsequentEventsDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,adap:LoanAndSecurityAgreementMember,us-gaap:NotesPayableToBanksMember,us-gaap:SubsequentEventMember,us-gaap:DebtInstrumentRedemptionPeriodFourMember,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
us-gaap_DebtInstrumentFaceAmount_As_Of_5_14_2024_us-gaap_DebtInstrumentAxis_adap_LoanAndSecurityAgreementMember_us-gaap_DebtInstrumentRedemptionPeriodAxis_us-gaap_DebtInstrumentRedemptionPeriodFiveMember_us-gaap_LongtermDebtTypeAxis_us-gaap_NotesPayableToBanksMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_7hU_7YaP5kqoekGfJKeDQQ,us-gaap:DebtInstrumentFaceAmount,As_Of_5_14_2024_us-gaap_DebtInstrumentAxis_adap_LoanAndSecurityAgreementMember_us-gaap_DebtInstrumentRedemptionPeriodAxis_us-gaap_DebtInstrumentRedemptionPeriodFiveMember_us-gaap_LongtermDebtTypeAxis_us-gaap_NotesPayableToBanksMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_7hU_7YaP5kqoekGfJKeDQQ,40000000.0,Unit_Standard_USD_Z0EnHFjRWkS9vH3Kmd3lcg,-5,40000000.0,instant,2024-05-14,0001621227,http://www.sec.gov/CIK,instant_2024-05-14,Amount of term loan facility,Amount of term loan facility,Disclosures,http://www.adaptimmune.com/role/DisclosureSubsequentEventsDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,adap:LoanAndSecurityAgreementMember,us-gaap:NotesPayableToBanksMember,us-gaap:SubsequentEventMember,us-gaap:DebtInstrumentRedemptionPeriodFiveMember,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
ecd_Rule10b51ArrAdoptedFlag_Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,ecd:Rule10b51ArrAdoptedFlag,Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,false,None,None,,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,None,None,None,None,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
ecd_NonRule10b51ArrAdoptedFlag_Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,ecd:NonRule10b51ArrAdoptedFlag,Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,false,None,None,,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,None,None,None,None,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
ecd_Rule10b51ArrTrmntdFlag_Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,ecd:Rule10b51ArrTrmntdFlag,Duration_1_1_2024_To_3_31_2024_WIFMsMuWHU2MUsj_j9rsHw,false,None,None,,duration,None,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,None,None,None,None,2024-01-01,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2024-05-15,Q2,2024,Adaptimmune Therapeutics PLC
